cid,tldr
PA10202,"Telithromycin's metabolism by CYP3A4 and transport by SLCO1B1 and SLCO1B3 is significantly influenced by genetic variations such as CYP3A4*1B, CYP3A4*22, and SLCO1B1*5, which impact its plasma levels, efficacy, and safety. Variants in these genes can lead to under-metabolism, increasing toxicity risk, or over-metabolism, which may reduce drug effectiveness, while altering drug distribution and elimination, thereby necessitating tailored management based on individual genetic profiles."
PA451704,"Variants in the gene MT-RNR1 impact mitochondrial susceptibility to the ototoxic effects of aminoglycosides like tobramycin, potentially leading to hearing loss. Additionally, resistance to tobramycin may be influenced by genes that encode aminoglycoside-modifying enzymes or by mutations in ribosomal RNA, affecting the drug's efficacy by enabling bacterial resistance mechanisms."
PA166246441,"Sotorasib targets the mutant KRAS G12C in certain cancers, impacting the MAP kinase signaling pathway pharmacodynamically due to the dependence of its therapeutic effect on the presence of this mutation. On the pharmacokinetic side, its metabolism involves several CYP enzymes (like CYP3A4, CYP3A5, CYP2C8, CYP2C9, and CYP2B6) and transporters (ABCG2 and ABCB1), where genetic variants can affect drug plasma levels, influencing both efficacy and toxicity, potentially necessitating dose adjustments."
PA451644,"Thalidomide's pharmacogenetic effects involve its metabolism by enzymes such as CYP2C19, which affects the formation of metabolites influencing drug safety and efficacy, and its interaction with the cereblon protein (CRBN), which modulates its therapeutic action, particularly in conditions like multiple myeloma. Variations in genes like CYP2C19 and CRBN can lead to differences in drug metabolism and effectiveness, thereby impacting individual therapeutic outcomes and side effect profiles."
PA166190621,"Trastuzumab deruxtecan's efficacy and safety are influenced by genetic variations in the ERBB2 gene, which affects drug binding and internalization through HER2 expression levels, and CYP3A4, which impacts the metabolism of its cytotoxic component DXd, affecting both effectiveness and toxicity. Additionally, genes like ABCB1, SLCO1B1, SLCO1B3, and ABCG2, involved in drug transport and excretion, are key to the drug's pharmacokinetic profile, influencing dosage optimization and therapeutic outcomes."
PA451512,"The MT-RNR1 gene, which encodes mitochondrial 12S rRNA, is associated with increased susceptibility to aminoglycoside-induced ototoxicity, influencing mitochondrial function in cochlear hair cells and heightening their vulnerability to damage from drugs like streptomycin. Additionally, the HLA-A gene, involved in immune responses, could potentially influence sensitivity to drug-induced tissue damage, although its direct role in interaction with streptomycin is less evident."
PA166131338,"Tamoxifen-N-glucuronide is formed mainly through the action of the UGT1A4 enzyme, which catalyzes the addition of glucuronic acid to Tamoxifen, aiding its excretion and affecting its pharmacokinetic profile. Genetic variations in UGT1A4 can alter the rate of this process, influencing the levels of active Tamoxifen metabolites such as endoxifen, thereby impacting the efficacy and toxicity of Tamoxifen therapy."
PA449394,"Donepezil, used for dementia, is metabolized by CYP2D6 and CYP3A4 enzymes, and variations in CYP2D6 can affect its plasma levels and efficacy. Additionally, genes like CHAT and CHRNA7, which are involved in acetylcholine synthesis and its receptor function, influence donepezil's pharmacodynamics by enhancing cholinergic transmission, while other genes such as PRKCE and BCHE may modify its effects through roles in neuronal signaling and cholinesterase activity, all contributing to the drug's therapeutic outcomes in dementia treatment."
PA165980594,"Ponatinib's effectiveness and safety are influenced by genetic factors impacting both its metabolism and therapeutic targeting mechanisms. Key interactions include mutations like T315I in the BCR-ABL fusion protein, which affects drug resistance, and polymorphisms in CYP enzymes such as CYP3A4, CYP2C8, and CYP2D6 that alter its metabolism, along with transporter proteins like ABCB1 and ABCG2 which can modify drug disposition and resistance, thus affecting ponatinib's efficacy and toxicity."
PA448817,"Carvedilol is metabolized mainly by CYP2D6, which turns it into active metabolites; genetic variations in CYP2D6 can significantly alter its plasma levels, impacting efficacy and potential toxicity. Other genes such as UGT1A1 and UGT2B7, which help in the glucuronidation of the drug, also affect its clearance, thus influencing both safety and effectiveness, while ADRB1 gene polymorphisms impact the drug's pharmacodynamics by modifying its binding and response in cardiovascular modulation."
PA450192,"Leflunomide's effectiveness and safety are influenced by interactions with genes like CYP1A2 and CYP2C9, which are involved in the drug's hepatic metabolism, and ABCG2, which affects drug distribution and excretion. Additionally, variations in these genes can lead to differing metabolic rates, potentially impacting drug levels, efficacy, and risk of toxicity. The drug's pharmacodynamics involve DHODH, an enzyme targeted by leflunomide to inhibit lymphocyte proliferation, essential in treating conditions like rheumatoid arthritis."
PA448771,"Capecitabine's efficacy and safety are affected by the pharmacogenetics of specific genes involved in its metabolization and activation, such as DPYD, CES1, TYMP, and CDA. DPYD variants can reduce enzyme activity, leading to higher levels of fluorouracil and increased toxicity; CES1 and TYMP are essential in converting capecitabine into its active form, while CDA influences intermediate steps in the drug's metabolism. Recognizing genetic variations in these genes allows for personalized medicine approaches, optimizing therapy outcomes and minimizing adverse effects."
PA450266,"Genetic variations in the cytochrome P450 enzymes, specifically CYP3A4 and CYP2D6, significantly impact the metabolism of loratadine, affecting its efficacy and safety. Those with different CYP2D6 alleles may experience a range from poor to ultrarapid metabolism, leading to variations in plasma levels which can influence the drug's side effects and necessary dosages for effective treatment."
PA448502,"Atovaquone targets the cytochrome bc1 complex and dihydroorotate dehydrogenase in Plasmodium species and humans, impacting mitochondrial functions essential for pathogen energy and pyrimidine synthesis. The drug's bioavailability and pharmacokinetics are influenced by the ABCB1 gene product, P-glycoprotein 1, which mediates its cellular efflux, and genetic variants in ABCB1 can significantly alter drug absorption and distribution, affecting therapeutic outcomes."
PA451268,"Rofecoxib's effectiveness and safety are largely influenced by genetic variations in PTGS2, its primary target, and CYP450 enzymes like CYP2C9 and CYP2C8 that are involved in its metabolism. These genetic differences can affect the drug’s plasma levels and side-effect profiles, while variations in PTGS1 and transporter gene ABCC4 could modify risks of adverse cardiovascular events and influence the drug’s distribution within the body, respectively."
PA450384,"Genetic polymorphisms in NAT1, which affect the metabolic processing of mesalazine, can influence the drug’s concentration and side effects by affecting its delivery to the colonic epithelium. Additionally, variations in genes like PTGS1, PTGS2, and PPARG, which are involved in the drug’s anti-inflammatory action, and in transporter genes such as SLCO1B1, SLCO1B3, and SLCO2B1, which impact the cellular uptake and removal of the drug, can also modify the efficacy and safety of mesalazine."
PA166160053,"Brexpiprazole's interaction with the CYP2D6 gene significantly influences its pharmacogenetic profile, where variations in the gene affect the drug's metabolism into less active metabolites, impacting its plasma levels and effects. Depending on their CYP2D6 genotype, individuals may experience varying degrees of drug exposure, with poor metabolizers facing higher risks of adverse effects and ultra-rapid metabolizers potentially observing reduced drug efficacy, prompting considerations for dose adjustments or alternative treatments to optimize outcomes."
PA166176885,"The pharmacokinetics and therapeutic efficacy of dihydrocodeine are significantly influenced by the CYP2D6 gene, which is responsible for converting dihydrocodeine into its more potent metabolite, dihydromorphine. Genetic polymorphisms in CYP2D6 can lead to varying enzyme activities, affecting drug efficacy and potential toxicity, while the CYP3A4 gene's role in producing less active metabolites also influences the overall drug metabolism but has a lesser impact on efficacy."
PA166178554,"Variants in the genes CYP3A4, CYP2B6, and CYP2D6, which are involved in methadone metabolism, significantly influence its plasma levels and effect due to differences in metabolic rates. For instance, certain alleles in CYP2B6 and CYP2D6 can make individuals slower metabolizers, leading to higher plasma levels of methadone, which increases the risk of overdose and adverse effects, thereby emphasizing the importance of genotyping for personalized dosing to optimize therapeutic outcomes and minimize side effects in pain management and opioid dependence therapy."
PA164774902,"Tolazamide's metabolism is significantly influenced by CYP2C9 enzyme polymorphisms, with the alleles CYP2C9*2 and CYP2C9*3 leading to reduced enzymatic activity and higher drug levels, increasing hypoglycemia risk. Additionally, variations in the ABCC8 and KCNJ11 genes, which affect ATP-sensitive potassium channels on pancreatic beta-cell surfaces, can alter insulin secretion and thus the drug's efficacy in treating Type II diabetes."
PA449809,"Granisetron's pharmacogenetic interactions are primarily dictated by the metabolizing enzymes CYP3A4 and CYP1A1, which are crucial for its N-demethylation and aromatic ring oxidation, respectively; genetic variants in these enzymes can therefore modify the drug's metabolism, altering efficacy and side effect profile. Additionally, the HTR3A gene, which encodes the 5-HT3 receptor targeted by granisetron, also plays a significant role, as variations in this gene may impact receptor sensitivity or expression, further influencing the drug's effectiveness."
PA166169917,"Midostaurin, a kinase inhibitor effective in treating acute myeloid leukemia (AML), specifically targets mutations in the FLT3 gene, which causes hyperactive signaling and uncontrolled cellular proliferation, thereby influencing the drug's efficacy. The drug is metabolized by the cytochrome P450 system, notably CYP3A4 and other CYP enzymes, where genetic variability can affect its metabolism, impacting plasma levels and toxicity, although specific dosing guidelines based on these polymorphisms are not yet established."
PA449918,"Hydromorphone's pharmacogenetic interactions involve its metabolism by UGT2B7, which glucuronidates the drug impacting efficacy and safety, and potential minor metabolic influences by CYP2D6. Additionally, its analgesic effects hinge on the interaction with opioid receptors mediated by OPRM1 gene variants, which can vary individual pain responses and addiction risk, while ABCB1 may affect its distribution by modulating drug efflux at the blood-brain barrier."
PA450353,"The metabolism of meloxicam is primarily influenced by CYP2C9, where alleles such as CYP2C9*2 and CYP2C9*3 reduce the enzyme's activity, leading to slower metabolism, increased drug levels, and potentially greater efficacy and risk of side effects. CYP3A4 also affects meloxicam's pharmacokinetics to a lesser extent, and the drug's transport involves ABCC4, although specific genetic interactions are less documented."
PA164747038,"The genes potentially involved in pharmacogenetic interactions with sulfametopyrazine, a sulfonamide antibiotic, include those encoding cytochrome P450 isoenzymes such as CYP2C9, which can affect drug metabolism and response, and genes such as HLA-B that may predispose individuals to hypersensitivity reactions like Stevens-Johnson syndrome. These interactions are inferred from known effects with similar sulfonamide drugs, though not directly documented for sulfametopyrazine."
PA450213,"Variations in genes such as DDC, which is responsible for converting levodopa into dopamine, along with dopaminergic receptors (DRD2, DRD3), influence the effectiveness of levodopa therapy in treating Parkinson's disease. Additional genetic factors like SLC22A1, which affects drug distribution, and non-enzyme genes like DBH and SLC6A3 that influence dopamine synthesis and reuptake, as well as HOMER1 which plays a regulatory role in neuronal signaling, further impact levodopa’s efficacy and side effects, necessitating a personalized approach to its use."
PA166171170,"Genetic variations in thymidine phosphorylase could impact the effectiveness of tipiracil hydrochloride by influencing how well the drug inhibits this enzyme, which is critical for preventing the degradation of trifluridine. This variation affects the amount of trifluridine that can be incorporated into DNA, subsequently influencing the efficacy of treatments for conditions like metastatic colorectal cancer."
PA450242,"Lisinopril interacts pharmacodynamically with the ACE gene by inhibiting the conversion of angiotensin I to angiotensin II and with the REN gene affecting the initial conversion of angiotensinogen to angiotensin I, impacting blood pressure regulation. Genetic variations in these genes, such as the ACE alleles (I and D), significantly influence lisinopril's efficacy and side effects, making genetic differences crucial in determining individual therapeutic responses to the drug."
PA451720,"Variations in the COMT gene influence the pharmacodynamic efficacy of tolcapone in Parkinson's disease treatment, with different alleles altering enzyme activity and consequently the drug's effectiveness at inhibiting COMT. On the pharmacokinetic side, polymorphisms in the CYP2C9 gene affect how tolcapone is metabolized, particularly through glucuronidation, which can alter plasma drug levels and impact both efficacy and the potential for adverse effects like hepatotoxicity."
PA166123386,"The effectiveness and safety of ruxolitinib are strongly influenced by genetic variations in the CYP3A4 and CYP2C9 genes, which are crucial in the drug's metabolism. Variants in CYP3A4 can lead to altered plasma concentrations of the drug, affecting its therapeutic efficacy and risk of toxicity, while variants like CYP2C9*2 and CYP2C9*3 in CYP2C9 result in reduced metabolism, increasing the potential for adverse effects like myelosuppression."
PA451771,"Trifluoperazine's efficacy and side effects are influenced pharmacodynamically by genetic variations in the DRD2 receptor and pharmacokinetically by variations in the CYP1A2 gene, which affect the drug's metabolism, as well as by ABCB1 gene variations, which affect the drug's distribution and excretion. This demonstrates the importance of considering individual genetic differences in managing dosing and potential side effects of the drug."
PA449015,"Genetic variations in CYP2C19 and CYP2D6 significantly influence the pharmacokinetics of citalopram by affecting the drug's plasma levels and dosing requirements respectively. In terms of pharmacodynamics, polymorphisms in genes like SLC6A4, GSK3B, BDNF, ABCB1, HTR2A, and HTR1A modulate the drug’s efficacy and side effect profile by altering its brain availability, antidepressant effects, and interactions with serotonin receptors."
PA451881,"Vinorelbine's interaction with TUBB inhibits microtubule assembly crucial for cell division, thus directly impacting tumor growth. The metabolism of vinorelbine is significantly influenced by genetic variations in CYP3A4 and CYP2D6, which affect the drug's pharmacokinetics, toxicity, and efficacy, with additional potential but less defined influences from CYP3A5, ABCG2, CASP7, STMN1, and MTHFR on drug levels and cellular responses."
PA166163690,"The pharmacokinetics of desmethylnaproxen, a metabolite of naproxen, can be affected by genetic variations in key metabolic enzymes. Specifically, the CYP2C9 gene, which metabolizes NSAIDs, and potentially the SULT1A1 gene, involved in drug sulfation, along with the less studied NPIPB8 gene, may influence the metabolism of desmethylnaproxen, thereby affecting its efficacy and safety through altered drug levels and effects."
PA166131379,"The gene CYP2D6 is crucial in the pharmacogenetics of o-desmethyltramadol, the active metabolite of tramadol, as it affects the drug's metabolic rate through genetic variations ranging from poor to ultrarapid metabolizers. Such variability can significantly influence the therapeutic efficacy and potential side effects, with poor metabolizers experiencing less pain relief and ultrarapid metabolizers at increased risk of side effects. Other genes such as SULT1A3 and SLC22A1 are suggested to be involved in further metabolism and excretion, though their specific roles require deeper investigation."
PA451605,"Telmisartan's pharmacogenetic interactions involve genetic variations in metabolic enzyme UGT1A3, which affect the drug's conjugation and clearance, and transporter genes SLCO1B3 and ABCB1, which influence its hepatic uptake and efflux, thereby impacting its plasma concentrations, bioavailability, and possibly pharmacodynamics. Additionally, variations in GNB3 may affect telmisartan's pharmacodynamics related to cardiovascular functions, with overall implications for the drug's efficacy and safety."
PA451906,"Warfarin's effectiveness and safety are influenced by genetic variations in the VKORC1 and CYP2C9 genes, affecting its pharmacodynamics and pharmacokinetics, respectively. Polymorphisms in VKORC1, such as rs9923231, modify the enzyme's sensitivity to warfarin impacting the drug’s mechanism of action on the vitamin K cycle and influencing dose requirements, while variants like CYP2C9 *2 and *3 reduce metabolism speed, increasing the risk of drug accumulation and bleeding."
PA164749650,"Pyridoxal phosphate's pharmacogenetic interactions predominantly relate to its role with enzymes such as AGXT2, GAD1, CBS, SHMT1, SHMT2, GOT1, GOT2, BCAT1, and BCAT2, which are crucial in amino acid and neurotransmitter metabolism. Genetic variations in these enzymes can significantly influence the metabolic effectiveness and therapeutic outcomes of pyridoxal phosphate, affecting processes like amino acid synthesis, detoxification, neuromodulation, and energy production."
PA451846,"Valproic acid's pharmacogenetic interactions involve several genes like *UGT1A6* and *CYP2C9*, which influence its metabolism through glucuronidation and oxidation; *POLG* gene variants are linked to severe liver toxicity risks. Other genetic interactions include valproic acid's effects on sodium channels (*SCN1A*, *SCN2A*), GABA receptors (*GABRA1*), and its inhibition of histone deacetylases (*HDAC1*, *HDAC2*, *HDAC3*), which play roles in its therapeutic effects on seizures, mood regulation, and neuroprotection."
PA134687937,"The metabolism of the antidepressant mianserin is significantly influenced by the enzyme CYP2D6, which varies due to genetic polymorphisms, creating different metabolic phenotypes (poor, intermediate, extensive, and ultrarapid metabolizers). These variations impact mianserin's plasma levels and thus its effectiveness and safety, leading to potential adjustments in dosing to optimize therapeutic outcomes and reduce side effects based on individual CYP2D6 status."
PA449130,"Cortisone acetate's effectiveness and safety are influenced by the metabolism through enzymes CYP3A4 and CYP3A5, which have genetic variants that affect metabolic rates and drug concentrations in the body. Additionally, variations in the NR3C1 gene, encoding the glucocorticoid receptor, alter the drug's effectiveness by modifying receptor sensitivity or expression levels. These genetic factors are essential for personalizing treatment to optimize efficacy and minimize adverse effects."
PA10352,"Palonosetron, a 5-HT3 receptor antagonist metabolized by hepatic enzymes CYP2D6, CYP3A4, and CYP1A2, is impacted by genetic variations in these enzymes, affecting its pharmacokinetics. Variants in CYP2D6 may lead to higher or lower plasma concentrations of the drug, influencing its efficacy and safety, while polymorphisms in CYP3A4 and CYP1A2 also alter enzyme activity and therefore the metabolism rate of palonosetron."
PA451547,"The efficacy and tolerability of sulfasalazine, utilized in treating inflammatory conditions, are influenced by pharmacogenetic interactions involving the transport gene ABCG2, which affects the drug’s absorption and bioavailability, and the NAT2 gene, crucial in the liver metabolism of sulfapyridine—a key metabolite. Variants in these genes can alter drug levels in the body, affecting efficacy and the risk of side effects such as hypersensitivity reactions, while other genes like SLC19A1, CYP2D6, MTR, HLA-B, G6PD, TYMS, and C18orf56 play subtler, more indirect roles in its pharmacokinetic and pharmacodynamic behaviors."
PA10232,"Variants in the CYP3A4 gene affect the metabolism of vindesine, potentially altering its pharmacokinetics and leading to increased toxicity or reduced efficacy due to variations in drug concentration. Additionally, the ABCB1 transporter, involved in drug efflux, could influence the distribution and elimination of vindesine, thereby affecting its overall efficacy and toxicity profile."
PA449001,"Cimetidine's pharmacogenetic interactions involve the cytochrome P450 system enzymes CYP2C19, CYP2D6, and CYP3A4, as well as the ABCB1 transporter gene, which can significantly affect its metabolism, distribution, and elimination. These genetic variations influence how different individuals respond to the drug, impacting its effectiveness and potential side effects by altering the drug's concentration profiles in the body."
PA449390,"Dolasetron's effectiveness and safety are influenced by its metabolism through cytochrome P450 enzymes, particularly CYP2D6, CYP2C9, and CYP3A4, as these enzymes convert dolasetron into its active form, hydrodolasetron. Variants in these genes, especially CYP2D6, can significantly alter the levels of hydrodolasetron, affecting the drug's efficacy and raising the risk of toxicity, thus necessitating personalized dosing based on individual metabolic profiles to optimize therapeutic outcomes and minimize side effects."
PA10323,"Genetic variations in the genes TPH1, TPH2, IDO1, TDO2, and SLC22A2 significantly impact tryptophan's metabolism through the serotonin and kynurenine pathways, affecting serotonin synthesis, tryptophan catabolism, and its cellular uptake. These variations can influence clinical outcomes related to mood disorders, sleep disturbances, neurodegeneration, and immune responses, altering the effectiveness of tryptophan-based treatments."
PA449050,"Clonazepam's metabolism is significantly influenced by genetic variants in the CYP3A4 enzyme, affecting its plasma levels and therefore its efficacy and side effect profile. Additionally, variations in the genes encoding GABA(A) receptor subunits can modify how clonazepam interacts with these receptors, thereby altering its anticonvulsant and anxiolytic effectiveness."
PA166114316,"Sodium phenylbutyrate transforms into phenylacetate, which binds to glutamine to promote ammonia excretion; genetic variations in urea cycle enzymes like OTC, ASS1, and CPS1, important in ammonia metabolism, can affect individual responses to this treatment due to differences in nitrogen processing rates. These pharmacogenetic correlations are inferred from the metabolic roles of these enzymes rather than direct drug interactions, indicating that individual metabolic capacities are crucial in optimizing treatment effectiveness."
PA165946873,"Vemurafenib's effectiveness is significantly influenced by the BRAF V600E mutation, which determines the drug's ability to target and inhibit the mutated BRAF kinase critical to the MAPK signaling pathway. Additionally, its pharmacokinetics are affected by CYP3A4, which metabolizes the drug, and its pharmacodynamics can be influenced by genetic variants in genes like NRAS, HRAS, and KRAS that activate alternative pathways, potentially conferring resistance and affecting the overall therapeutic outcome of vemurafenib."
PA451837,"The pharmacogenetics of Ursodeoxycholic acid (UDCA) involves the influence of genetic variations in cytochrome P450 enzymes (CYP3A4 and CYP3A5) and bile acid transporters (ABCB11 and SLC10A1) on its metabolism, clearance, and transport efficiency, affecting the drug’s concentration, therapeutic efficacy, and potential for adverse effects. Additional impacts on UDCA's actions may arise from interactions with the bile acid receptor NR1H4, where genetic differences could further influence the regulation of bile acids."
PA451866,"Venlafaxine's therapeutic efficacy and safety are influenced by genetic variations in key enzymes and transporters like CYP2D6, which metabolizes the drug into desvenlafaxine, and ABCB1, involved in the drug's efflux from cells. These genetic factors impact venlafaxine's plasma levels, distribution, and elimination, affecting both its effectiveness and side effect profile, which can necessitate personalized dose adjustments for optimal treatment outcomes."
PA164754754,"Cevimeline's metabolism is primarily governed by the enzymes CYP2D6 and CYP3A4, with variants in CYP2D6 significantly affecting its pharmacokinetics. Poor metabolizers with CYP2D6 variants may experience higher drug plasma levels, increasing both efficacy and side effects, whereas ultra-rapid metabolizers may see reduced effectiveness due to faster drug breakdown. Variations in CYP3A4 activity also modulate cevimeline's concentration and therapeutic outcomes, although its impact is generally less pronounced than that of CYP2D6."
PA451522,"Variants in the BCHE gene can result in prolonged paralysis effects of the muscle relaxant succinylcholine by impairing butyrylcholinesterase efficiency. Additionally, mutations in the RYR1 and CACNA1S genes, which affect muscle function, can lead to life-threatening reactions like malignant hyperthermia and hyperkalemic responses, particularly under anesthesia, thereby impacting the drug's pharmacodynamic interactions."
PA166212682,"The metabolism of Tilidine into its active form, nortilidine, is significantly influenced by the CYP2D6 enzyme, which is responsible for the demethylation process in the liver, although direct references to this enzyme are not well-documented. Additionally, variability in the ABCB1 gene, which codes for P-glycoprotein involved in drug efflux, may impact Tilidine's distribution and effects in the body, though specific studies on this are lacking."
PA449035,"The metabolism and transport of clindamycin involve genes such as CYP3A4, CYP3A5, and ABCB1, with variations in these genes affecting the drug's plasma levels, toxicity, distribution, and systemic exposure. CYP3A4 and CYP3A5 are vital for converting clindamycin into inactive metabolites, and polymorphisms in these genes can alter metabolic rates, while ABCB1 affects the drug's efflux from cells, influencing its pharmacokinetics and potentially its overall efficacy and safety."
PA165950341,"Ivacaftor's effectiveness and safety in treating cystic fibrosis are influenced by genetic variations in multiple genes: CFTR determines patient eligibility based on gating mutations, CYP3A4 and CYP3A5 majorly dictate its metabolism, CYP2C9 and ABCB1 affect its metabolism and distribution respectively, while ALB and ORM1 impact its plasma levels and distribution. Additionally, variations in non-pharmacokinetic genes like SLC26A9 may also affect treatment due to their roles in shared pathways of cystic fibrosis pathology, highlighting the importance of personalized medication approaches."
PA164784002,"Sertindole, an antipsychotic drug for schizophrenia, is metabolized mainly by CYP2D6 and CYP3A4 enzymes; variations in CYP2D6 significantly affect its plasma concentration, influencing drug efficacy and safety risks, such as cardiac side effects through prolonged QT intervals. CYP3A4 also affects metabolism but less so than CYP2D6, making the genetic variants of both crucial in determining the appropriate dosing and monitoring to manage adverse effects and ensure effective treatment outcomes."
PA10075,"Esomeprazole metabolism is principally mediated by the enzyme CYP2C19, and variations in the CYP2C19 gene, such as the CYP2C19*2 and CYP2C19*3 polymorphisms, can significantly reduce enzyme activity and increase drug exposure. Although lesser in impact, CYP3A4 also metabolizes esomeprazole, and its variations can affect the drug's metabolism; other enzymes like CYP2B6 and CYP3A5 might contribute but are not primary pathways."
PA450322,"Maprotiline metabolism is significantly influenced by the enzymes CYP1A2 and CYP2D6, where CYP1A2 is involved in its N-demethylation and CYP2D6 helps form its active metabolite, desmethylmaprotiline. Genetic variations in these enzymes can lead to altered plasma concentrations of maprotiline, affecting its efficacy and safety, with reduced CYP2D6 activity increasing drug levels and side effects, and increased activity potentially leading to ineffective drug levels."
PA450262,"Genetic variations in CYP3A4 and CYP2C8 significantly affect the metabolism of loperamide, altering its plasma levels and, hence, its effectiveness and safety by either enhancing or reducing drug metabolism. Additionally, mutations in the ABCB1 gene, which codes for the P-glycoprotein transporter, can influence loperamide's bioavailability and its ability to cross the blood-brain barrier, further impacting its therapeutic efficacy and potential toxicity."
PA166115580,"Tafenoquine's effectiveness and safety are influenced by interactions with CYP2D6 and G6PD genes. CYP2D6 is responsible for the metabolic activation of tafenoquine, with variations such as poor metabolizer status leading to reduced drug efficacy. Conversely, G6PD helps to mitigate the oxidative stress caused by tafenoquine; deficiencies in G6PD can increase the risk of hemolysis, affecting the drug’s pharmacodynamics and potentially its pharmacokinetics by altering red blood cell turnover."
PA450373,"Genetic variants in the CYP2C19 gene, such as rs4986893, rs41291556, and rs72558186, significantly impact the metabolism of mephenytoin, leading to poor metabolizer phenotypes that necessitate dosage adjustments to achieve therapeutic effectiveness and avoid toxicity. Although mephenytoin also interacts with other cytochrome P450 enzymes and could be influenced by NR1I2 which regulates these enzymes, the primary pharmacogenetic focus lies on the interactions involving CYP2C19."
nan-9f9d5b8c-2995-4fc5-8010-386955dfc597,"Genetic variations in the metabolic enzymes UGT1A9 and UGT2B7 substantially affect the metabolism of Artenimol, impacting drug levels and its effectiveness and safety. The enzymes CYP2D6 and CYP2C19 also play a role in Artenimol's metabolism, though their impact is less significant compared to UGT1A9 and UGT2B7; these differences could necessitate varied dosing strategies to optimize therapeutic outcomes and minimize adverse reactions."
PA131285527,"Genetic variations in enzymes like GSTP1, GSTM1, GSTT1, and NQO1, which are involved in the metabolism and detoxification of oxaliplatin, significantly influence the drug's effectiveness and side effects. Additionally, variations in transporters such as ABCG2, ABCC2, SLC22A2, SLC22A3, SLC31A1, ATP7A, and ATP7B affect oxaliplatin’s pharmacokinetics and intracellular concentrations, impacting its cytotoxic efficacy and drug resistance."
PA166160006,"Lesinurad, a drug for managing gout-associated hyperuricemia, significantly interacts with genetic variations in metabolism-related genes, particularly CYP2C9. Individuals with polymorphic variants like CYP2C9 *2 and *3 alleles may experience slower metabolism, resulting in higher plasma concentrations of the drug and increasing the risk of toxicity. Thus, genetic testing for these variants is recommended to optimize dosing and minimize adverse effects."
PA449969,"The metabolism of imipramine, a tricyclic antidepressant, is significantly influenced by the genetic variants of the CYP2D6 and CYP2C19 enzymes. Variability in CYP2D6 can alter the bioavailability of imipramine and its metabolite desipramine, leading to potentially higher plasma concentrations and increased adverse effects in poor metabolizers, while CYP2C19 variants affect the drug's metabolic rate and plasma levels, impacting therapeutic outcomes. This necessitates personalized dosing to enhance efficacy and minimize side effects based on individual genetic profiles."
PA450196,"Genetic variations in CYP2A6 and CYP3A4 can significantly influence the metabolism of letrozole, impacting its efficacy and toxicity, while variations in UGT2B7 and ABCB1 might affect the drug's clearance and absorption, respectively. Additionally, polymorphisms in CYP19A1, the target of letrozole, may alter drug binding and efficacy, underlining the importance of considering these genetic factors in optimizing letrozole therapy for individual patients."
PA448953,"Chlorothiazide targets the SLC12A3 gene, which encodes the Na-Cl cotransporter in kidney tubules, enhancing excretion of sodium and chloride to exert its diuretic effect, while variations in this gene impact its efficacy in managing blood pressure and fluid retention. Additionally, chlorothiazide inhibits enzymes encoded by the CA1/CA2 genes, affecting electrolyte and fluid balance, and altering vascular responses which contribute to its antihypertensive effects; genetic differences in these genes can modify the drug's effectiveness."
PA164746311,"Everolimus metabolism is significantly influenced by CYP3A4 and CYP3A5, with genetic variations in these enzymes affecting the drug's plasma levels, efficacy, and potential toxicity. Additionally, the ABCB1 gene impacts its pharmacokinetics via the drug's absorption and disposition, while polymorphisms in MTOR and other growth-related genes (ERBB2, ESR2, PIK3R1, RPTOR, ESR1, FGFR4) may alter its pharmacodynamic response by modifying the mTOR signaling pathway Everolimus targets."
PA448710,"The pharmacogenetic interactions of caffeine primarily involve the CYP1A2 gene, which governs its metabolism and can greatly affect plasma concentrations and efficacy; other contributing genes include CYP1A1, CYP2A6, and NAT2. Additionally, the AHR gene affects CYP1A2 expression, while variants in the ADORA2A gene alter caffeine's effectiveness as an adenosine receptor antagonist, influencing effects such as alertness and cardiac rhythm, with genes like DRD2 and RYR1 further affecting responses through dopamine receptor activity and calcium channel regulation."
PA451258,"Ritodrine's pharmacogenetic interactions primarily involve the ADRB2 gene, which impacts its effectiveness and side effects in managing premature labor by influencing uterine muscle relaxation; variations in ADRB2 can affect drug response and adverse effects like tachycardia and pulmonary edema. Additionally, genetic differences in sulfotransferase enzymes, specifically SULT1A1 and SULT1A3, modify Ritodrine's metabolism, which can alter plasma drug levels and affect both the drug's effectiveness and the risk of toxicity."
PA451089,"Pravastatin's pharmacogenetic interactions are influenced by genetic variations in several key genes, including HMGCR, which modulates the drug's cholesterol synthesis reduction, SLCO1B1 and SLCO2B1 which affect its hepatic uptake and plasma levels, ABCB1 that impacts its pharmacokinetics, and KIF6 where certain variants enhance cardiovascular benefits in high-dose therapy. These interactions can significantly affect pravastatin's efficacy, safety, and personalized dosing considerations."
PA451209,"Quinidine's effects and optimal dosages are influenced by genetic variations in metabolic enzymes like CYP3A4 and CYP2D6, which affect its metabolism and circulating levels, and in transporter genes like ABCB1, which modify drug distribution. Additionally, variations in ion channel genes such as SCN5A and multiple potassium channel genes (KCNH2, KCNK1, KCNK6) can alter quinidine's impact on cardiac action potentials, impacting its efficacy and the risk of arrhythmias."
PA165823907,"Variants in the *CYP2C9* and *CYP2C19* genes significantly influence the metabolism of phenytoin and its metabolite hydroxyphenytoin; specific alleles like *CYP2C9* *2 and *3 reduce enzyme activity, leading to higher phenytoin levels and potential toxicity, while *CYP2C19* polymorphisms affect metabolic rates, which can impact drug efficacy and adverse reactions. Thus, these genetic factors are critical in determining the appropriate dosing of phenytoin to optimize treatment efficacy and minimize toxicity risks in seizure management."
PA166189803,"Genetic variations in the enzymes CYP3A4 and CYP2D6 influence the metabolism of upadacitinib, a JAK1 inhibitor, potentially affecting its efficacy and safety. Additionally, polymorphisms in transporters ABCB1, ABCG2, and in SLCO1B1 can affect the drug's cellular transport and availability, thereby modifying therapeutic outcomes in the treatment of autoimmune diseases."
PA164771236,"Pegaptanib, a drug targeting the VEGFA gene, specifically binds to and inhibits VEGF165, reducing angiogenesis and vascular permeability associated with neovascular age-related macular degeneration. Genetic variations in VEGFA could potentially influence the effectiveness and safety of pegaptanib through its pharmacodynamic interactions, leading to variability in drug response among individuals."
nan-964acaa3-859b-44c7-9398-9335a446e9f2,"The efficacy and toxicity of Capreomycin, an atypical aminoglycoside used against Mycobacterium tuberculosis, can be influenced by genetic variations in genes related to protein synthesis and ion transport, and drug handling genes like MDR1 and SLC22A2, which may impact drug uptake and excretion. Genes such as MT-RNR1, associated with aminoglycoside-induced hearing loss, might also influence Capreomycin's side effects like nephrotoxicity and ototoxicity."
PA166131580,"Sacubitril's activation and efficacy are influenced by genetic variations in the CES1 gene, which affects its conversion into the active metabolite LBQ657. Additionally, polymorphisms in the SLCO1B1 and SLCO1B3 genes impact the transport efficiency of Sacubitril and its metabolites, altering distribution and elimination processes, and potentially affecting drug levels and associated risks of adverse effects."
PA448803,"The effectiveness and toxicity of carboplatin, a chemotherapy drug used for ovarian cancer, are influenced by interactions with genes such as GSTP1, GSTM1, and GSTT1, which are involved in detoxification, and ATP7B and ABCG2, which regulate its intracellular concentration. Variations in these genes affect how the drug is metabolized, determining individual responses and potential resistance to the treatment."
PA448852,"Variations in the genes SLC22A6, SLC22A8, SLC15A1, and SLC15A2, which are responsible for drug transport, can impact the pharmacokinetics of cefotaxime, affecting its absorption, distribution, metabolism, and excretion. For instance, SLC22A8 influences cefotaxime's renal clearance, potentially altering its levels, efficacy, and susceptibility to side effects, while variants in other mentioned genes may modify its transport, availability, and toxicity."
PA448687,"Bupropion metabolism is primarily influenced by genetic variations in CYP2B6, particularly CYP2B6*6, which affect enzymatic activity and, consequently, drug levels and patient responses. Additionally, variations in other genes such as CYP2C19, CYP2D6, and DRD2 also modify bupropion's pharmacokinetics and pharmacodynamics, impacting treatment efficacy and the risk of adverse effects by affecting neurotransmitter systems and receptor interactions."
PA166110257,"The metabolism of dexlansoprazole is greatly affected by the CYP2C19 gene, where genetic variants of this gene categorize individuals as extensive, intermediate, or poor metabolizers, influencing the drug's pharmacokinetics. This variation affects dexlansoprazole's efficacy and side effects; poor metabolizers may experience increased drug exposure and side effects, while extensive metabolizers might have reduced drug efficacy due to lower drug levels."
PA166122627,"Chlorocresol, used as a preservative and antiseptic, might interact with the RYR1 gene, which regulates calcium channels in tissues. This potential interaction is theoretical and could influence intracellular calcium levels, affecting cellular responses in individuals sensitive to chlorocresol, especially during hypersensitivity reactions. This relationship is more inferential, considering the limited systemic absorption of chlorocresol."
PA448547,"Variants in the CYP3A4 and CYP3A5 enzymes significantly impact the metabolism of beclomethasone dipropionate into its active form, 17-BMP, thus affecting its plasma levels and potentially its efficacy and safety. Additionally, genetic variations in the NR3C1 gene influence the sensitivity of the glucocorticoid receptor, altering the drug’s anti-inflammatory response, while variations in transporter genes like ABCB1 and ABCG2, and carriers such as SERPINA6, affect the distribution and elimination of the drug."
PA165958363,"The pharmacogenetic interactions of agomelatine are significantly influenced by its metabolism through cytochrome P450 enzymes, especially CYP1A2 and to a lesser extent CYP2C9. Genetic variants in CYP1A2 can greatly affect agomelatine's metabolic clearance, leading to either elevated plasma levels that increase the risk of adverse effects, such as hepatotoxicity or severe depression, or decreased drug concentrations that might result in insufficient therapeutic effects; similarly, variations in CYP2C9 could also modify drug levels and response."
PA448926,"Chlorambucil's metabolism is influenced by polymorphisms in the glutathione S-transferases (GSTs) enzymes such as GSTP1, GSTA1, GSTA2, GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, GSTT1, GSTT2, and GSTT2B, which are involved in the drug's detoxification through glutathione conjugation. Variations or deletions in genes like GSTM1 and GSTT1 can lead to reduced enzyme activity, impacting drug toxicity and efficacy, while SLCO1A2 variants affect the drug’s pharmacokinetic profile by altering its distribution and elimination."
PA449409,"Variations in the CYP2D6 and CYP2C19 genes significantly influence the metabolism of Doxepin, a tricyclic antidepressant, affecting its efficacy and safety due to differences in plasma drug levels. Poor metabolizers with reduced enzyme activity may face increased adverse effects, while ultra-rapid metabolizers could find standard doses ineffective; genetic variations in P-glycoprotein function also affect Doxepin's distribution and excretion, further impacting treatment response."
PA448866,"Ceftriaxone interacts pharmacogenetically with various transporters such as SLC22A6 (OAT1), SLC22A8 (OAT3), and ABCB1 (P-glycoprotein), affecting its clearance, plasma concentration, efflux from cells, and tissue distribution, which impacts therapeutic outcomes and side effects. Genetic variants in these transport genes and others like SLC22A11, SLC15A1, SLC15A2, as well as minimal interactions through metabolic pathways involving GLUL and binding variables like ALB, influence the drug’s pharmacokinetics."
PA448765,"Candesartan's effectiveness and pharmacokinetics are influenced by genetic variations in CYP2C8, CYP2C9, which affect the drug's biotransformation, and ABCB1, SLCO1B1, which are involved in its absorption and distribution. Additionally, genes like AGTR1 impact the drug's pharmacodynamics by affecting its ability to block angiotensin II effects, potentially altering its efficacy."
PA450272,"Genetic variations in the enzymes CYP3A4 and CYP2C8 influence the metabolic rate of lovastatin, affecting its efficacy and side effects, while variations in the SLCO1B1 transporter, such as the c.521T>C SNP, significantly impact its uptake in the liver and risk of myopathy. Additionally, variations in non-ADME genes like CETP, LDLR, and APOA5 indirectly influence lovastatin's therapeutic outcomes by altering lipid profiles, and variants in HMGCR, the drug's primary target, could modify its effectiveness."
PA449256,"Dexmedetomidine acts as an agonist at the ADRA2A gene's alpha-2 adrenergic receptor, inhibiting norepinephrine release which results in sedative and analgesic effects. Variations in genes such as COMT that metabolize neurotransmitters like norepinephrine might influence dexmedetomidine's effectiveness and safety by altering neurotransmitter levels, while genetic differences in enzymes like CYP2A6 and other proteins such as PRKCB, USP5, CDCA3, and GNB3 could affect the drug's metabolism, clearance, and signaling pathways, thereby modifying its response and safety profile."
PA166124616,"Ceritinib interacts pharmacogenetically with CYP3A4, ABCB1, and ALK genes, impacting its metabolism, distribution, and effectiveness in NSCLC treatment. Variants in CYP3A4 affect ceritinib’s metabolic clearance, while ABCB1 variants alter its absorption and distribution; mutations in ALK influence ceritinib's efficacy and resistance patterns, determining the therapeutic response in NSCLC."
PA166163482,"Brigatinib's metabolism is strongly influenced by the CYP2C8 and CYP3A4 enzymes, with variations in these genes affecting the drug’s plasma levels and, consequently, its efficacy and toxicity. Additionally, brigatinib's effectiveness also depends on mutations in its target genes, ALK and EGFR, which influence the drug's therapeutic response, particularly in conditions like ALK-positive NSCLC where resistance to previous treatments like crizotinib has developed. Therefore, genetic profiling of these metabolic enzymes and target genes is crucial to optimizing treatment outcomes."
PA10034,"Genetic variants in the cytochrome P450 enzymes CYP2C9 and CYP3A4 significantly influence the metabolism of bosentan, a drug used for pulmonary arterial hypertension, affecting drug levels and risk of adverse effects. Additionally, variability in the ABCB11 gene impacts the drug's excretion and overall disposition, which further affects bosentan's pharmacokinetics."
PA449165,"Cyclophosphamide's effectiveness and toxicity are influenced by genetic variations in enzymes like CYP2B6 and CYP3A4, which are involved in its metabolism into active metabolites, and GST genes such as GSTP1, GSTM1, GSTM3, and GSTT1, which are involved in the detoxification of its toxic byproducts like acrolein. Additionally, genes like ABCC1, ABCC2, and ABCB1, which encode ATP-binding cassette transporters, impact the drug's pharmacokinetics by affecting its efflux from cells, thereby affecting both its effectiveness and side effects."
PA164745461,"Bacampicillin, a prodrug of ampicillin, is activated by intestinal esterases, and its efficacy might be influenced by genetic variations in these enzymes. Furthermore, once converted to ampicillin, it targets bacterial genes such as dacA, dacB, dacC, mrcA, mrcB, mrdA, and ftsI, which encode penicillin-binding proteins (PBPs), essential for understanding resistance patterns in bacteria."
PA166278301,"Ganaxolone, sold as ZTALMY, enhances the functioning of GABA_A receptors by targeting multiple subunits, crucial for its role in treating seizures linked to CDKL5 deficiency disorder. It is metabolized mainly by CYP3A4, with additional involvement from CYP3A5, CYP2B6, CYP2C19, and CYP2D6, and genetic variations in these enzymes can significantly affect the drug's metabolism, efficacy, and safety, highlighting the importance of considering these pharmacogenetic factors in patient management."
PA449373,"Genetic variations in the enzymes CYP1A2 and CYP3A4, which are crucial for the metabolism of the Class Ia antiarrhythmic drug disopyramide, can significantly affect the drug's clearance and consequently its blood levels, potentially altering its efficacy and increasing toxicity risks. Moreover, genetic variants in the KCNH2 gene, which influences the function of the Kv11.1 protein involved in cardiac repolarization, can impact disopyramide's effectiveness in prolonging the QT interval, thus affecting its antiarrhythmic activity."
PA134687907,"Formoterol metabolism is primarily influenced by genes like CYP2D6, CYP2C19, CYP2C9, CYP2A6, UGT1A1, and several other UGT enzymes, which affect its pharmacokinetics and can alter efficacy and side effects through changes in drug concentration and elimination rates. Pharmacodynamically, formoterol targets the ADRB2 gene related to the beta-2 adrenergic receptor, and genetic variations in ADRB2 and other adrenergic receptors (ADRB1, ADRB3) as well as transporter genes (SLC22A1, SLC22A3, SLC22A4, SLC22A5) can modify receptor response and drug bioavailability, thereby impacting therapeutic outcomes."
PA451775,"Trifluridine's effectiveness and resistance particularly in cancer therapy can be impacted by genetic variations in the enzymes TYMS, TK1, and TYMP which are essential for its activation and function. Additionally, variations in solute carrier transporters, especially SLC29A1, can affect the drug's cellular uptake and distribution, influencing the drug's availability at target sites and potentially altering pharmacokinetics and patient response."
PA449233,"Desipramine metabolism is significantly influenced by genetic variations in the CYP2D6 enzyme, affecting drug efficacy and safety due to differences in drug plasma levels among individuals with poor or ultrarapid metabolizer statuses. Additionally, genes like CYP2C19, SLC6A2, TUBB3, BDNF, PDE11A, and MC1R may play roles in desipramine's pharmacodynamics, influencing its therapeutic outcomes and side effects through their effects on neurotransmitter systems and enzyme activities."
PA164749631,"Decitabine's effectiveness is influenced by interactions among various genes: DCK, crucial for activating the drug; CDA, affecting its degradation; SLC28A1, responsible for its cellular uptake; and DNA methyltransferases (DNMT1, DNMT3A, DNMT3B), which are inhibited by the drug impacting DNA methylation and tumor suppressor gene activation. Additionally, variations in HLA-A could subtly influence immune responses, potentially affecting treatment outcomes in myelodysplastic syndromes and leukemia."
PA10233,"The metabolism of voriconazole is significantly influenced by genetic variations in enzymes such as CYP2C19, CYP2C9, and CYP3A4, which determine individual metabolic rates, affecting drug levels and efficacy. Other genes like ABCC2, POR, and ABCB1 also play roles by altering enzyme activities or transporter functions, essentially impacting how voriconazole is absorbed and excreted, highlighting the need for personalized dosing based on genetic testing."
PA451686,"Ticlopidine's effectiveness and safety are affected by genetic variations, particularly in the CYP2C19 gene, which influences the drug's metabolic transformation into active metabolites and thereby impacts drug levels and response. Additionally, variants in HLA alleles may affect the incidence of immune-mediated adverse reactions like neutropenia and agranulocytosis, although their role in the drug's pharmacodynamics is less clear."
PA451457,"Sotalol's effectiveness and safety are influenced by genetic variations in the KCNH2, ADRB1, and ADRB2 genes. Variants in KCNH2 can affect cardiac repolarization and the risk of arrhythmias, while changes in ADRB1 and ADRB2 can modify the drug's beta-blocking effects on heart rate and myocardial contractility, impacting its overall efficacy and side-effect profile."
PA449051,"Clonidine's pharmacogenetic interactions involve its metabolism primarily by the cytochrome P450 enzymes CYP2D6 and CYP3A4, affecting its plasma levels and clearance, and consequently influencing therapeutic outcomes and side effect profiles. Additionally, genetic variants in alpha-2 adrenergic receptors (ADRA2A, ADRA2B, and ADRA2C) and the G protein subunit encoding gene GNB3 impact the drug's efficacy, particularly in managing hypertension and sedation, highlighting the importance of considering these genetic factors in optimizing clonidine's usage."
PA449273,"Dextromethorphan's metabolism is primarily influenced by the cytochrome P450 enzyme CYP2D6, with genetic variations in CYP2D6 leading to a spectrum of metabolic phenotypes from poor to ultra-rapid metabolism, impacting drug concentration and efficacy. Other genes like SIGMAR1 and NMDA receptor subunits may also affect drug pharmacodynamics, though their roles are less clearly defined than CYP2D6."
PA450688,"Olanzapine metabolism involves CYP1A2 and CYP2D6 enzymes, where genetic variations can affect drug pharmacokinetics and lead to differing plasma concentrations, impacting clearance and risk of adverse effects. Additionally, variations in neurotransmitter receptor genes like HTR2A and DRD2, and the ABCB1 gene related to the blood-brain barrier, influence olanzapine's efficacy and side effects by affecting drug distribution and response at the cellular level."
PA450519,"Variants in transporter genes SLC22A6 and SLC22A7 can affect the absorption and elimination of Minocycline, altering its plasma levels and effects. Additionally, genetic changes in pharmacodynamic genes like IL1B, ALOX5, MMP9, and MAPK pathway genes (MAPK1, MAPK3, MAPK8) may influence individual responses to Minocycline by affecting inflammatory and apoptotic processes, potentially altering the drug’s efficacy and safety."
PA451976,"Zolpidem's metabolism is largely governed by the cytochrome P450 enzymes, particularly CYP3A4 and CYP2C9, whose genetic variants can alter drug levels and influence both the efficacy and safety of the drug, by affecting its plasma levels and clearance. Additionally, while zolpidem acts pharmacodynamically by enhancing the inhibitory action of GABA via GABA_A receptor subunits, the specific impacts of genetic variants on this mechanism are not well-delineated."
PA166252061,"Infigratinib's effectiveness in treating cholangiocarcinoma depends critically on FGFR2 gene alterations, necessitating genetic screening due to its significant pharmacogenetic interaction. Additionally, its pharmacokinetics are influenced by gene variations in CYP3A4, which affects metabolism, and in ABCB1 and ABCG2, which modify drug distribution, excretion, and plasma concentrations."
PA451735,"Tramadol's metabolism and efficacy are significantly influenced by genetic interactions, particularly with the CYP2D6 gene which controls its conversion to the active metabolite O-desmethyltramadol. Furthermore, additional genes such as CYP3A4, OPRM1, ABCB1, and COMT also play roles in its metabolism, transport, and pharmacodynamic effects, affecting both the analgesic effectiveness and the occurrence of side effects."
PA134687947,"Eletriptan, a drug for acute migraines, metabolizes chiefly via CYP3A4, with contributions from CYP2D6, CYP2C9, CYP2C19, and CYP2A6. Gene variations, especially in CYP3A4, affect its metabolism, influencing drug efficacy and safety. Eletriptan is also influenced by the P-glycoprotein transporter (ABCB1 gene) in terms of absorption and elimination, and interactions with the GNB3 gene's rs5443 SNP can predict treatment responses, impacting its clinical effects."
PA164754755,"Bepridil's metabolism is primarily influenced by the cytochrome P450 enzymes CYP2D6 and CYP3A4, where polymorphisms in these genes can significantly affect its metabolism rate and plasma concentrations, thereby impacting its safety and efficacy. Additionally, genetic variations in the transporter protein ABCB1 can affect bepridil's absorption and distribution, which also alters its pharmacokinetic profile."
PA166184081,"Nicorandil, used to treat chronic stable angina, interacts primarily with the ABCC9 gene, which is responsible for encoding components of ATP-sensitive potassium channels in cardiac and vascular smooth muscles. Variants in ABCC9 can affect the function of these channels, thereby impacting the drug's efficacy and safety by altering the flux of potassium ions across the cellular membranes, which influences membrane potential and muscle relaxation."
PA165860812,"Berberine's interaction with the CYP2D6 enzyme, which is crucial for its metabolism, can vary based on genetic variants in the CYP2D6 gene, affecting the drug's effectiveness and safety. This variation explains why different individuals experience different therapeutic and adverse effects from berberine."
PA451581,"Tamoxifen's effectiveness is significantly influenced by the gene CYP2D6, which is pivotal in converting the drug to its active form, endoxifen; variations in CYP2D6 can result in decreased efficacy due to lowered endoxifen levels. Other genes like CYP3A4, CYP3A5, ABCB1, various UGT family members, and additional enzymes and transporters such as CYP2C19 and SLCO1B1 also affect the metabolism and bioavailability of tamoxifen and its metabolites, further contributing to the pharmacokinetic variability observed in different patients."
PA449247,"The metabolism of dexamethasone is influenced by the CYP3A4 and CYP3A5 genes, where polymorphisms can significantly alter the drug's metabolism rates and systemic concentrations, necessitating potential dosage adjustments. Additionally, the drug's pharmacodynamics are affected by genetic variants in the NR3C1, HSD11B1, and ABCB1 genes, which modify its sensitivity, response, local effects in tissues, and distribution across cellular barriers, impacting both efficacy and side effect profiles."
PA10074,"Variants in the CYP2C19, CYP2D6, and CYP3A4 genes can affect the metabolism of escitalopram, leading to differences in drug efficacy and the likelihood of side effects. Additionally, polymorphisms in ABCB1, which influences drug distribution, and SLC6A4, which affects the function of the targeted serotonin transporter, can alter drug exposure and response, further influencing the pharmacodynamic outcomes of escitalopram treatment."
PA166235322,"Risdiplam functions as an mRNA splicing modifier of the SMN2 gene to alleviate SMN1 deficiency in spinal muscular atrophy, with its therapeutic effectiveness depending on the genetic variability of SMN2 copies. Additionally, its metabolism and efficacy are influenced by genetic polymorphisms in enzymes (FMO1, FMO3, CYP1A1, CYP2J2, CYP3A4, CYP3A7) and transporters (MATE1, MATE2-K, ABCB1, ABCG2), as well as potential variants in the albumin gene ALB, which can affect drug distribution and elimination."
PA448966,"Genetic variations in the CYP2C9 and CYP2C19 enzymes affect the metabolism of chlorpropamide, a drug used to manage Type 2 diabetes. Variants such as CYP2C9*2 and CYP2C9*3 decrease enzyme activity, resulting in slower drug metabolism and higher plasma concentrations, which increases the risk of hypoglycemia; thus, monitoring these genetic variations is important for appropriate dosing to avoid toxicity. Additionally, G6PD deficiency may heighten the risk of hemolytic anemia when using this medication."
PA164746157,"The pharmacogenetic interactions of mitotane are influenced by genes affecting its metabolism and transport, with CYP3A4 and CYP3A5 being primary enzymes for its metabolism and variations in these genes potentially altering mitotane's plasma levels and efficacy. Additionally, mitotane is a substrate of the transporter ABCB1, and variations in this gene could affect mitotane's pharmacokinetics and toxicity, while binding interactions with thyroxine-binding globulin (SERPINA7), sex hormone-binding globulin (SHBG), and corticosteroid-binding globulin (SERPINA6) could influence its distribution and activity in the body."
PA450150,"Genetic polymorphisms in enzymes CYP2C9 and UGT2B7 significantly affect the metabolism of ketorolac, influencing the drug's efficacy and safety. Variants in CYP2C9 can lead to variability in plasma levels of the drug, resulting in either increased risk of adverse effects or reduced efficacy, while variations in UGT2B7 impact its conjugation and excretion."
PA166242461,"Dihydrostreptomycin, an aminoglycoside antibiotic, exhibits ototoxicity primarily due to pharmacogenetic interactions involving the MT-RNR1 gene, which affects mitochondrial function crucial for energy production in the cochlea. These interactions are pharmacodynamic, focusing on how the drug influences cellular processes and leads to adverse effects rather than affecting drug metabolism and elimination."
PA166251581,"Genetic variations in the CYP2D6 enzyme significantly influence the metabolism of viloxazine, affecting individual responses and plasma concentrations of the drug. Additionally, variations in the SLC47A1 transporter impact the excretion of viloxazine, which can modify drug levels and action duration, while potential involvement of UGT1A9 and UGT2B15 through glucuronidation may further affect its pharmacokinetics."
PA450206,"Levetiracetam primarily interacts with the SV2A protein, enhancing its control over synaptic vesicle activity and neurotransmitter release, crucial for managing neuronal excitability and seizure propagation, with minimal genetic variability impacting this interaction. Additionally, levetiracetam's interaction with the CACNA1B gene and the ABCB1 transporter protein may affect its antiepileptic effects and pharmacokinetics, respectively, though these interactions' significance remains unclear due to limited evidence of pronounced pharmacogenetic impacts."
PA450164,"Lamotrigine's effectiveness and safety are influenced by the interactions of various genes affecting its pharmacokinetics and pharmacodynamics. Gene variants in UGT1A4 and UGT2B7 modify its metabolic rate, potentially altering drug clearance and increasing toxicity risks, while polymorphisms in ABCB1 affect drug distribution in the brain, impacting efficacy and side effects. Furthermore, variations in SCN1A and SCN2A, which encode sodium channel proteins, may influence lamotrigine’s mechanism in stabilizing neuronal membranes and controlling neuronal firing, crucial for its anticonvulsant effects."
PA166122593,"Sofosbuvir's pharmacogenetics involves its metabolism and transport influenced by genes such as CES1, which is crucial for the hydrolysis and activation of the prodrug, and CTSA that aids in its activation process. Variations in genes like ABCB1 and ABCG2, which are involved in the drug's absorption and distribution, as well as HINT1, which is involved in later stages of drug activation, can affect sofosbuvir's bioavailability, efficacy, and overall therapeutic outcomes."
PA166114929,"Homoharringtonine, used to treat chronic myeloid leukemia, may have variable treatment outcomes influenced by genetic variations in the ribosomal subunits and proteins like ABL1 and BCR, which are critical due to their involvement in the BCR-ABL1 fusion protein impacting drug sensitivity. Additionally, the ABCB1 gene affects the drug’s pharmacokinetics by regulating the efflux of the drug out of cells, which can indirectly modify its effectiveness."
PA448422,"Amprenavir's efficacy and safety are greatly influenced by its metabolism and transport, governed by key genes such as CYP3A4, CYP3A5, ABCB1, ABCC1, and SLCO1B1. Variations in these genes lead to differences in the drug's metabolism rates, efflux from cells, and hepatic uptake, thus requiring dosage adjustments to optimize therapeutic outcomes and minimize toxicity."
PA165958346,"Vildagliptin, a drug used in managing type II diabetes, interacts with the ABCB1 gene, which impacts its pharmacokinetics by potentially altering the expression or function of P-glycoprotein, affecting the drug’s absorption and distribution. Concurrently, although vildagliptin's direct pharmacodynamics mainly involves the DPP-4 enzyme and incretin hormones, variations in the GLP1R gene, encoding the GLP-1 receptor, may also indirectly influence the drug’s efficacy and safety by affecting the physiological response to these hormones."
PA166224201,"Capmatinib pharmacogenetic interactions involve mutations in the MET gene, which are crucial for predicting therapeutic responsiveness in NSCLC treatment, and variants in CYP3A4 that affect its metabolism. Additionally, genetic variations in transporters such as ABCB1, SLC47A1, SLC47A2, and ABCG2 influence the drug's bioavailability and excretion, impacting its efficacy and safety."
PA166189802,"Genetic variations in enzymes like CYP3A4, CYP2C19, CYP2B6, and CYP2C9 can significantly influence the metabolism of voxelotor, affecting its plasma levels, efficacy, and safety. While polymorphisms in these enzymes affect how the drug is metabolized, genetic variations in hemoglobin genes (HBB) do not impact voxelotor's mechanism, which targets and stabilizes hemoglobin to prevent sickling of red blood cells."
PA448432,"Anastrozole's effectiveness and side effect profile are significantly influenced by genetic variants in enzymes like CYP3A4, CYP3A5, CYP2C8, which are involved in its metabolism, and UGT enzymes such as UGT1A4, responsible for its glucuronidation. Additionally, transporter protein ABCB1 gene variations can affect the distribution and excretion of the drug, thereby impacting drug response among individuals."
PA450125,"Isosorbide dinitrate acts via vasodilation influenced by the NPR1 receptor, enhancing cGMP in vascular smooth muscles and reducing myocardial oxygen demand. The CYP2E1 gene's variability affects the drug's metabolism, potentially altering its clearance and efficacy, though the overall pharmacogenetic profile of this drug is not well-defined."
PA451249,"Rifabutin metabolism is significantly affected by the activity of cytochrome P450 enzymes such as CYP3A4, CYP2C9, CYP2C19, CYP2C8, and CYP2B6, as well as transport proteins like ABCB1 (P-glycoprotein). Genetic variants in these genes can alter the metabolic rate and distribution of rifabutin, leading to variations in drug efficacy and the risk of side effects such as uveitis or leukopenia."
PA164752812,"Milnacipran, an SNRI, targets neurotransmitter transporters such as SLC6A4 and SLC6A2 affecting serotonin and norepinephrine reuptake, and interacts with NMDA receptor subtypes (GRIN1, GRIN2A, etc.), possibly affecting glutamatergic neurotransmission. It is metabolized primarily by CYP3A4 and other CYP enzymes (CYP2C8, CYP2C19, CYP2D6, CYP2J2), where genetic variations can influence drug metabolism and patient response, indicating a potential need for personalized dosage adjustments based on these genetic factors."
PA166131581,"Dalcetrapib, a CETP inhibitor for treating acute coronary syndrome, has its efficacy potentially influenced by genetic variations in the ADCY9 gene. These gene variations can affect the pharmacodynamics of dalcetrapib, particularly in how it alters lipid metabolism or plaque stability in the arteries, thus impacting therapeutic responsiveness."
PA166131610,"Niraparib’s effectiveness and safety are influenced by genetic variations in multiple genes, such as BRCA1, BRCA2, PARP1, PARP2, CES1, ABCG2, and ABCB1. These genes affect the drug’s mechanism of action, metabolism, and disposition, with roles in DNA repair, drug targeting, and the pharmacokinetic profile, thus impacting individual therapeutic outcomes and necessitating personalized dosing strategies."
PA166268803,"Maralixibat inhibits SLC10A2 (IBAT) to reduce bile acid reabsorption in treating cholestatic pruritus associated with Alagille syndrome. Its metabolism and efficacy may be affected by genetic variations in CYP3A4, which can influence drug levels and response, and genetic variations in SLCO2B1 could alter its distribution, elimination, and bioavailability, leading to significant interpatient variability in treatment outcomes."
PA448641,"The pharmacogenetics of bisoprolol is influenced by gene interactions primarily with CYP3A4 and CYP2D6, which affect its metabolism, and ADRB1, which influences its pharmacodynamics by altering receptor sensitivity. Variations in these genes necessitate dose adjustments to optimize therapeutic effects and minimize side effects, while polymorphisms in ABCB1 also play a role in the drug’s transport and excretion, impacting its pharmacokinetic behavior."
PA166110256,"Bufuralol, a beta-blocker targeting ADRB1, ADRB2, and ADRB3 receptors, is metabolized by the CYP2D6 enzyme, which exhibits genetic variability affecting drug plasma levels and therapeutic outcomes. Individuals with different CYP2D6 genetic profiles, such as poor and ultrarapid metabolizers, may experience heightened risk of adverse effects or reduced drug efficacy, respectively, necessitating personalized dosing adjustments to optimize treatment effectiveness and safety."
PA166182002,"Amifampridine phosphate, used to treat Lambert-Eaton myasthenic syndrome by enhancing acetylcholine release via voltage-gated potassium channels, generally does not involve genetic factors in its pharmacodynamics. However, the NAT2 gene, involved in phase II acetylation reactions, could potentially influence the pharmacokinetics or pharmacodynamics of amifampridine phosphate indirectly through its metabolizing enzymes, although this connection remains speculative and not directly studied."
PA448406,"Amoxicillin interacts with specific genes that affect its pharmacokinetics and the risk of adverse reactions. The transport genes SLC15A1 and SLC22A6 influence its absorption and elimination, affecting its levels and efficacy, while variations in HLA gene variants like HLA-DRB1, HLA-A, and HLA-B are crucial in predisposing individuals to hypersensitivity reactions such as skin rashes and severe allergies. Although CYP2C19's role in amoxicillin metabolism is unclear, it may have an indirect effect on the drug's deamination processes."
PA164746007,"Genetic variations in metabolic enzymes CYP3A4 and CYP2D6 and transport proteins like ABCB1 significantly impact the pharmacokinetics of ranolazine, influencing its levels, efficacy, and safety. These genetic differences can lead to altered metabolism and transport of the drug, affecting therapeutic outcomes and the risk of adverse effects like QT prolongation."
PA448927,"Chloramphenicol metabolism is heavily influenced by cytochrome P450 enzymes such as CYP2C19, CYP3A4, CYP3A5, and CYP3A7, whose genetic polymorphisms can lead to variable drug metabolism rates, affecting drug efficacy and toxicity risks like aplastic anemia. Additionally, the distribution and elimination of chloramphenicol may be affected by genetic variants in the SLC22A6 transporter, while a genetic deficiency in G6PD poses a separate risk for hemolysis, which calls for careful consideration when using drugs causing oxidative stress."
PA166153469,"Variability in genes like CYP3A4 and SULT2A1, which are involved in the metabolism of palbociclib, can significantly impact the pharmacokinetics of the drug in individuals, affecting both its efficacy and risk of adverse effects. Additionally, genetic variations in transport proteins such as ABCB1 and ABCG2 may also modify the pharmacokinetic profile of palbociclib by altering its bioavailability and systemic clearance."
PA449688,"Fluvastatin's pharmacogenetic interactions involve its metabolism by the CYP2C9 enzyme, with its genetic variants influencing the drug's efficacy and safety by altering metabolism rates, thereby impacting plasma drug levels and potentially increasing the risk of adverse effects such as myopathy. Additionally, polymorphisms in the SLCO1B1 gene, encoding a liver transporter protein, affect fluvastatin's hepatic uptake, influencing its bioavailability and plasma concentrations, which can modify the drug’s toxicity risk."
PA164746334,"Cilostazol's pharmacogenetic effects are heavily influenced by its metabolism through various cytochrome P450 enzymes, notably CYP3A4 and CYP2C19, where genetic polymorphisms in these enzymes lead to variable drug levels and effects. Poor metabolization by CYP2C19 can cause higher drug concentrations, potentially increasing both cilostazol’s efficacy and the risk of side effects, while CYP3A4 plays a central role in its oxidative metabolism, affecting pharmacokinetics and thereby the drug’s overall effectiveness and safety profile."
PA449197,"Variants in the cytochrome P450 enzymes CYP1A1, CYP1A2, and CYP2E1 significantly affect the metabolism of dacarbazine, a drug used for treating malignant melanoma and Hodgkin's disease, influencing its efficacy and toxicity. Genetic polymorphisms in these enzymes can lead to variations in metabolism speed, causing either increased toxicity from higher systemic drug levels or decreased efficacy due to faster than usual drug breakdown."
PA451877,"Vinblastine's pharmacogenetics are influenced by its metabolism and transport involving CYP3A4 and CYP2D6 enzymes and ABCB1 and ABCC1 transporters. Variations in these genes can affect vinblastine's metabolic rate, plasma levels, distribution, and elimination, thereby impacting its therapeutic efficacy and toxicity, such as increasing risks of neutropenia or neurotoxicity."
PA162363968,"Lenalidomide’s interaction with the CRBN gene is vital for its antitumor effects as it mediates protein degradation critical for tumor cell survival and immune modulation, with variants in CRBN potentially altering the drug's efficacy. Additionally, lenalidomide is affected by the ABCB1 gene which influences its pharmacokinetics through drug efflux, with ABCB1 polymorphisms potentially impacting drug absorption, distribution, and side effects, while genetic variability in genes like TNFSF11, CDH5, and PTGS2 could affect its anti-angiogenic and anti-inflammatory actions."
PA166118341,"Vandetanib's interaction with key genes like CYP3A4, ABCB1, SLC22A2, RET, EGFR, and VEGFR influences its metabolism, absorption, and anti-tumor effects, affecting drug efficacy and toxicity. Genetic variations in these genes can lead to differences in how patients metabolize the drug, respond to treatment, and experience side effects, making tailored therapy based on these genetic profiles critical for optimizing treatment outcomes."
PA165282097,"Polymorphisms in the dopamine D2 receptor gene (DRD2) may affect the efficacy of bromperidol, a butyrophenone antipsychotic, by altering receptor binding, while genetic variations in the cytochrome P450 enzyme CYP2D6 can significantly influence the drug's pharmacokinetics. These genetic factors are critical in determining both the therapeutic effectiveness and the side effect profile of bromperidol, necessitating consideration for personalized treatment strategies."
PA449381,"Dobutamine's effectiveness and safety are influenced by its interaction with genes like ADRB1, ADRB2, ADRA1A, ADRA1B, and ADRA1D, which affect its pharmacodynamic properties, and COMT, which affects its metabolism. Variations in these genes can alter myocardial contractility, metabolic clearance, and drug response, requiring potential dose adjustments."
PA166163415,"The effectiveness and safety of velpatasvir, a drug used in treating hepatitis C, are significantly influenced by genetic variations in metabolic enzymes (CYP2B6, CYP2C8, and CYP3A4) and transporters (ABCB1, ABCG2, SLCO1B1, SLCO1B3, and SLCO2B1). Polymorphisms in these genes can alter the drug's metabolism and transport, impacting its plasma concentrations, which may affect therapeutic outcomes and potential toxicity, thereby necessitating tailored dosing and monitoring."
PA449061,"Clozapine metabolism is significantly affected by variations in the genes CYP1A2, CYP2D6, and CYP3A4, with polymorphisms in these genes influencing the drug's plasma levels and risk of adverse effects. Additionally, pharmacodynamic interactions involve genes like HTR2C and DRD2, which encode receptors targeted by clozapine and influence its efficacy and side effects, with gene variations possibly affecting the therapeutic response and side effect susceptibility."
PA451527,"Variants in the CYP3A4 gene significantly impact the metabolism of sufentanil, affecting its efficacy and safety by altering drug exposure. Additionally, genetic differences in μ-opioid receptors (encoded by OPRM1), as well as δ-type (OPRD1) and κ-type (OPRK1) receptors, and other genes like ABCB1, CYP3A5, COMT, and NFKBIA, influence patient responses in terms of analgesic effects and side effect profiles, as well as sufentanil's distribution, elimination, and overall pharmacodynamics. This highlights the importance of genetic factors in determining the pharmacological action and patient-specific outcomes of using sufentanil."
PA451494,"Stavudine, an HIV drug categorized under nucleoside reverse transcriptase inhibitors, predominantly interacts through genetic pathways that influence its cellular uptake rather than its metabolism due to minimal liver enzyme involvement. The transporter genes SLC22A6 and SLC28A1 play vital roles in its absorption and distribution, with genetic variants in these genes potentially affecting the drug's effectiveness and toxicity due to altered pharmacokinetic profiles."
PA451614,"Terbinafine metabolism is significantly impacted by genetic variations in cytochrome P450 enzymes, such as CYP2C9, CYP1A2, CYP3A4, and CYP2C19, which undertake processes like deamination, hydroxylation, and N-demethylation. Variants in these genes can alter drug metabolism rates, impacting terbinafine's efficacy and safety, leading to potential adverse effects like hepatotoxicity; additionally, interactions with HLA-A may influence immune-mediated adverse reactions, such as cutaneous effects."
PA166128806,"Variations in the ABCB1 gene, which encodes P-glycoprotein, significantly impact the pharmacokinetics of the factor Xa inhibitor edoxaban by affecting its absorption and plasma levels due to altered efflux across the intestinal barrier. While edoxaban undergoes minor metabolism via CYP3A4, its effects on edoxaban are not considered a significant pharmacogenetic interaction, highlighting ABCB1 as the predominant gene influencing edoxaban's pharmacokinetic profile."
PA449212,"Daunorubicin interacts with genes such as CBR1, which converts it into its active metabolite daunorubicinol, influencing cardiotoxicity, and ABCB1, which encodes for P-glycoprotein that can pump the drug out of cells, altering effectiveness and side effect profiles. Other genes like SZRD1, MAN1B1, G6PD, SLCO1B1, UGT1A1, TPMT, SLC28A3, and SLC22A17 also contribute to its pharmacokinetics and pharmacodynamics by affecting drug metabolism, transport, susceptibility to oxidative stress, and cellular uptake, impacting the drug's efficacy and toxicity."
PA164748978,"Sitagliptin's interactions with metabolic enzymes CYP3A4 and CYP2C8, as well as transporters ABCB1 and SLC22A8, substantially influence its pharmacokinetics by affecting the drug's plasma levels, absorption, and renal excretion. Additionally, genetic variations in the GLP1R gene could impact the drug’s therapeutic efficacy through alterations in the incretin response, which is central to sitagliptin’s glucose-lowering effect."
PA448368,"Amiloride's pharmacogenetic interaction is primarily influenced by its interaction with the genes SCNN1A, SCNN1B, SCNN1G, and SCNN1D, which encode the subunits of epithelial sodium channels crucial for its potassium-sparing effect by blocking sodium reabsorption in the kidneys. Additionally, amiloride's pharmacodynamics involve acid-sensing ion channels (ASIC1 and ASIC2) and the enzyme AOC1, which could influence pain perception and pharmacokinetics, while transporter genes like SLC22A2 and SLC22A4 impact its renal handling and excretion."
PA166201941,"Genetic variants in key transport proteins like OAT1 (SLC22A6) and OAT3 (SLC22A8) can significantly affect the pharmacokinetics of Tenofovir disoproxil fumarate (TDF), influencing drug clearance and potentially leading to differences in drug levels and toxicity, such as nephrotoxicity. Additionally, interactions with other genes such as ABCC2, ABCC4, CYP27B1, CYP24A1, and SLC28A2 may impact TDF's disposition, effectiveness, and side effects, including its bone toxicity and intracellular activation, which are crucial for tailoring effective and safe therapy for treating HIV and hepatitis B."
PA164746899,"Phenazopyridine functions as a local anesthetic likely by inhibiting the sodium channel subunit SCN1A, reducing pain by dampening nerve signal transmission. It poses increased risk of hemolysis in individuals with G6PD gene variants and can lead to methemoglobinemia in those with deficiencies affecting methemoglobin reductase, especially in overdose situations, highlighting its critical pharmacogenetic interactions regarding toxicity due to inherited enzymatic deficiencies."
PA451731,"Toremifene's effectiveness and safety are influenced by genetic interactions with CYP3A4, which is pivotal for its metabolism, ABCB1 which affects the drug's distribution and excretion, and ESR1, a receptor gene that defines the drug’s pharmacodynamics by altering its actions in tissues. Genetic variations in these genes can significantly impact the metabolism, bioavailability, and clinical effectiveness of Toremifene in treating breast cancer."
PA449479,"The drug epoprostenol's efficacy and safety are influenced by genetic variations in PTGIS, PTGIR, and potentially PTGS2. PTGIS is crucial for synthesizing prostacyclin from arachidonic acid, affecting drug levels and response, while PTGIR mediates the drug effects on smooth muscle relaxation and platelet function through cyclic AMP, with genetic variations potentially impacting therapeutic efficacy. PTGS2, though less directly involved, could also influence the prostaglandin pathway, affecting the drug’s overall effects."
PA164778930,"Genetic variations in the SLC6A8 gene significantly affect the creatine transportation system which is vital for its uptake into muscle and brain cells, potentially leading to conditions like cerebral creatine deficiency syndromes. Additionally, genes such as CKM, CKB, CKMT1A, and CKMT2, which regulate the metabolism of creatine into phosphocreatine, influence the effectiveness of ATP replenishment during high-energy demands, thereby affecting muscle performance and recovery. Variants in the SLC22A5 gene may also theoretically influence creatine transport due to its role in organic cation transport."
PA449958,"Ibutilide, a drug used for treating atrial arrhythmias, interacts pharmacodynamically with genes regulating ion channels, notably CACNA1C, CACNB1, CACNA2D1 for L-type calcium channels, and KCNH2 for the hERG potassium channel, which are essential for action potential duration and cardiac repolarization. Variability in these genes, especially KCNH2, can impact the risk of drug-induced arrhythmias like torsades de pointes, crucial for understanding the drug’s safety and efficacy."
PA166169881,"Deutetrabenazine's pharmacogenetic interactions primarily involve the genes SLC18A2, CBR1, CBR3, CYP2D6, CYP1A2, and CYP3A4/5, with SLC18A2 crucial for its mechanism of action by inhibiting VMAT2 to reduce neurotransmitter release, aiding in the treatment of movement disorders. Variations in CYP2D6 significantly affect deutetrabenazine metabolism and patient response, influencing the formation of its active metabolites α-HTBZ and β-HTBZ, thus impacting both efficacy and potential adverse effects, which calls for personalized dosing strategies based on individual genetic makeup."
PA450267,"Lorazepam metabolism is significantly influenced by the UGT2B15 gene, where genetic variants can slow metabolism leading to prolonged drug effects and heightened side effects like excessive sedation. Other enzymes such as CYP2C8 and UGT2B7 also affect its metabolism to a lesser degree, with CYP2C8 making a minor contribution and UGT2B7 assisting in glucuronidation alongside UGT2B15."
PA166177519,"Umeclidinium, used in managing COPD, is metabolized primarily by the cytochrome P450 enzyme CYP2D6, and its pharmacokinetics are also influenced by the transport proteins ABCB1, SLC22A1, and SLC22A2, affecting the drug's distribution and elimination. These genetic variations can lead to different drug exposures in individuals, impacting the efficacy and safety of the drug; moreover, genetic variants in muscarinic receptor genes (CHRM1-CHRM5) could also influence responses to the drug, although their clinical relevance has not been fully established."
PA164745398,"Butorphanol, an opioid analgesic, interacts with the μ-opioid receptor (OPRM1), κ-opioid receptor (OPRK1), and to a lesser extent, the δ-opioid receptor (OPRD1), which dictate its effects and antagonist properties. Variants in these receptor genes (OPRM1, OPRK1, OPRD1) may impact the drug's efficacy and safety, influencing its analgesic potency and the occurrence of adverse effects such as opioid-induced hyperalgesia or reduced effectiveness."
PA165958376,"The pharmacokinetics of fesoterodine, a prodrug metabolized into 5-hydroxymethyl tolterodine primarily via plasma esterases and then by CYP2D6 and CYP3A4, are significantly influenced by genetic variations in CYP2D6 and CYP3A4. Variations in CYP2D6 can lead to different rates of metabolism, affecting the drug's efficacy and safety, while CYP3A4 variations alter drug exposure and effectiveness. These genetic interactions affect how the active metabolite acts on muscarinic receptors involved in bladder contraction, impacting both drug concentration and pharmacodynamics."
PA450144,"Ketamine's pharmacogenetic interactions involve its metabolism by cytochrome P450 enzymes, including CYP2B6, CYP3A4, and CYP2C9, which affect its clearance and action due to individual genetic variations. These variations influence ketamine's efficacy and safety, creating differences in therapeutic effects and side effects among individuals. Additionally, genetic polymorphisms in receptor genes like GRIN2B and BDNF may alter ketamine's pharmacodynamics, affecting its effectiveness as an anesthetic and its antidepressant properties."
PA450395,"Genetic variations in genes such as SLC22A1, SLC22A2, SLC22A3 (encoding OCT1, OCT2, and OCT3), and SLC47A1, SLC47A2 (encoding MATE1 and MATE2) significantly influence the pharmacokinetics and pharmacodynamics of metformin by affecting drug transport, metabolism, and excretion. These variations can alter metformin's effectiveness and safety, impacting its ability to control blood glucose and its risk of causing lactic acidosis."
PA448682,"Bumetanide's effectiveness and side effects are influenced by genetic variations in the PTGS2 gene, affecting its metabolism, and in the SLC22A6, SLC22A8, and SLC10A1 genes, impacting its renal excretion. These genetic differences may lead to variability in plasma levels of the drug, consequently affecting both its efficacy and toxicity."
PA166268761,"Belzutifan metabolism and transport are influenced by specific genes such as UGT2B17, CYP2C19, and CYP3A4, where genetic variations in CYP2C19 significantly affect the drug's pharmacokinetics, altering plasma levels and impacting efficacy and safety. Additionally, transporter genes like ABCB1, SLCO1B1, SLCO1B3, and SLC47A2 play roles in the drug's absorption and elimination, affecting its bioavailability and clearance, which are crucial for personalized dosing strategies."
PA450226,"Genetic variations in the CYP3A4 and CYP2D6 enzymes significantly impact the metabolism of lidocaine, affecting its plasma concentration and duration of action; individuals with reduced enzyme activity may experience higher plasma levels and increased risk of toxicity. Additionally, lidocaine's effectiveness and safety are influenced by its interaction with sodium channels such as SCN10A, SCN9A, SCN5A, and SCN4A, which it blocks to achieve its anesthetic and antiarrhythmic effects."
PA165958395,"The metabolism of lornoxicam is primarily influenced by the CYP2C9 enzyme, with genetic variants such as CYP2C9*2 and CYP2C9*3 leading to reduced enzyme activity and resulting in slower drug metabolism. This genetic variation can cause prolonged exposure to lornoxicam, increasing the risk of side effects like gastrointestinal and renal issues, thus highlighting the importance of genetic testing for CYP2C9 variants to customize lornoxicam dosage for safer and more effective use."
PA166171182,"The pharmacogenetic interactions of voxilaprevir are primarily influenced by its metabolism and transport involving genes such as CYP3A4, CYP2C8, CYP1A2, ABCB1, ABCG2, SLCO1B1, and SLCO1B3. Variations in these enzymes and transporters affect the metabolic rate and pharmacokinetics of voxilaprevir, altering drug plasma levels, concentration in the body, and impacting efficacy and toxicity."
PA165981154,"Afatinib's pharmacogenetic interactions are primarily determined by variations in the EGFR gene, with sensitizing mutations like exon 19 deletions and the L858R substitution in exon 21 enhancing drug response, and resistance mutations such as T790M reducing efficacy in NSCLC treatment. Further, while not detailed, the pharmacokinetic behavior of afatinib might be affected by polymorphisms in efflux transporter genes like ABCB1 and ABCG2, altering drug levels and responses."
PA450121,"Isoprenaline's pharmacodynamics are influenced by its interaction with ADRB1, ADRB2, and ADRB3 genes, which encode for beta-1, beta-2, and beta-3 adrenergic receptors, affecting clinical responses such as heart rate changes and bronchodilation. Pharmacokinetically, COMT, CYP1A1, and CYP1B1 are significant as they metabolize isoprenaline, with genetic variations in these enzymes potentially affecting the drug's clearance, efficacy, and safety."
PA164776671,"Cinacalcet's interaction with the CASR gene influences its pharmacodynamic efficacy by affecting how the drug mimics calcium and regulates PTH secretion. In terms of pharmacokinetics, variations in the cytochrome P450 enzymes CYP3A4, CYP2D6, and CYP1A2, which metabolize cinacalcet in the liver, can significantly alter drug levels by affecting the rate of metabolism, thus impacting the drug's effectiveness and potential for adverse effects."
PA448946,"The metabolism of chloroprocaine is chiefly influenced by the BCHE gene, where genetic variations can affect the drug’s metabolic rate, impacting its clearance and duration of action, potentially leading to prolonged effects and increased toxicity in individuals with decreased BCHE activity. Additionally, genes such as CYB5R3 and G6PD also affect chloroprocaine's response, with CYB5R3 influencing drug metabolism through electron transfer processes, and G6PD deficiencies increasing oxidative stress risks, which may affect recovery post-anesthesia."
PA449376,"Disulfiram inhibits the enzyme ALDH2, escalating acetaldehyde syndrome symptoms to deter alcohol consumption, with its effectiveness and safety impacted by ALDH2 genetic variants, especially in East Asian populations. Additionally, disulfiram's metabolism by cytochrome P450 enzymes, such as CYP3A4, CYP3A5, and CYP2E1, and its potential interactions with dopamine metabolism through DBH and genes like DRD2 and ANKK1, suggest that genetic variability can significantly influence both the metabolic rate and neurological effects of the drug."
PA165374673,"Ticagrelor's metabolism is significantly influenced by CYP3A4 and CYP3A5 gene variants, which affect the drug's active concentration in the body, altering its effectiveness and safety. Additionally, variations in the ABCB1 gene, which encodes P-glycoprotein, impact ticagrelor's absorption, excretion, and ultimately its plasma concentrations, thereby affecting both its efficacy and risk profile."
PA10005,"The effectiveness and safety of adefovir dipivoxil, primarily affected by its renal elimination and activation mechanisms, are influenced by genetic variations in specific transporters and kinases. Variants in the transporters SLC22A6 and ABCC4 may affect drug clearance and toxicity, while polymorphisms in kinases like AK2, AK4, NME1, and NME2 could alter the activation of the prodrug, impacting its antiviral efficacy."
PA10227,"Variations in esterase-related genes may impact the hydrolysis of valganciclovir, a prodrug of ganciclovir, while genetic variability in solute carrier genes SLC15A1, SLC15A2, and SLC6A14 can influence its absorption and bioavailability. Additionally, gene variants in ABCB1 and ABCC4, involved in drug transport and efflux, may alter the distribution and elimination of ganciclovir, potentially affecting the drug's effectiveness and toxicity profile."
PA166163411,"Genetic variations in the enzymes CYP2C8, CYP3A4, and UGT1A1 significantly influence the metabolism of dasabuvir, a drug used to treat hepatitis C, potentially affecting the drug’s levels, efficacy, and side effects. Additionally, genetic variants in transport proteins ABCG2, ABCB1, and ABCB5, as well as in the IFNL3 gene, which impacts immune response, can also modify how dasabuvir is distributed, eliminated, and how it interacts with the host's antiviral response, respectively."
PA451991,"4-Methoxybenzenesulfinate interacts with MMP13 and MMP3, which are involved in tissue remodeling and matrix degradation. Genetic variations in these genes could potentially affect the drug's effectiveness by altering expression or activity of these enzymes, influencing the outcomes of drug therapy, although this impact is currently based on educated assumptions rather than confirmed data."
PA166129539,"Silibinin's pharmacogenetic interactions include its metabolism mediated by the UGT1A1 gene, which is crucial for its glucuronidation and elimination; variations in this gene can affect silibinin’s therapeutic levels and toxicity. Additionally, transporter genes such as SLC22A6, SLCO1B1, SLCO1B3, and SLCO2B1, which are involved in silibinin’s hepatic uptake and systemic distribution, may impact its pharmacokinetics by altering drug absorption, distribution, and clearance, affecting drug efficacy and safety."
PA451744,"Variants in the CYP3A4 and CYP2D6 genes influence the metabolism of trazodone, affecting its plasma concentration and thus its therapeutic outcomes and side effects. Additionally, genetic variations in serotonin-related genes, including SLC6A4, HTR2A, and HTR2C, influence the pharmacodynamics of trazodone by affecting serotonin transport and receptor interaction, which are critical for its antidepressant efficacy and side effects like weight gain or sexual dysfunction. Furthermore, the ABCB1 gene impacts the transport of trazodone across the blood-brain barrier, influencing its effectiveness and side effects by altering brain levels. These genetic interactions are pivotal in tailoring personalized trazodone therapy."
PA450428,"Methotrexate (MTX) has pharmacogenetic interactions involving several key genes, such as MTHFR which affects MTX metabolism through folate pathway alterations leading to increased toxicity risk, TPMT that impacts MTX response via thiopurine metabolism, and various transport genes including ABCB1 and SLCO1B1 which alter MTX's pharmacokinetics through effects on drug efflux and hepatic uptake respectively. These genetic factors collectively influence MTX's efficacy and toxicity, guiding personalized dosing strategies to optimize treatment outcomes and minimize adverse effects."
PA451566,"Sumatriptan, a serotonin receptor agonist used for migraines, primarily metabolizes via MAOA and interacts pharmacogenetically with several genes. Notably, the GNB3 gene's rs5443 polymorphism is linked with improved responses in cluster headache patients, suggesting its relevance in personalized medicine, while transporter genes like ABCB1 and ABCG2, and genes such as OPRM1, COMT, DBH, BDNF, HTR2A, and DRD2, affect its pharmacokinetics and pharmacodynamics, potentially influencing drug effectiveness and side effects through their roles in neurotransmission and pain pathways."
PA166182748,"Lusutrombopag's metabolism is significantly influenced by the CYP4A11 gene, with genetic variations affecting how quickly the drug is metabolized, and thus its levels and effectiveness. Additionally, genes ABCB1 and ABCG2, encoding transport proteins, impact the drug’s absorption and excretion, altering its bioavailability and required dosage. These interactions are crucial for optimizing treatment effectiveness and minimizing adverse effects in individuals."
PA131625240,"Variations in the TYMS gene can affect the efficacy and toxicity of raltitrexed, an antimetabolite used in colorectal cancer, as these polymorphisms alter enzyme expression or activity, and thus influence the drug's ability to inhibit thymidylate synthase. Additionally, the genes encoding for the reduced folate carrier and folylpolyglutamate synthase (FPGS) are important as they modulate the pharmacokinetics of raltitrexed by affecting how the drug is transported into and retained in cells, respectively."
PA451316,"Selegiline, an MAO-B inhibitor, has pharmacogenetic interactions with multiple cytochrome P450 enzymes (including CYP2B6, CYP3A4, CYP2A6, CYP1A2, CYP2C19, CYP2C8, CYP2C9, and CYP2D6) and the transporter gene ABCB1, which affect its metabolism and pharmacokinetics. Variations in these genes can lead to differences in the metabolism, efficacy, safety, and brain availability of Selegiline, necessitating potential dose adjustments or monitoring to optimize treatment outcomes and minimize adverse effects."
PA164781042,"Genetic variants in the CYP3A4 gene can significantly influence the metabolism of flucloxacillin, affecting its efficacy and adverse effects due to variations in drug plasma levels. Additionally, variations in the ABCB11 gene affect the transport and clearance of flucloxacillin, which can modify its pharmacokinetics, while specific HLA alleles like HLA-B*57:01 are linked to hypersensitivity reactions, impacting the drug's pharmacodynamics and overall clinical outcomes."
PA449563,"Exemestane, a potent aromatase inhibitor used in hormone-receptor-positive breast cancer, is metabolized mainly by CYP3A4 and acts by irreversibly binding to CYP19A1, an enzyme crucial for estrogen synthesis. Genetic variations in CYP19A1 and CYP3A4 can significantly affect the efficacy and safety of Exemestane, influencing both estrogen levels necessary for its therapeutic action and the drug’s pharmacokinetics, which may necessitate dose adjustments."
nan-237fff83-c685-4caf-8d2a-f4cf7ea74cd5,"The pharmacokinetics of piperaquine are affected by the activity of various cytochrome P450 enzymes such as CYP3A4, CYP2C19, CYP2C9, CYP2B6, and CYP2E1, with variations in these genes impacting the drug's metabolism and, consequently, its efficacy and safety. Genetic polymorphisms, particularly in CYP2C19, can lead to altered metabolic rates, affecting plasma levels of piperaquine and potentially leading to therapeutic failures or toxicity due to changes in drug clearance and bioavailability."
PA450198,"Levoleucovorin, used in methotrexate treatments and with 5-fluorouracil in colorectal cancer, is metabolically activated to 5-methyltetrahydrofolate, which primarily involves the folate cycle where the enzyme SHMT1 plays a key role; polymorphisms in SHMT1 may affect its efficacy by altering DNA synthesis. Other genes like ABCC2 and UMPS also affect levoleucovorin's pharmacokinetics and synergistic effects with 5-fluorouracil, involving processes of drug transport and pyrimidine metabolism, respectively, thereby influencing therapeutic outcomes."
PA166114943,"Regorafenib's metabolism primarily involves liver enzymes CYP3A4, CYP2C8, CYP2C9, CYP2B6, and glucuronidation enzymes UGT1A9 and UGT1A1, with genetic polymorphisms in CYP3A4 and UGT1A1 significantly influencing its pharmacokinetics. Furthermore, the transport of its active metabolites M-2 and M-5 by ABCB1 and ABCG2 transporters can be affected by genetic variants in these genes, altering the drug's distribution and excretion, thereby affecting its effectiveness and toxicity profiles."
PA451262,"Rivastigmine's effectiveness in managing dementia symptoms in Alzheimer's and Parkinson's disease is predominantly influenced by its interactions with the ACHE and BCHE genes, which encode acetylcholinesterase and butyrylcholinesterase, enzymes vital in acetylcholine metabolism. Genetic variations in these genes can alter acetylcholine hydrolysis rates, impacting the drug's efficacy and safety by influencing the availability of acetylcholine in the brain."
PA166123415,"Ivabradine's pharmacokinetic properties are significantly affected by genetic polymorphisms in the CYP3A4 enzyme, which metabolizes the drug in the liver, leading to variations in drug efficacy and safety due to different metabolic rates among individuals. Additionally, the drug's pharmacodynamic interaction involves the HCN2 gene, which affects the heart rate-lowering effect of ivabradine, although this interaction is not yet well characterized."
PA448419,"Variations in genes encoding penicillin-binding proteins (PBPs) can affect the efficacy of Ampicillin by modifying drug-target interactions, impacting its pharmacodynamics. Additionally, genetic differences in transporters like SLC22A5, SLC15A1, and SLC15A2, as well as ALB, which serves as a carrier molecule, can influence the pharmacokinetics of Ampicillin by altering its absorption, distribution, and elimination, thereby changing drug exposure and response."
PA165291492,"Genetic variations in the CYP3A4 enzyme, responsible for metabolizing pazopanib, significantly influence the drug's pharmacokinetics, impacting drug concentrations and potentially altering treatment outcomes and toxicity levels. Moreover, variations in the ABCB1 and ABCG2 transporters and the UGT1A1 gene affect the distribution, elimination, and metabolism of pazopanib, respectively, contributing to differences in drug exposure and side effects such as hyperbilirubinemia. This highlights the complex interaction between genetic factors and pazopanib's pharmacokinetics and pharmacodynamics, underscoring the need for personalized dosing and management strategies in treatment with this drug."
PA451100,"Prednisone is metabolized by enzymes such as CYP3A4, CYP3A5, and CYP2C19 affecting its pharmacokinetics through variations in metabolization rates, and influenced by transporter proteins like ABCB1 and variations in the glucocorticoid receptor (NR3C1), altering its absorption, distribution, effectiveness, and side effect profile due to changes in P-glycoprotein function and receptor sensitivity or expression. These genetic factors contribute substantially to individual differences in response to the drug, making pharmacogenetic awareness crucial for optimizing treatment efficacy and reducing adverse effects."
PA450522,"Mirtazapine, a tetracyclic antidepressant, shows pharmacogenetic variability tied to its metabolism and receptor interactions, primarily influenced by cytochrome P450 enzymes (CYP2B6, CYP2D6, CYP3A4) and serotonin receptor genes (HTR2C, SLC6A4). Genetic variations in these enzymes and receptors can significantly alter mirtazapine's plasma levels and its antidepressant and anxiolytic effects, impacting both its efficacy and safety."
PA450433,"Methoxsalen is metabolized by the cytochrome P450 enzymes CYP1A1, CYP1A2, CYP2A6, and CYP2A13, and variations in the genes encoding these enzymes can affect the drug's metabolic rate, influencing its efficacy and safety. Genetic polymorphisms in these enzymes can lead to differences in Metoxsalen's metabolism, altering drug levels, therapeutic outcomes, and the risk of adverse effects."
PA162364313,"Bezafibrate's interactions are influenced by genetic variants in PPAR genes (PPARA, PPARG, PPARD) which affect its efficacy in modulating lipid levels, and by polymorphisms in metabolic enzymes (CYP1A1, CYP2C8, CYP3A4) and the transporter gene SLCO1B1 that alter the drug's metabolism and plasma concentrations, impacting its overall effectiveness and safety."
PA450640,"Nitrofurantoin's effectiveness and safety are influenced by polymorphisms in human transporter genes such as ABCG2, ABCB11, ABCB1, and ABCC2, which affect the drug's efflux, distribution, and excretion, and by the G6PD gene, where variations increase the risk of hemolysis in individuals with G6PD deficiency, particularly because the drug can induce oxidative stress. Although primarily acting through bacterial enzymes, these human genetic factors significantly impact the drug's clinical use and patient response."
PA451868,"Verapamil's pharmacogenetic interactions involve its metabolism, which is predominantly managed by the liver enzymes CYP3A4 and CYP3A5, with genetic variations in these enzymes affecting the drug's metabolic rate, plasma levels, and efficacy. Additionally, its interaction with the transporter protein ABCB1 influences its bioavailability and distribution across cell membranes, while pharmacodynamic interactions with genes like ADRB1 can affect dosage requirements, particularly for cardiovascular treatments, highlighting the need for personalized medication strategies based on individual genetic profiles."
PA152031327,"Geldanamycin, an HSP90 inhibitor, targets the HSP90 isoforms HSP90B1, HSP90AA1, and HSP90AB1, disrupting the protein folding activity crucial for the survival of cancer cells by promoting the degradation of oncogenic client proteins like EGFR. Genetic variations in these HSP90 isoforms and their client proteins may influence the effectiveness of geldanamycin by affecting how this drug induces degradation of these proteins, ultimately impacting therapeutic outcomes in cancer treatment."
PA166178387,"The effectiveness and safety of iguratimod, used for rheumatoid arthritis, could be influenced by genetic variations in genes like NAT2, ABCG2, ABCB1, and CYP2C19, which impact drug metabolism, distribution, and elimination, potentially affecting iguratimod's degradation, efficacy, and toxicity."
PA166182736,"Siponimod, an S1P receptor modulator used in treating relapsing multiple sclerosis, primarily interacts with CYP2C9, which is responsible for its metabolism. Genetic variations in CYP2C9 can lead to different metabolic rates of Siponimod, affecting drug levels in the blood and influencing both efficacy and potential adverse effects; as such, these variations necessitate individualized dosing adjustments to optimize treatment safety and effectiveness."
PA166160632,"Nucleotide analogs like thioguanosine diphosphate (thio-GDP) may interact pharmacogenetically with genes involved in their metabolic pathways. For instance, variations in the TPMT gene, which is involved in metabolizing thiopurines, could potentially affect the activity, toxicity, or efficacy of thio-GDP, assuming it has a similar metabolism. Additionally, mutations in genes encoding enzymes like kinases or polymerases that might metabolize thio-GDP, or transporters aiding its cellular uptake or efflux, can also impact its pharmacological effects."
PA166182767,"Gilteritinib's effectiveness and safety for treating AML are influenced by variations in the FLT3 gene, which determine the drug’s targetability, and by polymorphisms in CYP3A4, ABCB1, and ABCG2 genes that affect its metabolism, absorption, and excretion. These genetic interactions significantly impact both the pharmacodynamics, with FLT3 mutations influencing efficacy as a tyrosine kinase inhibitor, and the pharmacokinetics involving the ADME properties of gilteritinib."
PA165945764,"Bucindolol's interaction with genes CYP2D6, ADRA2C, and ADRB1 affects its metabolism and effectiveness. Variability in CYP2D6 influences bucindolol's pharmacokinetics, impacting drug levels and patient responses, while genetic variants in ADRA2C and ADRB1 alter the functionality and expression of beta-adrenergic receptors, affecting the drug's impact on heart rate and myocardial contractility."
PA166131262,"The gene CYP2A6 significantly influences the metabolism of 3-hydroxycotinine by affecting the conversion rate of nicotine to cotinine and subsequently to 3-hydroxycotinine, with genetic variations resulting in individuals metabolizing nicotine at different rates. This interaction primarily pertains to pharmacokinetics, as 3-hydroxycotinine does not engage pharmacologically with other targets."
PA164746820,"Fosphenytoin's metabolism into phenytoin is mainly facilitated by CYP2C9 and CYP2C19 enzymes; variants in these genes can significantly influence metabolic rates and plasma levels of phenytoin, impacting drug efficacy and risk of toxicity. Genetic variations like CYP2C19 loss-of-function alleles (*2, *3) decrease metabolism, necessitating genotype-guided dosing for optimal therapeutic outcomes, while other genes such as HLA-B may influence hypersensitivity reactions to the drug."
PA166129557,"Lurasidone metabolism is significantly affected by variations in the CYP3A4 gene, leading to differences in its effectiveness and safety due to altered enzyme activity that impacts drug exposure. Additionally, the drug's action on 5-HT1A receptors is influenced by genetic variants in the HTR1A gene, affecting its ability to modulate serotonergic neurotransmission, which is crucial for its efficacy in treating psychiatric conditions."
PA166129446,"The genes CYP3A4 and SLCO1B1 are central to the pharmacogenetics of simvastatin, influencing its metabolism and transport. Variants in CYP3A4 affect the conversion of simvastatin to its active form, simvastatin acid, thereby altering drug efficacy, while polymorphisms in SLCO1B1 can modify hepatic uptake and increase the risk of adverse effects such as myopathy by affecting the plasma levels of simvastatin acid."
PA452615,"Moclobemide, a selective reversible inhibitor of monoamine oxidase A (MAOA), is affected by genetic variations in the MAOA and MAOB genes, which can influence the drug's effectiveness by impacting neurotransmitter levels and monoamine catabolism. Additionally, its metabolism is influenced by polymorphisms in CYP2C19 and CYP2D6, affecting the drug’s bioavailability and necessitating dosage adjustments to optimize safety and efficacy based on different metabolizer statuses ranging from poor to ultra-rapid."
PA450601,"Nedocromil's effectiveness in treating asthma is influenced by genetic variations in its target genes—CYSLTR1, CYSLTR2, PTGDR, FPR1, and HSP90AA1—which impact cellular responses such as leukotriene receptor function, prostaglandin D2 signaling, peptide-mediated inflammation, and protein folding. These genetic differences can lead to variability in how individuals respond to the drug, affecting its anti-inflammatory efficacy and individual therapeutic outcomes."
PA164754818,"Betamethasone's interaction with the glucocorticoid receptor gene (NR3C1) and polymorphisms in this gene can affect sensitivity to the drug, impacting therapeutic and adverse responses. Additionally, genes like CYP3A4, CYP3A5, and ABCB1, which are involved in the metabolism and transport of betamethasone, harbor variations that might alter the drug's clearance and systemic availability, thereby affecting dosing requirements and overall drug effectiveness."
PA166182743,"Lorlatinib, a drug used for ALK-positive metastatic NSCLC, is metabolized by the enzymes CYP3A4 and CYP3A5, whose genetic variations can significantly influence the drug's plasma concentration, effectiveness, and toxicity. These variations affect lorlatinib's metabolism and clearance rates, while mutations in the ALK gene can impact its therapeutic efficacy by altering drug resistance, indicating the importance of these genetic interactions in personalizing treatment plans."
PA450842,"Benzylpenicillin's interaction and effectiveness are influenced by genetic variations in human solute carriers such as SLC22A8, SLC15A1, SLC15A2, SLC22A6, SLC22A5, and the SLCO family, which affect the drug’s pharmacokinetics by altering renal reabsorption, hepatic uptake, and biliary excretion. Furthermore, polymorphisms in genes like SLC22A5 or SLCO1B1, as well as variations affecting albumin (ALB), which impacts the drug's plasma distribution, can modify benzylpenicillin’s therapeutic efficacy or toxicity by altering its plasma levels and the free fraction available in the bloodstream."
PA450741,"The pharmacogenetics of oxycodone involves its metabolism and receptor interactions, primarily affected by genetic variants in CYP2D6, CYP3A4, CYP3A5, ABCB1, and OPRM1 genes. CYP2D6 influences the conversion of oxycodone into the more potent oxymorphone, impacting clinical outcomes due to differences in enzyme activity among individuals, while CYP3A4 and CYP3A5 impact the drug's clearance. ABCB1 affects oxycodone’s distribution in the brain, and OPRM1 variants may alter how well oxycodone binds to opioid receptors, thereby affecting its analgesic effectiveness."
PA449456,"Enalapril's pharmacogenetics are affected by genetic variations in genes such as CES1, which is crucial for its metabolism into active enalaprilat, and ACE, which influences the drug's efficacy and side effects like angioedema and cough through the alteration of angiotensin and bradykinin pathways. Other genes, including SLCO1B1, NOS3, ABO, VEGFA, and NR3C2, play roles in modulating drug uptake, vascular response, and cardiovascular risk, thereby affecting therapeutic efficacy and the profile of adverse events."
PA451141,"Genetic variations in the CYP2B6, CYP2C9, UGT1A9, UGT1A8, and ABCB1 genes influence the pharmacokinetics of propofol by affecting its hepatic hydroxylation, glucuronidation and elimination, significantly impacting the drug's metabolic clearance, and hence, its sedative effects. Additionally, variations in the GABRA1 and GABRA2 genes can modify the pharmacodynamic response to propofol, influencing its sedative efficacy, although these effects are less clearly established in clinical practice. These genetic interactions contribute to individual variability in metabolizing and responding to propofol, crucial for personalized anesthetic management."
PA449407,"Genetic variations in the enzymes CYP3A4 and CYP2C19 influence the pharmacokinetics of doxazosin by affecting its rate of metabolism, which can impact the drug’s efficacy and safety due to either increased or decreased drug exposure. Additionally, variants in the ABCB1 gene affect doxazosin’s pharmacokinetics by altering the activity of P-glycoprotein, impacting the drug’s absorption and elimination, thereby influencing therapeutic outcomes."
PA166170051,"Valbenazine targets the SLC18A2 gene and is metabolized by enzymes CYP3A4, CYP3A5, and CYP2D6; variations in these genes affect the drug’s metabolism, efficacy, and safety. Differences in gene activity can lead to variable patient responses and, specifically, altered activity of CYP2D6 can increase the risk of QT prolongation."
PA451223,"Ramipril's metabolism into its active metabolite, ramiprilat, is driven by the liver enzyme BCHE, and variations in BCHE can alter the drug's efficacy and safety. Additionally, the ACE gene influences how effectively ramipril lowers blood pressure and alters cardiovascular risk, with different ACE genotypes causing variable patient responses. Moreover, genetic variations in the BDKRB1 receptor might affect the occurrence or severity of cough, a side effect associated with ACE inhibitors like ramipril. These genetic interactions are crucial in determining the pharmacokinetic and pharmacodynamic responses to ramipril in the treatment of cardiovascular diseases."
PA451363,"Simvastatin pharmacogenetics involves key genes such as **CYP3A4**, **CYP3A5**, **CYP2C8**, **CYP2C9** which are essential for drug metabolism, and **SLCO1B1**, **ABCB1**, **ABCG2** that affect drug transport. Variants in these genes can influence simvastatin's levels and side effects, and can alter its efficacy due to changes in enzyme activity, drug uptake, and bioavailability. Additionally, variations in the **HMGCR** gene, the target of simvastatin, can affect the drug's ability to inhibit the enzyme and modify cholesterol reduction, while **KIF6** gene variants may impact cardiovascular benefits from high-dose simvastatin treatment."
PA449977,"Indinavir's pharmacokinetics are significantly influenced by genetic variations in metabolic enzymes such as CYP3A4 and CYP3A5, which affect its metabolism, and consequently, its effectiveness and toxicity. Additionally, its interaction with transporters like ABCB1 and metabolic enzymes like UGT1A1 also affects its absorption, distribution, and glucuronidation, further impacting drug levels and side effects, indicating that genetic testing might be beneficial to customize indinavir therapy for individual patients."
PA166252761,"Fosdenopterin interacts pharmacogenetically primarily through mutations in the _MOCS1_ gene, which disrupts molybdenum cofactor synthesis and affect the drug's pharmacodynamics by compensating for deficient cyclic pyranopterin monophosphate (cPMP). Additionally, genetic variations in renal transporters SLC47A2, SLC22A6, and SLC47A1 may influence the drug's pharmacokinetics, particularly affecting the renal elimination of fosdenopterin or its metabolites, potentially altering drug levels and efficacy."
PA166177476,"Cariprazine's pharmacogenetics involves crucial interactions with the **CYP3A4** and **CYP2D6** genes which are key in its metabolism, affecting the drug's plasma levels and requiring potential dosage adjustments based on individual genetic variations. Further, genes like **DRD2**, **DRD3**, and various serotonin and adrenaline receptor genes (**HTR1A**, **HTR2A**, **HTR2B**, **HTR2C**, **HRH1**, and **ADRA1A**) influence its pharmacodynamics, where genetic variations might impact the drug's effectiveness in treating schizophrenia and bipolar disorder."
PA451124,"Proguanil's effectiveness as an antimalarial drug is significantly influenced by genetic polymorphisms in the CYP2C19 enzyme, which are responsible for its conversion into the active metabolite, cycloguanil. Variants like rs4244285 and rs4986893 in CYP2C19 lead to reduced enzyme activity and hence lower levels of cycloguanil, particularly affecting populations such as Asians and Africans where these polymorphisms are common, leading to potentially reduced antimalarial protection."
nan-ce6d233b-d53d-486a-87c8-5abecf87eb64,"Doxycycline's effectiveness and safety may be influenced by genetic variants in MATE proteins, which affect the renal excretion of the drug, altering its blood levels and potentially its efficacy or toxicity. Despite the drug's primary elimination path being fecal, and only partial urinary excretion, these genetic factors primarily impact the pharmacokinetics of doxycycline, specifically its clearance."
PA166115579,"Pamaquine, an antimalarial drug, interacts pharmacogenetically with the G6PD gene, which is crucial for protecting red blood cells from oxidative damage. Deficiencies in G6PD can lead to severe hemolytic anemia in individuals treated with pamaquine, due to the oxidative nature of the drug, highlighting a significant safety concern for those with this genetic susceptibility."
PA165111722,"Variants in the CYP3A4 gene significantly affect the metabolism of lumefantrine, altering drug levels and impacting its efficacy and safety, while the role of CYP2D6 is secondary but still contributes to variability in treatment outcomes. These pharmacokinetic gene interactions are crucial for personalizing malaria treatment regimens based on individual genetic profiles."
PA449720,"Gabapentin acts on the auxiliary α2δ-1 and α2δ-2 subunits of voltage-gated calcium channels (CACNA2D1, CACNA2D2) influencing neurotransmitter release, and its effectiveness and safety may be influenced by genetic variations in these channels. Additionally, the transporter LAT1 (SLC7A5), crucial for gabapentin's absorption, may also be affected by genetic variations altering its bioavailability, making pharmacokinetic and pharmacodynamic interactions significant factors in the drug's effects in different patients."
PA450268,"Losartan's metabolism is influenced by genetic variations in CYP2C9, leading to differences in drug levels and potential side effects, while transporter genes like ABCB1 impact its distribution and elimination. Additionally, variations in the AGTR1 receptor gene affect losartan's efficacy in reducing blood pressure, with other genes such as SLC22A12 and UGTs (UGT1A1, UGT2B7) also playing roles in its renal handling and clearance."
PA166153472,"Genetic variations in metabolic enzymes CYP3A4 and CYP3A5 significantly influence the pharmacokinetics of lenvatinib, impacting drug levels and thus affecting its efficacy and toxicity, as these enzymes metabolize lenvatinib into less active forms. Additionally, variations in transporter genes ABCB1 and ABCG2 affect lenvatinib's distribution and excretion, altering plasma concentrations and tissue distribution, which consequently impacts therapeutic outcomes."
PA449782,"Glyburide's pharmacogenetic profile is significantly affected by genetic variations in the CYP2C9 and CYP3A4 enzymes, which alter its metabolism leading to variations in efficacy and safety, particularly influencing the risk for hypoglycemia. Additionally, genetic modifications in the ABCC8 and KCNJ11 genes, which affect components of the ATP-sensitive potassium channels in pancreatic beta cells, can alter glyburide's effectiveness in stimulating insulin secretion, impacting the management of type 2 diabetes."
PA450379,"Mercaptopurine's effectiveness and safety are affected by genetic variants in several enzymes crucial to its metabolism, most notably TPMT, ITPA, NUDT15, and NT5C2, which influence drug catabolism, increase toxicity risks, and can cause drug resistance. Genes like SLC28A3 and ABCC4, which mediate drug transport, also play roles in its pharmacokinetics, highlighting the need for patient genotyping to tailor treatments and minimize adverse effects."
PA164781163,"Genetic variations in enzymes such as CYP2B6, CYP2C8, CYP3A4, CYP3A5, UGT, and SULT can affect the pharmacokinetics of apomorphine by influencing its metabolism, plasma concentration, clearance, and bioavailability. Additionally, polymorphisms in dopamine receptor genes like DRD2 and regulatory genes such as ANKK1 impact the drug's pharmacodynamics, affecting its therapeutic efficacy and the management of symptoms in Parkinson's disease patients."
PA449654,"Flucytosine, metabolized into 5-fluorouracil mainly by gut flora, can be impacted by genetic variations in the DPYD gene, which is crucial for the catabolism of 5-fluorouracil. These variations may affect the pharmacokinetics and toxicity of 5-fluorouracil, thus influencing the safety and efficacy of flucytosine treatment."
PA449957,"Ibuprofen's metabolism is primarily governed by the CYP2C9 enzyme, and variations in the CYP2C9 gene can alter metabolic rates, impacting its therapeutic effectiveness and side effect profile; CYP2C8 and possibly CYP3A5 also play roles in its metabolism. Additionally, genetic variations in PTGS2, which encodes COX-2 targeted by ibuprofen, may influence the drug’s effectiveness in reducing pain and inflammation."
PA166190161,"Entrectinib's effectiveness in treating tumors is influenced by gene fusions or mutations in NTRK1, NTRK2, NTRK3, and ROS1, as it targets these genes to inhibit tumor growth and induce apoptosis. The pharmacokinetics of entrectinib involve CYP3A4, primarily responsible for its metabolism, and ABCB1, which affects the drug's distribution and excretion, with variations in these genes impacting drug concentration, efficacy, and side effects."
PA449594,"Fenofibrate's efficacy and safety are influenced by genetic variations in enzymes and transporter genes crucial for its metabolism and transport. Key enzymes such as CES1, CYP2C8, and CYP2C19, along with UGT1A9, govern its metabolic transformation and clearance, whereas transporter genes like ABCB11 and SLCO1B1 affect its hepatic uptake and biliary excretion, leading to variability in drug levels and individual patient responses."
PA166114922,"The pharmacogenetics of lomitapide are influenced by CYP3A4, which affects the drug's metabolism and plasma concentration, impacting its efficacy and risk of adverse effects like hepatotoxicity. Additionally, the ABCB1 gene affects lomitapide's absorption and distribution, influencing its bioavailability, while genes such as APOB, LDLR, and PCSK9 are crucial to its efficacy in lowering LDL cholesterol through pharmacodynamic processes not related to its metabolism or transport."
PA164781375,"The interaction of Ibritumomab tiuxetan with the CD20 antigen, determined by the MS4A1 gene, facilitates its use in treating non-Hodgkin's lymphoma by targeting and destroying B-cells with a radioactive isotope. Variations in the MS4A1 gene can influence the expression and structure of CD20, potentially affecting the drug's binding affinity and therapeutic efficacy."
PA166152829,"Flupirtine's analgesic effects are partially mediated by its interaction with the alpha-2A adrenergic receptor (ADRA2A) and potentially influenced by genetic polymorphisms in ADRA2A, which could impact its efficacy or adverse effects. Additionally, genetic variations in liver enzymes, such as cytochrome P450, which are involved in the hepatic metabolism of flupirtine, may also affect the drug's processing and bioavailability, thus influencing individual responses in terms of therapeutic effectiveness and potential toxicity."
PA166128130,"Deleobuvir, a drug targeting HCV's NS5B polymerase, may interact with genetic factors through its role in inhibiting viral replication, specifically involving the genes IFNL3 and IFNL4. These genes, which affect the immune response to HCV, can influence the natural clearance of the virus and the response to antiviral therapies, thereby potentially impacting the effectiveness of treatments including deleobuvir, primarily through pharmacodynamic mechanisms related to host-virus interactions."
PA449476,"Genetic variations in key genes like **UGT2B7**, **ABCC1**, and **TOP2A** significantly influence the pharmacokinetics and pharmacodynamics of epirubicin. These variations can impact epirubicin's metabolism, elimination, and its ability to inhibit the DNA replication enzyme TOP2A, thereby affecting the drug's toxicity and anticancer efficacy. Additionally, genes such as **CBR3**, **SLCO1B1**, **ABCC2**, and **GSTT1** also play roles in the metabolism, distribution, excretion, and detoxification of epirubicin, further influencing its effectiveness and safety profile."
PA450403,"The metabolism of methamphetamine is significantly influenced by the genetic variants of the enzyme CYP2D6, which affect the drug's plasma levels, efficacy, and risk of adverse effects, with poor metabolizer variants possibly leading to increased toxicity and dependence. Additionally, genetic differences in neurotransmitter transporter genes (SLC6A3, SLC6A4, SLC6A2) and PICK1 affect individual responses to methamphetamine by altering neurotransmitter reuptake and synaptic levels, which can impact addiction risk and therapeutic outcomes."
PA450761,"The pharmacogenetic profile of paclitaxel is influenced by the CYP2C8 and CYP3A4 genes, which are crucial for its hepatic metabolism; variations in these genes affect the drug's efficacy and toxicity. Additionally, genes like ABCB1, which encodes the P-glycoprotein transporter, affect paclitaxel's distribution and excretion, with polymorphisms in ABCB1 and potentially ABCC2 and SLCO1B1 altering intracellular concentrations and impacting therapeutic outcomes and side effects."
PA165958403,"Chenodeoxycholic acid's metabolism and therapeutic efficacy are significantly influenced by genetic interactions involving CYP3A4, which affects its metabolic rate, and UGT2B7, impacting its clearance and detoxification. Additionally, the drug's pharmacodynamics are modulated by nuclear receptors such as NR1H4 and NR1I2, which regulate cholesterol synthesis and drug metabolism pathways, along with GPBAR1 and AKR1C2 that govern bile acid signaling and steroid metabolism, respectively. These genetic variations can lead to differences in treatment outcomes and adverse effects."
PA165981594,"Eltrombopag metabolism involves CYP1A2, CYP2C8, UGT1A1, UGT1A3, and UGT1A9 enzymes, where polymorphisms, particularly in UGT1A1, could impact the drug's clearance and overall exposure. Additionally, genes like SLCO1B1 and ABCG2 affect eltrombopag's absorption and distribution, while genetic variants in F5 and SERPINC1, specifically rs6025 in F5 and rs121909567 in SERPINC1, are linked to an increased risk of thromboembolic events, highlighting the significant role of these genetic interactions in the drug’s pharmacodynamics and safety profiles."
PA448031,"Genetic variations in ACHE and BCHE genes can significantly influence the breakdown of acetylcholine (ACh), altering its availability and efficacy at synaptic junctions. Additionally, variations in muscarinic and nicotinic receptor genes (CHRM1, CHRM2, CHRM3, CHRM4, CHRNA7) and transport protein genes (SLC22A5, SLC22A1) can modify the pharmacodynamic responses and systemic distribution of ACh, impacting drug efficacy and side effects in therapies targeting the cholinergic system."
PA166129466,"Lonafarnib's pharmacogenetics are influenced by the metabolism via enzymes such as CYP3A4, CYP3A5, and several other CYP enzymes, with polymorphisms in these genes impacting its pharmacokinetics, which can affect drug levels and risk of toxicity. Additionally, variations in transport proteins like ABCB1 and SLCO1B1 affect its distribution and elimination, while its pharmacodynamics involve targeting the farnesyltransferase subunits FNTA and FNTB, and potentially affecting protein processing genes like LMNA and ZMPSTE24 in specific diseases."
nan-2b15062b-9e70-452d-bf7b-eb623e2d07a0,"The antitubercular drug aminosalicylic acid primarily inhibits folic acid synthesis in *Mycobacterium tuberculosis*. Although it interacts with genes like PTGS2, CHUK, ALOX5, and PLA2G2E, which are involved in inflammation, these do not directly contribute to its main action against tuberculosis. However, the gene MPO, which codes for myeloperoxidase metabolizing the drug, can affect its pharmacokinetics, with variations potentially impacting the drug's efficacy and safety."
PA450466,"The pharmacogenetics of methylprednisolone involve variations in genes such as CYP3A4, CYP3A5, CYP3A7, ABCB1, and NR3C1 that impact the drug's metabolism, distribution, and receptor sensitivity. These genetic differences can significantly affect the rate of methylprednisolone metabolism and its tissue distribution, leading to variations in drug levels, efficacy, and the risk of side effects, depending on the individual genetic makeup."
PA450526,"Mitoxantrone's metabolism and clearance are influenced by genes such as CYP1B1, CYP3A4, and CYP2E1, which affect its toxicity and therapeutic effectiveness through variations in oxidative metabolism rates among individuals. On the pharmacodynamics side, genetic variants in ABCB1, ABCC1, and ABCG2 impact the drug's distribution, excretion, and cellular concentration, respectively, altering mitoxantrone’s effectiveness and contributing to differential drug resistance profiles in cancer treatments."
PA451949,"Variants in cytochrome P450 enzymes, such as CYP2C9, CYP2C8, and CYP3A4, significantly affect the pharmacogenetic profile of zafirlukast, a drug used in asthma management, by altering its metabolic clearance and thus impacting its effectiveness and the risk of adverse effects. Additionally, genetic differences in enzymes like LTC4S, involved in leukotriene synthesis, and MGAT4B, associated with glycolipid biosynthesis, may theoretically influence the pharmacodynamics of zafirlukast, affecting how well the drug suppresses inflammation and interacts with cellular responses to leukotrienes."
PA450947,"Genetic variations significantly influence the metabolism and efficacy of phenytoin, primarily through variations in hepatic enzymes CYP2C9 and CYP2C19 that affect drug clearance and toxicity risk. Additionally, other genes such as HLA-B, ABCB1, EPHX1, SCN1A, and SCN2A impact phenytoin's pharmacokinetics and pharmacodynamics, which include transport, metabolic activation, and neuronal excitability, ultimately influencing therapeutic outcomes and the occurrence of adverse reactions like Stevens-Johnson syndrome."
PA162372840,"Sunitinib's pharmacogenetic interactions are primarily mediated by metabolic genes, such as CYP3A4 and CYP3A5, and transport proteins like ABCG2, ABCB1, ABCC2, and ABCC4. Variants in these genes can impact sunitinib's plasma levels, metabolism, and efflux, affecting the drug's efficacy, toxicity, and overall bioavailability, thereby necessitating tailored therapeutic approaches based on individual genetic profiles."
PA450644,"Nitroglycerin's effectiveness and the development of tolerance are heavily influenced by the mitochondrial enzyme ALDH2, as variations in the ALDH2 gene can alter enzyme activity, impacting drug efficacy. Particularly, reduced activity of ALDH2, often seen in East Asian populations due to specific genetic variants, leads to decreased effectiveness of nitroglycerin and an increased likelihood of developing tolerance. Other genes may also play a role in nitroglycerin's response, but their influence is less clear and speculative."
PA166131242,"The pharmacogenetics of 3-hydroxycotinine glucuronide involves the enzymes UGT1A4 and possibly UGT2B10, which are responsible for converting 3-hydroxycotinine into its glucuronide form, facilitating nicotine metabolite clearance via genetic polymorphisms that affect enzyme activity and glucuronidation efficiency. This variation influences how quickly nicotine metabolites are cleared from the body, focusing exclusively on pharmacokinetic interactions due to the lack of pharmacodynamic activity of 3-hydroxycotinine glucuronide as it does not interact with biological targets."
PA164748741,"Mepivacaine acts as a local anesthetic by binding to and inhibiting sodium channels, particularly SCN10A, and its effectiveness and safety may be influenced by genetic variants in SCN10A and metabolic genes like CYB5R3 and G6PD. Variations in these genes could affect how the drug interacts with nerve impulse propagation and how cells respond to oxidative stress induced by the drug, thereby altering individual responses to the anesthetic."
PA450654,"The metabolism and clearance of Norfloxacin are significantly influenced by genetic variations in the cytochrome P450 enzymes CYP1A2 and CYP3A4, which impact its hepatic metabolism and subsequently affect the drug's efficacy and safety. Additionally, transport-related genes like SLC22A5 and SLC22A6 also influence Norfloxacin's pharmacokinetics by modifying renal clearance, thereby affecting its absorption, elimination, and overall therapeutic outcomes."
PA166163659,"Variations in the genes CYP1A2 and CYP3A4 significantly affect the metabolism of N-desmethylclozapine (norclozapine) and can markedly alter its therapeutic efficacy and side effects due to differences in norclozapine levels. Additionally, polymorphisms in other relevant enzymes like UGT2B10, CYP2C19, and UGT1A4 also influence norclozapine's pharmacokinetics, impacting its plasma concentration and effectiveness, thereby playing a crucial role in personalizing clozapine treatment to optimize efficacy and minimize side effects."
PA164746560,"Thyrotropin alfa acts primarily through interaction with the TSHR gene, stimulating thyroid tissue to uptake iodine, with its effectiveness potentially influenced by genetic variations in the TSHR gene that affect receptor expression or function. There are no specific interactions with drug-metabolizing enzymes or transporters noted for thyrotropin alfa, indicating its action is primarily pharmacodynamic rather than pharmacokinetic."
PA166129536,"Regadenoson targets the ADORA2A gene and binds to the A2A adenosine receptor, with variations in the ADORA2A gene potentially affecting the drug’s effectiveness in coronary vasodilation. Additionally, the AMPD1 gene, which plays a role in adenosine metabolism, may influence Regadenoson's response, although direct interactions with the drug are not explicitly documented."
PA450631,"Nifedipine's metabolism and transport are significantly influenced by genetic variations in CYP3A4 and CYP3A5 enzymes, which can result in variable plasma levels and influence the drug's efficacy and side effect profile. Additionally, transporter proteins such as ABCG2 and P-glycoprotein, encoded by ABCB1, affect nifedipine's absorption and efflux from cells, thereby altering its bioavailability and tissue distribution. Genetic variations in these enzymes and transporters can significantly impact the pharmacokinetics of nifedipine."
PA450413,"Methazolamide, a carbonic anhydrase inhibitor used for glaucoma, interacts with enzyme isoforms CA1, CA2, CA3, CA4, and CA7, affecting aqueous humor secretion and intraocular pressure. Genetic variations in these enzymes and the SLC22A6 transporter may significantly influence the drug’s efficacy and pharmacokinetics, potentially altering therapeutic outcomes and drug levels in patients due to modified enzyme activity and altered renal excretion or absorption."
PA448015,"Acetaminophen metabolism in the liver is significantly affected by genetic variations in enzymes such as CYP2E1, which metabolizes the drug into its toxic metabolite NAPQI; GSTP1 and GSTM1, which help detoxify NAPQI; and UGT enzymes like UGT2B15 and UGT1A6, which are involved in its glucuronidation. Additionally, polymorphisms in SULT1A1 and SULT1A3 can influence the sulfation of acetaminophen, thereby impacting drug clearance and systemic exposure, which are crucial in determining the risk and severity of hepatotoxicity, especially during overdose."
PA166182883,"The metabolism of ospemifene is significantly influenced by polymorphisms in several cytochrome P450 enzymes, including CYP3A4, CYP2C9, CYP2C19, and CYP2B6, which affect the drug’s pharmacokinetics and individual responses. Genetic variations in these enzymes can lead to different metabolizing phenotypes from poor to extensive, impacting ospemifene's plasma levels, efficacy, and safety, thus underscoring the importance of genetic considerations in its clinical use."
PA146123005,"Talinolol's metabolism is influenced by the CYP2D6 enzyme, where genetic variations can lead to different metabolic rates affecting the drug’s plasma levels and efficacy. Additionally, talinolol's interaction with ABCB1 and ABCC2 transporter proteins impacts its absorption and excretion, which are crucial in determining the drug's bioavailability and systemic exposure, ultimately affecting its effectiveness and safety."
PA164754789,"The pharmacogenetics of conjugated estrogens involve metabolism by CYP3A4 and CYP1A2, where genetic variants can affect drug levels and effectiveness, and COMT, which influences metabolism through methyltransferase activity. Additionally, receptor genes ESR1 and ESR2 impact drug effectiveness due to genetic variations, and the transporter gene SLCO1B1 affects the drug's bioavailability. Other genes like ABCC1 and SULT1A1 also play roles in drug elimination and metabolism, respectively."
nan-393b660e-ea90-458d-af12-ab04e004e28d,"Cycloserine interacts with the human proton-coupled amino acid transporter 2 (SLC36A2) and the enzyme aromatic-L-amino-acid decarboxylase (DDC), where variants in SLC36A2 affect the drug's absorption and pharmacokinetics, and polymorphisms in DDC can influence its side effects, particularly neurological ones, due to DDC's role in neurotransmitter synthesis. These genetic variations can lead to differences in how individuals respond to Cycloserine both in terms of efficacy and safety."
PA449466,"Ephedrine interacts pharmacogenetically by acting as an agonist at ADRA1A, ADRB1, and ADRB2 receptors, with genetic variants in these receptors potentially affecting the drug's efficacy and side effects such as respiratory and cardiovascular responses. Additionally, variations in the SLC6A2 gene, encoding a noradrenaline transporter, influence ephedrine's ability to elevate synaptic noradrenaline levels, impacting its sympathomimetic effects, while genetic variants in the BCHE and ACHE enzymes may affect drug metabolism and the duration of ephedrine's action."
PA448809,"Carisoprodol metabolism and its efficacy are significantly influenced by the CYP2C19 gene, which dictates the rate at which carisoprodol is converted to its active metabolite, meprobamate. Genetic variations in CYP2C19 can lead to different metabolic rates among individuals, with poor metabolizers experiencing prolonged effects and potential side effects due to slower drug clearance, while rapid metabolizers may see reduced effects as the drug is cleared more quickly."
PA166225084,"Selpercatinib's metabolism is significantly affected by genetic variations in the enzymes CYP3A4 and CYP2C8, impacting its plasma levels, efficacy, and potential toxicity, with polymorphisms in CYP3A4 altering enzyme activity and affecting drug concentration. Additionally, genetic variants in transporter proteins such as ABCB1 and ABCG2 influence selpercatinib's distribution and elimination, affecting patient responses and necessitating potential dosing adjustments to optimize therapeutic outcomes."
PA10816,"Ezetimibe's efficacy and safety are influenced by its metabolism and transport, with key genes including UGT1A1, UGT2B15, NPC1L1, SLCO1B1, and ABCB1 playing pivotal roles. Polymorphisms in these genes affect the drug's metabolism rate, plasma levels, and interaction with cellular targets, thereby impacting its lipid-lowering effectiveness."
PA451213,"Genetic polymorphisms in metabolic enzymes, primarily CYP3A4 and CYP3A5, and transport proteins like SLC22A1 and ABCB1, significantly influence the clearance, distribution, and excretion of quinine, leading to variability in its efficacy and safety profiles. Additional variations in genes like CYP2D6 and pathological conditions like G6PD deficiency can modify quinine's pharmacokinetics and induce adverse effects like hemolytic anemia in susceptible individuals."
PA451182,"Pyrazinamide, an antitubercular drug, is metabolized in the liver by enzymes such as AOX1 and XDH, with genetic variants in XDH influencing the enzyme activity and potentially affecting the drug's pharmacokinetics and toxicity. Additionally, variations in NAT2 affect the drug's acetylation process, impacting its efficacy and side effect profile, particularly hepatotoxicity, while GSTM1 may also play a role in the drug’s metabolism and disposition. Other genes like CYP2E1, CYP2C19, and TNF could be involved, but their direct impact on pyrazinamide's pharmacokinetic profile is less clearly established."
PA451145,"Propranolol interacts with adrenergic receptors (ADRB1, ADRB2, ADRB3) to achieve its therapeutic effects on heart rate and blood pressure, with gene variations in ADRB2 possibly affecting receptor sensitivity and treatment efficacy. Its metabolism involves several cytochrome P450 enzymes including CYP2D6, CYP1A2, CYP3A4, and CYP2C19, with CYP2D6 genetic variations significantly impacting plasma levels and clearance rate, suggesting possible needs for dosage adjustments. Additionally, genes like ABCB1 and SLC22A2 related to drug transport could affect propranolol's distribution and excretion, influencing overall drug response."
PA450369,"Variations in the CYP2D6, CYP3A4, and CYP2B6 genes affect the metabolism of meperidine, influencing drug efficacy and side effect risks, including toxicity, due to differences in the rate at which individuals metabolize the drug. Additionally, genetic variants in the OPRM1 and OPRK1 genes, which encode for the mu and kappa opioid receptors, respectively, influence the pharmacodynamics of meperidine by altering receptor binding and response, affecting the analgesic effectiveness and risk of side effects such as opioid dependency."
PA449512,"Estrone's effectiveness and side effects are influenced by interactions with estrogen receptors ESR1 and ESR2, and by its metabolism through cytochrome P450 enzymes, particularly CYP3A4 and CYP1B1. Genetic variations in these receptors and enzymes can significantly affect the pharmacodynamics and pharmacokinetics of estrone, impacting its overall therapeutic efficacy and safety profile in hormone replacement therapies."
PA449683,"Flurbiprofen metabolism is critically influenced by genetic variations in the CYP2C9 enzyme, affecting its clearance and altering efficacy and safety by changing plasma drug levels. Additionally, gene variations in UGT enzymes (including UGT2B7, UGT1A1, UGT1A3, UGT1A9, UGT2B4) and transporters such as ABCC4 and SLC22A6 influence flurbiprofen’s elimination and distribution, impacting therapeutic outcomes and toxicity risks, suggesting a need for personalized dosing strategies."
PA451114,"Prochlorperazine's efficacy and side effect profile are influenced by polymorphisms in the CYP2D6 gene, which affects drug metabolism, leading to variations in plasma concentrations among different metabolizers. Additionally, the interaction between the DRD2 and ANKK1 genes, which are involved in dopamine signaling, affects individual responses to the drug, potentially explaining variability in pharmacodynamic responses and emphasizing the importance of considering these genetic interactions for personalized treatment strategies."
PA450338,"The metabolism of meclizine, an antihistamine for motion sickness and vertigo, is mediated by the CYP2D6 enzyme, whose genetic variants can affect the drug's pharmacokinetics. Depending on whether someone is a poor, intermediate, extensive, or ultrarapid metabolizer, as categorized by CYP2D6 gene variants, the dosage of meclizine might need adjustment to avoid inadequate treatment or adverse effects due to altered plasma concentrations."
PA166241801,"Mutations in the genes MT-RNR1 and MT-ND1 are associated with increased susceptibility to ototoxicity from aminoglycosides like Micronomicin. MT-RNR1 is linked to the susceptibility because it plays a role in mitochondrial ribosomal function, which is similarly targeted by aminoglycosides, while MT-ND1 is involved in mitochondrial oxidative phosphorylation, potentially exacerbating the toxicity by affecting cellular energy metabolism."
PA449621,"Fexofenadine's pharmacogenetics are influenced by interactions with transport proteins encoded by the ABCB1 and SLCO gene families, which affect the drug’s absorption, distribution, metabolism, and excretion. Variants in these genes can lead to individual differences in the drug's levels and effectiveness through modulation of the P-glycoprotein and organic anion-transporting polypeptides, which govern cellular efflux and hepatic uptake respectively."
PA165958369,"Genetic polymorphisms in the CES1 gene affect the hydrolysis and activation of the prodrug dabigatran, while variants in the ABCB1 gene influence the drug's plasma levels through changes in the activity of the P-glycoprotein transporter. Additionally, genetic variability in UDP-glucuronosyltransferase enzymes like UGT1A9, UGT2B15, and UGT2B7 can alter the clearance of dabigatran, affecting both its therapeutic efficacy and risk of adverse effects such as bleeding."
PA166114906,"The metabolism of bosutinib, a tyrosine kinase inhibitor used for treating chronic myelogenous leukemia, is significantly influenced by the CYP3A4 gene, where variants like CYP3A4*22 can lead to increased plasma drug concentrations and higher toxicity risk. Additionally, the ABCB1 gene, encoding P-glycoprotein, impacts bosutinib's absorption and distribution, also affecting the drug's efficacy and side effects due to alterations in pharmacokinetics."
PA449761,"The pharmacokinetics of glimepiride are significantly influenced by genetic variations in CYP2C9, which affects drug metabolism, leading to potential changes in hypoglycemia risk. Additionally, genetic differences in KCNJ11 and ABCC8, which encode for ATP-sensitive potassium channel subunits that glimepiride targets, can alter the drug's efficacy by affecting insulin release. Other genes like SLCO1B1 and SLC22A1, involved in drug transport, along with NOS1AP and G6PD, which influence metabolic responses and oxidative stress, also play roles in the drug's overall effect and patient-specific response."
PA166153491,"Brivaracetam's metabolism is highly influenced by genetic variants in CYP enzymes such as CYP2C19, CYP3A4, CYP2B6, and CYP2C9, with CYP2C19 playing a pivotal role. Variants in CYP2C19 can lead to different metabolizer phenotypes, causing variable drug plasma concentrations and impacting the efficacy and safety of brivaracetam, suggesting that personalized dosing may be necessary to optimize treatment outcomes."
PA449661,"The pharmacogenetic interactions of flunisolide involve its metabolism by the enzyme CYP3A4 and its mechanism of action through the glucocorticoid receptor (NR3C1), where genetic variations in CYP3A4 affect drug levels and efficacy, and variations in NR3C1 impact the drug’s anti-inflammatory effect. Moreover, SERPINA6 influences flunisolide’s bioavailability by modulating the binding to corticosteroid-binding globulin, affecting both drug efficacy and side effect profiles."
PA451105,"Primidone’s effectiveness and safety are influenced by genetic variations in enzymes such as CYP2C9 and CYP2C19, which are pivotal in converting primidone into its active metabolite, phenobarbital, impacting the drug's levels and patient response. Variations in these genes can either increase the risk of side effects due to higher drug exposure or lead to insufficient therapeutic effects by hastening the drug's metabolism. Other enzymes like CYP2E1, CYP3A4, and UGTs also play roles in its metabolism and elimination, while interactions with the TRPM3 channel affect neuronal excitability, though the genetic implications on this are less clear."
PA449503,"Variations in the genes CYP3A4 and CYP1A2, which govern the hepatic metabolism of estradiol, can affect its pharmacokinetics and therapy efficacy by influencing how fast the drug is metabolized. Additionally, genetic differences in transporters like ABCG2 and ABCC10, and receptor genes ESR1 and ESR2, can affect estradiol’s bioavailability, distribution, and receptor binding, thereby altering therapeutic responses in conditions like menopausal symptoms or hormone-sensitive cancers."
PA449692,"Genetic variations in the MTHFR gene, such as the C677T and A1298C polymorphisms, significantly influence the enzymatic conversion of folic acid to its active form, methyltetrahydrofolate, affecting homocysteine levels and cardiovascular disease risk. Other genes like ABCB1, SLC19A1, MTR, MTRR, and several related to downstream pathways of folic acid metabolism, impact its transport, cellular uptake, and overall supplementation efficacy, with potential implications for conditions like megaloblastic anemia."
PA166153473,"Variations in the genes CYP3A4, ABCB1, and ABCG2 significantly impact the metabolism, transport, bioavailability, and elimination of the drug venetoclax, which is used to treat chronic lymphocytic leukemia (CLL) and other hematologic malignancies. Genetic polymorphisms in these genes require careful dose management to prevent toxicity and ensure therapeutic efficacy, while variations in the BCL2 gene, though less established, could theoretically influence treatment outcomes due to its role in the drug's mechanism."
PA449412,"Key genes like ABCB1, ABCC1, and CYP3A4 impact the pharmacokinetics of doxorubicin by modulating its cellular concentration and metabolism, affecting the drug's efficacy and toxicity. Meanwhile, genes such as TOP2A, TOP2B, and variations in SLC28A3 influence its pharmacodynamics and are linked to therapeutic outcomes and side effects such as cardiotoxicity during doxorubicin treatment."
PA449552,"Etoposide's pharmacogenetics is significantly affected by genetic variations in key enzymes and transporters, such as CYP3A4, CYP3A5, UGT1A1, GSTP1, GSTT1, ABCB1, and ABCG2, which are involved in the drug's metabolism, detoxification, and transport. These variations influence etoposide's clearance, efficacy, and toxicity, impacting therapeutic outcomes and individual dosing regimens."
PA449655,"The efficacy and toxicity of fludarabine, a chemotherapeutic drug, are influenced by genetic interactions, particularly involving the deoxycytidine kinase gene (DCK), which activates fludarabine to its effective form, and the solute carrier family genes SLC29A1 and SLC28A3, which affect the drug’s cellular uptake. Variations in these genes can impact the drug's pharmacodynamics and pharmacokinetics, affecting both the drug's availability and its successful therapeutic outcomes in patients, especially those with chronic lymphocytic leukemia."
nan-49458a0d-1633-48b5-b88c-6f8ea989f9f7,"Terizidone, similarly to cycloserine, might have its efficacy and safety influenced by pharmacogenetic factors such as metabolism by aldehyde dehydrogenases (e.g., ALDH1A1, ALDH2) and transport via members of the SLC and ABC transporter families like SLC22A1 and ABCB1. These genetic interactions can affect Terizidone's pharmacokinetics and pharmacodynamics by altering drug absorption, distribution, metabolism, and elimination."
PA451193,"Pyrimethamine's pharmacogenetic interactions involve the enzyme CYP2C8, which affects its metabolism, and the transporters SLC47A1 and SLC47A2, which impact its transport; polymorphisms in these genes can alter the drug's efficacy and toxicity, necessitating possible dosing adjustments. Additionally, gene variants in G6PD and IKBKG could influence treatment responses and risk profiles in certain parasitic infections through their roles in cellular processes and immune responses."
PA451131,"Propafenone metabolism is significantly influenced by the CYP2D6 gene, which encodes an enzyme that converts propafenone into less active metabolites; this affects the drug's plasma concentration and therapeutic efficacy, varying with patients' genetic differences from poor to ultra-rapid metabolizers. Additionally, propafenone interacts with other genes such as SCN5A, which influences cardiac sodium channels, ADRB1 and ADRB2, which affect its beta-blocking effects, and ABCB1, CYP3A4, and CYP1A2 that modulate its pharmacokinetics and clearance, thereby impacting the drug's efficacy and safety profiles in patient-specific ways."
PA164742950,"Olmesartan, a hypertension drug, is affected by genetic variants in key genes like SLCO1B1 and ABCC2, which impact its uptake, systemic exposure, excretion, and clearance, thereby influencing its efficacy and dosing requirements. Additionally, variations in AGTR1, the drug's target, could alter its interaction with the angiotensin II receptor, affecting its therapeutic effectiveness in managing blood pressure and other cardiovascular conditions."
PA166123486,"Eliglustat's pharmacokinetics are significantly influenced by the activity of CYP2D6 and CYP3A4 enzymes, with CYP2D6 having a major role in determining the drug's metabolic rate and therefore its dosage requirements. Additionally, the ABCB1 transporter gene affects the drug's absorption and distribution, with genetic variability in CYP2D6 affecting individual metabolizer status (extensive, intermediate, or poor), which necessitates personalized dosage adjustments to prevent toxicity and ensure therapeutic efficacy."
PA166153416,"CYP2D6, a key enzyme in the cytochrome P450 family involved in metabolizing various substances, likely plays a significant role in the metabolism of coptisine, an isoquinoline alkaloid from Coptis spp. Genetic variations in CYP2D6 could affect the metabolic clearance of coptisine, thereby influencing its plasma levels, action duration, and potentially leading to differences in therapeutic efficacy and safety among individuals."
PA448004,"Abacavir, a drug used for HIV-1 treatment, interacts significantly with the HLA-B*57:01 allele and SNP rs2395029 in the HCP5 gene, both of which increase the risk of developing severe hypersensitivity reactions. These genetic factors are crucial in guiding preventive genetic testing and therapeutic decisions, although they are not involved in the drug's metabolism, which is primarily handled by ADH6 and UGT1A1."
PA165958402,"Carglumic acid treats hyperammonemia by interacting with the NAGS gene, compensating for deficiencies in N-acetylglutamate synthase caused by mutations in this gene. This action assists in activating carbamoyl phosphate synthetase 1 (CPS1), facilitating ammonia detoxification in the urea cycle."
PA166182733,"Larotrectinib sulfate targets the products of NTRK gene fusions (NTRK1, NTRK2, and NTRK3), which encode the neurotrophin receptors TRKA, TRKB, and TRKC, respectively. The drug's efficacy depends on inhibiting the proteins produced from these gene fusions, as these altered receptors are significant in the development of various cancers, making the presence of these fusions critical in determining a tumor's response to larotrectinib."
PA450731,"Genetic variants in the UGT2B15 and UGT2B7 enzymes significantly impact the metabolism of oxazepam, affecting the drug’s clearance and plasma levels, which can alter its efficacy and side effect profile. Additionally, allelic differences in these genes can lead to variations in glucuronidation rates, resulting in either increased or decreased drug exposure and influencing therapeutic and adverse effects."
PA10268,"Genetic variations in dopamine receptor gene DRD2 and serotonin receptor HTR2A affect the efficacy and side effects of flupentixol due to its antagonistic actions on these receptors. Additionally, variations in CES1, which metabolizes flupentixol, and ABCB1, a transporter protein, influence the drug's plasma levels, distribution, and elimination, thereby impacting its therapeutic effectiveness and toxicity."
PA450576,"Nafcillin's metabolism involves cytochrome P450 enzymes, specifically CYP1A2 and CYP3A4, where genetic variations in these enzymes can lead to different metabolic rates of the drug, potentially impacting its efficacy and safety. Additionally, genetic variants in the SLC22A6 transporter may affect nafcillin's elimination through the kidneys, and variations in albumin levels, which also bind nafcillin, could influence its bioavailability."
PA450705,"The metabolism of ondansetron is majorly influenced by the enzymes CYP2D6 and CYP3A5, with CYP2D6 having a significant impact on the pharmacokinetics, where different genetic variants can lead to variations in drug clearance and exposure, affecting its therapeutic effectiveness and risk of side effects. Additionally, genes like ABCB1, CHRM3, SLC6A4, HTR3B, and HTR3A are involved in the drug's distribution, absorption, and receptor interactions, potentially influencing the efficacy and side effects of ondansetron."
PA166182707,"Genetic polymorphisms in CYP3A4 and transport proteins ABCB1 and SLC22A8 affect the metabolism, distribution, and excretion of Ivosidenib, influencing its efficacy and safety. Furthermore, mutations in the IDH1 gene, particularly at the R132 position, are essential for the drug's effectiveness, as Ivosidenib targets the abnormal enzyme produced by these mutations, determining patient eligibility and response to treatment."
PA164760860,"Pegaspargase, used in acute lymphoblastic leukemia treatment, universally targets the amino acid asparagine in leukemia cells without involving specific genes affecting its pharmacodynamics. However, genes like HLA-DRB1, HLA-DQB1, HLA-DQA1, and IGHMBP2 may impact the immune response, influencing hypersensitivity or other immune-mediated reactions to the drug, suggesting a pharmacogenetic interaction that could guide personalized treatment by monitoring these genetic profiles."
PA451578,"The efficacy and safety of tacrolimus, an immunosuppressant, are significantly influenced by pharmacogenetic interactions involving several genes. Primarily, CYP3A4 and CYP3A5 impact its hepatic metabolism, determining dosing requirements, while ABCB1 affects tacrolimus absorption and efflux, influencing drug levels and potential adverse effects. Additional genes like CYP2C8, CYP2C19, POR, NR1I2, and SLCO1B1 also play roles in its pharmacokinetics by affecting metabolism, expression of metabolism-related genes, and drug distribution and elimination."
PA450595,"The metabolism and efficacy of naproxen are significantly influenced by mutations in genes such as CYP2C9, which is crucial for hepatic metabolism. Variants in this gene can alter enzyme activity, potentially leading to higher drug plasma levels and an increased risk of side effects like gastrointestinal bleeding and renal impairments. Other genes like SLCO1A2, ABCB1, and UGT2B7 also play a role in its pharmacokinetics by affecting naproxen's absorption, distribution, and excretion, impacting its bioavailability and systemic clearance."
nan-c67b39b1-3fa3-49ee-b1da-784271b69bc7,"Genetic variations in the CYP3A4 and CYP2C9 enzymes significantly affect the metabolism of rifapentine, impacting drug efficacy and toxicity. Polymorphisms in CYP3A4 can alter metabolism rates, while certain alleles of CYP2C9 may decrease enzyme activity, leading to increased drug exposure and potential adverse effects."
PA166131342,"The pharmacogenetic interactions of noroxycodone, derived from oxycodone, are significantly influenced by the enzymes CYP3A4 and CYP2D6. Variations in the activity of CYP3A4 and CYP2D6, due to genetic polymorphisms, alter the metabolism rate of noroxycodone, impacting its plasma concentrations and thus affecting its efficacy, safety, and potential side effects in individuals."
PA451539,"Genetic variations in the CYP2C8, CYP3A4, and CYP2C9 enzymes influence the metabolism and clearance of Sulfadiazine, affecting its efficacy and toxicity. Additionally, the G6PD gene plays a key role, as G6PD deficiency can result in hemolytic anemia in patients treated with Sulfadiazine due to increased oxidative stress in red blood cells."
PA450484,"Metronidazole's pharmacokinetics are influenced by interactions with cytochrome P450 enzymes like CYP2C8, CYP2C9, CYP3A4, CYP3A5, and CYP2A6, which are responsible for its oxidative metabolism, while UGT1A1 is involved in its glucuronidation. Additionally, genetic variations in these enzymes can alter metronidazole's metabolism speed and efficacy, and the transporter gene ABCB1 affects the drug's absorption and distribution, impacting its bioavailability and systemic circulation."
PA448082,"Alendronate's effectiveness and safety in preventing bone loss may be influenced by genetic variations in genes such as DKK1 and SOST, which regulate bone density, and MVK and VDR, which are involved in the mevalonate pathway and vitamin D metabolism, respectively. These variations in genes associated with bone metabolism could potentially modulate the response to alendronate, despite the drug's minimal systemic bioavailability and metabolism."
PA450566,"Mycophenolate mofetil (MMF) pharmacogenetics is impacted by key metabolic enzymes UGT1A9 and UGT2B7, which influence the levels of its active form, mycophenolic acid (MPA), affecting the drug's efficacy and safety. Transporter genes ABCB1, SLCO1B1, and SLCO1B3, alongside less directly involved CYP enzymes, and pharmacodynamic impacting genes like IMPDH1 and IMPDH2, also affect MMF's plasma concentrations, tissue distribution, and effectiveness in inhibiting immune cell proliferation, vital for personalizing treatment in transplant patients."
PA166213481,"The gene UGT1A1 significantly influences the metabolic rate of raloxifene through its role in the transformation of the drug into raloxifene-4′-glucuronide by UDP-glucuronosyltransferase enzymes. Variations, or polymorphisms, in UGT1A1 can lead to different levels of the drug and its metabolite in the body, thereby affecting both the efficacy and safety of raloxifene by altering how quickly it is metabolized and eliminated."
PA450721,"The pharmacogenetic profile of oseltamivir is influenced by the CES1 gene, which is critical for the metabolic activation of the drug, and variants in CES1 can affect the transformation of oseltamivir to its active metabolite, oseltamivir carboxylate, impacting its antiviral efficacy. Additionally, ABCC4, a transporter gene, may alter the pharmacokinetics of the drug by affecting the distribution and excretion of oseltamivir and its metabolites, thereby influencing drug levels and modifying therapeutic outcomes."
PA166182723,"Eribulin interacts with the tubulin gene (TUBB1) to disrupt microtubule functions essential for cell division, and with the apoptosis regulator Bcl-2 (BCL2) to enhance apoptosis, contributing to its cancer treatment effectiveness. Although it is minimally metabolized by CYP3A4, genetic variations in the CYP3A4 gene could slightly alter eribulin's pharmacokinetic profile, but are unlikely to significantly affect dosage requirements due to its minimal metabolism by this enzyme."
PA450962,"The efficacy and plasma levels of pilocarpine, a muscarinic acetylcholine receptor agonist used in treating xerostomia and glaucoma, are influenced by genetic polymorphisms in CYP2A6, an enzyme responsible for its metabolism. Variants in CYP2A6 can lead to differing drug actions, where reduced activity can cause higher plasma concentrations and possibly more adverse effects, whereas increased enzyme activity might necessitate higher drug doses for effectiveness. Additional influence on pilocarpine’s metabolism is seen with PON1, though its pharmacogenetic impact is less defined."
PA10229,"Genetic variations in enzymes like CYP3A4, CYP3A5, and the CYP2C family significantly influence the metabolism of vardenafil, affecting its efficacy and risk of adverse effects. Additionally, variations in the PDE5A gene, the primary pharmacodynamic target of vardenafil, and in ABCB1, which encodes for the transporter P-glycoprotein, can alter the drug's effectiveness and its pharmacokinetic profile."
PA164744510,"Lofexidine, a medication used for opioid withdrawal, is significantly affected by the CYP2D6 enzyme due to genetic polymorphisms that alter drug metabolism. Poor metabolizers, with lower CYP2D6 activity, may face increased risk of adverse effects due to higher drug concentration in the plasma, whereas rapid metabolizers may see reduced effectiveness due to lower drug levels, underscoring the need to tailor dosing based on individual genetic profiles to optimize efficacy and minimize side effects."
PA448385,"Amitriptyline’s metabolism and effect are significantly influenced by genetic variations in CYP2D6 and CYP2C19, which alter its enzymatic breakdown, and ABCB1, which affects its distribution across the blood-brain barrier. Poor metabolizers of CYP2D6 may have increased drug levels leading to a higher risk of adverse effects, while variations in CYP2C19 and ABCB1 can impact the drug’s efficacy and side-effect profile by affecting metabolic rate and drug transport, respectively."
PA131301952,"The pharmacogenetics of gefitinib involve interactions with the EGFR gene, where polymorphisms such as rs121434568, rs28929495, and rs121913444 significantly affect patient responses, and with CYP3A4 and CYP3A5 enzymes, which influence its metabolism and plasma concentrations. Variants in these genes, along with the ABCG2 gene polymorphism rs2231142, which impacts drug excretion and side effects like diarrhea, are critical for optimizing gefitinib's therapeutic effects and minimizing adverse reactions through tailored dosing based on individual genetic profiles."
PA448045,"Acyclovir's effectiveness as an antiviral drug is influenced by genetic variations in several cellular enzymes involved in its activation and metabolism. The drug is initially activated by viral thymidine kinase and further phosphorylated by human enzymes such as guanylate kinase and creatine kinase, with genetic variants in these enzymes potentially altering the drug's efficacy. Additionally, genetic variations in renal transporters like SLC22A1, SLC22A6, and SLC22A8 could affect acyclovir’s clearance, thereby impacting drug levels and toxicity risk."
PA449269,"The pharmacokinetics and pharmacodynamics of dextroamphetamine are significantly influenced by genetic variations: CYP2D6 affects its metabolism, where variations can alter drug clearance rates leading to different therapeutic outcomes; genes such as SLC6A3 and DRD1 impact its effects on dopamine pathways, thereby affecting the drug’s effectiveness in managing ADHD symptoms."
PA448948,"Chloroquine metabolism primarily involves CYP2C8, alongside other cytochrome P450 enzymes like CYP3A4, CYP3A5, CYP2D6, and CYP1A1, where genetic variations in these enzymes can significantly influence chloroquine's plasma levels and thus its efficacy and toxicity. Additionally, the transporter gene ABCB1 affects its distribution and excretion, while non-enzymatic factors such as G6PD deficiency impact the risk of hemolysis in treated patients, illustrating a complex interaction between genetic factors and chloroquine's pharmacological effects."
PA166152838,"Genetic variants in the KEAP1 gene, influencing the Nrf2 pathway related to oxidative stress, and in the HLA-DRB1 gene, important for immune response, could impact the effectiveness and patient response to dimethyl fumarate due to their roles in the drug’s pharmacodynamic properties. Additionally, gene GSTP1, while implicated in oxidative stress may affect the drug’s pharmacodynamics, though direct clinical evidence is lacking."
PA166175754,"Tezacaftor is designed to rectify CFTR protein defects (notably those from the F508del mutation) by improving ion transfer across cell membranes, with its effectiveness dependent on variations in the CFTR gene. Its metabolism, primarily through CYP3A4 and CYP3A5, and interactions with other CYP enzymes and various transporters, suggest that genetic differences in these metabolic pathways could impact its pharmacokinetics, influencing both the drug's plasma levels and its overall efficacy and safety."
PA166114484,"XK469, a topoisomerase II inhibitor aimed at treating cancer, primarily interacts with the TOP2 gene that encodes the enzyme it targets, influencing its ability to impair DNA replication and cell division in cancer cells. Additionally, variations in the AOX1 gene, which is involved in the drug's metabolism, could affect the clearance and overall exposure of XK469, thereby impacting treatment outcomes."
PA449972,"Imiquimod's pharmacogenetic interactions involve its activation of TLR7, influencing cytokine production like interferon-alpha and tumor necrosis factor-alpha, with genetic variants potentially impacting its efficacy and safety. Additionally, variations in the CYP3A4 gene, responsible for the drug's hepatic metabolism, can affect imiquimod's pharmacokinetics, suggesting that differing genetic profiles can lead to variable patient responses based on both immune response and drug levels."
PA164742987,"Clavulanic acid functions primarily as a beta-lactamase inhibitor with its action targeting bacterial enzymes rather than human genetic variations, hence showing limited direct pharmacogenetic interactions. However, variations in human transport proteins, such as those encoded by the gene SLC5A1, could influence the absorption and pharmacokinetics of clavulanic acid, potentially affecting its effectiveness in combination with other antibiotics."
PA449591,"Felodipine’s metabolism is primarily influenced by the cytochrome P450 enzymes CYP3A4 and CYP3A5, with genetic variations in these enzymes significantly affecting its pharmacokinetic profile, plasma concentrations, and thus its effectiveness and side effect potential. Differences in metabolic activity due to these genetic variations could lead to either an overresponse or a need for higher doses in affected individuals, highlighting the importance of genetic considerations in treatment plans. The ABCG2 and CACNA1C genes also play roles in felodipine’s pharmacokinetics and pharmacodynamics respectively, but their effects are less directly established in clinical settings compared to CYP3A4 and CYP3A5."
PA165958348,"Indacaterol's effectiveness and tolerability are influenced by genetic variations in ADRB2, which affect its bronchodilatory efficacy, and in the metabolic enzymes CYP3A4 and UGT1A1, which alter the drug's plasma levels and clearance rates. These genetic factors can lead to clinical variability in therapeutic responses among patients, necessitating adjusted dosing regimens or precautions based on individual genetic profiles."
PA451346,"Sildenafil's pharmacogenetics prominently involves the metabolism-related CYP3A4 gene, which affects the drug’s plasma concentration and safety by varying metabolic rates, and PDE5A, which sildenafil directly targets to enhance erectile function, indicating potential efficacy changes depending on genetic variants. Additionally, genes such as ABCB1, ACE, and GNB3 influence pharmacokinetics and therapeutic responses through their roles in drug transport, distribution, and cardiovascular physiology relevant to sildenafil’s action."
PA451257,"Risperidone metabolism is heavily influenced by the CYP2D6 gene, with variants affecting drug plasma levels and, consequently, its efficacy and side effects. Other genes such as CYP3A4 and ABCB1 also affect its metabolism and transport, while the pharmacodynamics involve interactions with neuroreceptors like DRD2 and HTR2A, which can impact therapeutic outcomes based on genetic variations affecting receptor expression or function."
PA166128206,"Metamizole is metabolized by cytochrome P450 enzymes CYP2C9 and CYP2C19, which are responsible for the transformation of the drug into active metabolites such as MAA and AA, with genetic variants in these enzymes potentially leading to variations in drug efficacy and safety. Additionally, NAT2, involved in drug acetylation, influences metamizole metabolism and side effects like agranulocytosis through genetically determined fast or slow acetylator phenotypes."
PA166241781,"Isepamicin can cause pharmacogenetic interactions leading to ototoxicity, particularly in individuals with genetic mutations in mitochondrial genes MT-RNR1 and MT-ND1. These mutations increase mitochondrial vulnerability to the drug's effects, with MT-RNR1 impacting mitochondrial ribosomal functions related to hearing and MT-ND1 affecting the mitochondrial respiratory chain, thereby exacerbating the impact on sensory hair cells of the ear."
PA449533,"The pharmacogenetics of ethosuximide, an anticonvulsant for absence seizures, is influenced by variability in genes CYP3A4 and CYP2E1 that encode for hepatic enzymes responsible for the drug's metabolism. Polymorphisms in these genes can lead to differing metabolic rates, affecting the drug’s plasma levels, efficacy, and side-effect profiles, indicating the potential benefit of genetic testing in personalizing dosage and minimizing adverse effects."
PA450348,"The pharmacogenetics of mefloquine is influenced by variations in genes such as CYP3A4, which affects the drug's metabolism rate and could lead to variable plasma concentrations and neuropsychiatric side effects. Additionally, polymorphisms in the ABCB1 gene impact the drug's distribution and elimination, while genetic factors like G6PD deficiency can enhance sensitivity to oxidative stress induced by malaria, all of which potentially modify the therapeutic outcomes and side effects of mefloquine."
PA451232,"The analgesic effects of remifentanil, an ultra-short acting opioid, are primarily mediated by the mu-type opioid receptor encoded by the OPRM1 gene; variations in this gene can alter remifentanil's efficacy and side effects, such as respiratory depression. Additionally, genes like ABCB1, COMT, KCNJ6, SLC6A4, ADRB2, SLC9A9, and TMEM8A can influence remifentanil’s effects by affecting opioid signaling pathways, neurotransmitter metabolism, CNS excitability, or pain perception, though remifentanil's metabolism through nonspecific esterases rather than hepatic enzymes means these interactions might be indirect or less pronounced."
PA166177513,"Variants in the genes CYP3A4 and CYP2D6 can significantly influence the metabolism of mirabegron, affecting its plasma levels and pharmacological efficacy, while genetic diversity in UGT enzymes (UGT2B7, UGT1A3, UGT1A8) and several transporters (ABCB1, SLCO1A2, SLC22A1, SLC22A2, SLC22A3) impacts the drug’s clearance, bioavailability, and distribution, potentially altering therapeutic outcomes and adverse effects. Genetic variations in the ADRB3 receptor also play a role, directly affecting the therapeutic efficacy of mirabegron."
PA451101,"Prilocaine's effectiveness and safety are influenced by its interaction with the SCN5A gene, which affects the sensitivity of nerve cells to the drug's sodium channel blocking action, and the G6PD gene, where deficiency might increase the risk of methemoglobinemia, a serious side effect where hemoglobin is unable to efficiently carry oxygen. These genetic factors necessitate tailored prilocaine administration strategies to mitigate potential adverse reactions in susceptible individuals."
PA450523,"Misoprostol's pharmacological effects, such as reducing gastric acid secretion and stimulating uterine contractions, are mediated through the activation of PTGER1, PTGER2, PTGER3, and PTGER4 receptor subtypes. Genetic variations in these receptor genes could influence individual responses to misoprostol, affecting drug efficacy and side effect profiles, although specific pharmacokinetic interactions involving metabolism or transport enzymes are not evident."
PA164746757,"Variants in the genes CYP2D6, CYP2C19, and CYP3A4 significantly influence the metabolism of tolterodine, affecting drug levels and patient responses. CYP2D6 polymorphisms, in particular, categorize individuals into different metabolizer types (from poor to ultra-rapid), impacting drug clearance and necessitating tailored dosing to optimize therapeutic outcomes and minimize side effects for treating symptoms of overactive bladder."
PA166185163,"Pitolisant's metabolism is largely impacted by the CYP2D6 enzyme, with variations in this gene affecting drug plasma levels and patient response due to genetic polymorphisms. Additional enzymes such as CYP3A4, CYP1A2, and CYP2B6 also metabolize pitolisant, contributing further to the complexity of its pharmacogenetic interactions that influence individual drug efficacy and side effects."
PA450546,"Variations in the cytochrome P450 enzyme genes, **CYP2C8** and **CYP2C9**, significantly impact the pharmacokinetics of montelukast by altering drug levels in the body, which in turn affects the drug’s efficacy and safety profile. Additionally, montelukast pharmacokinetics can also be influenced by genetic variations in **SLCO2B1**, a gene that affects the drug's absorption and clearance, as well as indirectly by **ALOX5**, which is involved in leukotriene synthesis pathways."
PA451978,"The pharmacogenetics of zonisamide, a sulfonamide anticonvulsant, is influenced by the CYP3A4 gene, which affects the drug’s metabolism and consequently its pharmacokinetics, impacting efficacy and toxicity. Additional genes such as CYP3A5, ABCB1, and those encoding sodium channel subunits (SCN1A, SCN2A, SCN3A, SCN4A, and SCN5A) and carbonic anhydrases (CA1, CA2) also potentially modulate its metabolic processes, transport, and pharmacodynamic properties, which can alter zonisamide’s effectiveness and susceptibility to side effects like metabolic acidosis."
PA450985,"The pharmacogenetic profile of piroxicam is significantly influenced by its interactions with CYP2C9 and CYP2C8 genes, which are vital in its metabolism. Polymorphisms in CYP2C9 can lead to altered metabolic clearance, resulting in higher drug levels and an increased risk of gastrointestinal side effects. While CYP2C8 also plays a role in metabolism, transporter proteins like SLC22A6, SLC22A8, and SLCO2B1 impact the renal excretion of piroxicam, affecting drug accumulation and elimination."
PA151958426,"Nebivolol's effectiveness and safety are influenced by genetic variations in the CYP2D6 gene, affecting how different individuals metabolize the drug via the cytochrome P450 system. Additionally, while not directly evidenced, variations in beta-adrenergic receptor genes (ADRB1, ADRB2, ADRB3) may hypothetically affect individual responses to nebivolol related to its pharmacodynamics, whereby different gene variations could impact the drug's efficacy and side effects."
PA451688,"Tiludronate, a drug used to treat bone conditions like Paget's disease, impacts osteoclast function and survival by targeting tyrosine-protein phosphatases (PTPN12, PTPN6, PTPRE) and inhibiting subunits of the vacuolar-type H+-ATPase (V-ATPase, e.g., ATP6V0A1 and ATP6V0A2), which are essential for osteoclast attachment to bone and bone resorption. Genetic variations in these protein-coding genes could potentially affect the drug's efficacy and safety, although clear pharmacogenetic correlations have yet to be conclusively documented in clinical settings."
PA448333,"Alprazolam's metabolism is significantly affected by variants in the cytochrome P450 enzymes CYP3A4 and CYP3A5, leading to variability in how quickly the drug is processed in the body. This impacts alprazolam's efficacy and safety, where increased enzyme activity can lead to reduced effectiveness, and decreased activity can result in higher, potentially toxic drug concentrations. These differences guide adjustments in dosage to optimize therapeutic outcomes and minimize adverse effects for treating anxiety and panic disorders."
PA128406956,"Fluorouracil's metabolism and risk of toxicity are significantly influenced by the DPYD gene, where polymorphisms such as rs3918290 and rs55886062 can reduce enzyme activity needed for the drug's catabolism. On the pharmacodynamic side, efficacy is impacted by the TYMS gene, which is involved in DNA synthesis inhibition, and other pharmacogenetic interactions occur with genes like GSTP1 and UMPS, which affect toxicity and drug effectiveness, respectively."
PA166160633,"Thio-GTP, a research tool used to study GTP-binding proteins, interacts primarily through pharmacodynamics with GTPases such as KRAS, HRAS, and NRAS. Variations in the genes encoding these GTPases could affect thio-GTP's binding efficiency and inhibitory effects, providing insights into the modulation of signaling pathways and the potential impact of genetic differences on these interactions."
PA165958406,"Dimercaprol forms complexes with metals such as arsenic and lead using its sulfhydryl groups, and its efficacy is primarily linked to this binding activity rather than interactions with metabolic enzymes influenced by genetic variations. While the potential influence of genetic variations in the G6PD gene on the side effects of dimercaprol is theoretically possible because individuals with G6PD deficiency may react differently to the oxidative stress from metal toxicity and dimercaprol's chelation process, this pharmacogenetic relationship remains largely unexplored and speculative."
PA451799,"Genetic variations in the metabolic enzymes CYP3A4 and CYP2C8 influence the metabolism of Troglitazone, affecting its plasma levels, efficacy, and safety, while variants in pharmacodynamic gene PPARG and transporters ABCB11 and SLCO1B1 can impact responses related to insulin sensitivity, glucose regulation, and increase the risk of hepatotoxicity by modifying hepatic exposure."
PA450774,"Genetic variations in the CYP2C19 enzyme significantly influence the metabolism of pantoprazole, affecting drug concentrations, efficacy, and side effect risks, with poor metabolizers experiencing increased drug exposure and ultrarapid metabolizers having reduced levels. Additionally, variants in the transporter proteins ABCB1 and ABCG2 can alter the absorption and elimination of pantoprazole, thereby impacting its plasma levels and distribution, which further affects its therapeutic outcomes and side effect profile."
PA450877,"Perindopril, an ACE inhibitor, has pharmacogenetic interactions primarily influenced by the ACE gene that affects its ability to inhibit the conversion of angiotensin I to angiotensin II, altering its antihypertensive effects. Further, the BCHE gene modifies how perindopril is metabolized into its active form, perindoprilat, affecting its efficacy and safety, while transporter genes SLC15A1 and SLC15A2, along with the BDKRB1 gene in the bradykinin pathway, adjust the drug's pharmacokinetics and vasodilatory effects. Genes like G6PD and AGTR1 also play secondary roles in impacting the cardiovascular response to perindopril through mechanisms involving oxidative stress and angiotensin II receptor functionality."
PA164769031,"Lumiracoxib, a COX-2 selective NSAID, primarily interacts pharmacogenetically through the CYP2C9 enzyme, where variants like CYP2C9*2 and CYP2C9*3 result in reduced metabolic activity, thus potentially increasing the drug's plasma levels and the risk of liver toxicity. While minor metabolic pathways involving CYP2C19, CYP1A2, and UGT1A9, and potential associations with HLA variants like HLA-DQB1, HLA-DQA1, and HLA-DRB1 are noted, their impact on lumiracoxib's pharmacokinetics and safety is less significant than that of CYP2C9."
PA452620,"The pharmacogenetic profile of tegafur is influenced by genes related to its metabolism, such as CYP2A6, which affects its conversion to the active drug 5-FU, and DPYD, where variants like rs3918290, rs55886062, and rs67376798 can cause significant toxicity by impairing 5-FU breakdown. Other genes such as FASTKD3, MTRR, EGFR, SMAD7, TYMS, and UMPS also affect tegafur's pharmacodynamics and therapeutic effectiveness, either by impacting the metabolism of pyrimidine or through pathways related to cellular growth and replication."
PA166160623,"Thioguanine, used in treating acute myeloid leukemia, is metabolized into active metabolites primarily through the purine salvage pathway, with TPMT and NUDT15 genetic variants influencing the drug's metabolism and toxicity. Variants in TPMT can reduce enzyme activity and increase toxicity risks, while NUDT15 variants similarly affect thioguanine's toxicity profile, underlining the importance of genetic testing before treatment to adjust dosages and minimize toxicities."
PA166272922,"Variations in the CYP2C19 gene, along with contributions from CYP3A4 and CYP2C9 polymorphisms, significantly affect mavacamten metabolism. Such genetic differences lead to varying plasma concentrations in individuals; where poor metabolizers might experience higher drug concentrations and potential side effects, ultra-rapid metabolizers might see reduced drug levels and efficacy, indicating a need for customized dosing to optimize treatment outcomes."
PA165983956,"Acetaminophen metabolism involves critical pharmacogenetic interactions primarily with the CYP2E1 enzyme that produces the hepatotoxic metabolite NAPQI and the glutathione S-transferases (GSTM1 and GSTT1) that help detoxify NAPQI. Genetic variations in these enzymes affect the rate of NAPQI production and detoxification, influencing liver toxicity risk, especially under conditions of high dosage or concurrent alcohol consumption that induce CYP2E1 activity."
nan-6db9e41e-6ed1-4c78-a35e-c50096481921,"Linezolid's pharmacokinetic and pharmacodynamic properties may be impacted by genetic variants in human enzymes such as MAOA and MAOB, which it inhibits, potentially raising the risk of serotonin syndrome when used with other serotonergic drugs. Additionally, genetic variations in transporters like SLC22A6 and SLC22A8, crucial for its renal excretion, as well as variations in the albumin gene affecting ALB binding, can influence the drug's clearance, distribution, and half-life."
PA448010,"Acarbose acts by inhibiting enzymes like MGAM, SI, AMY2A, and GAA in the gastrointestinal tract, affecting the pharmacodynamics rather than the pharmacokinetics due to its minimal systemic absorption. Genetic variations in these enzymes or in metabolic regulators like PPARA, which influences lipid and possibly carbohydrate metabolism, could hypothetically affect the drug's effectiveness and side effects, even though specific pharmacogenetic interactions are not well-documented for acarbose."
PA451879,"Vincristine metabolism is significantly affected by variations in CYP3A4 and CYP3A5 genes, influencing its metabolic clearance, and thereby altering drug exposure and risks of toxicity. Additionally, genetic variations in transporters like ABCB1, ABCC1, ABCC2, and ABCC3 can modify vincristine's distribution and elimination, affecting drug resistance and toxicity, while interactions with proteins like TUBB and TUBA4A impact its pharmacodynamics."
PA166226561,"The genetic variability in CYP2B6, including alleles like CYP2B6*6, influences the metabolism of bupropion into its primary active metabolite, hydroxybupropion, causing differences in drug plasma levels and thereby affecting its efficacy and side effect profile. Variations in enzyme activity lead to varied pharmacodynamic outcomes due to altered levels of hydroxybupropion, which maintains the pharmacological properties of bupropion, influencing the reuptake of norepinephrine and dopamine."
PA166127652,"The pharmacogenetic interaction of the drug 4-hydroxytamoxifen is influenced by the activity and genetic variants of metabolic enzymes such as CYP2D6, which is critical for its conversion from tamoxifen into its active form. Additionally, genes like SULT1A1 and UGT2B15 further metabolize 4-hydroxytamoxifen, affecting its solubility, excretion, and elimination; variations in these genes can significantly alter drug efficacy and safety, emphasizing the importance of these genetic factors in personalized cancer treatment strategies."
PA450480,"Metoprolol's effectiveness and safety are influenced by genetic variations in the CYP2D6 gene affecting its metabolism and polymorphisms in the ADRB1 gene altering receptor sensitivity. These genetic differences impact metoprolol's plasma levels and its therapeutic efficacy in controlling heart rate and arrhythmias, underscoring the need for tailored drug dosing."
PA166258723,"Tenofovir alafenamide's activation into its pharmacologically active form, tenofovir diphosphate, relies on CTSA and CES1, with CES1 variants affecting the rate of this activation and consequently the drug's efficacy and safety. Additionally, the drug's bioavailability and systemic exposure are significantly influenced by transporters like ABCB1, ABCC4, SLCO1B1, SLCO1B3, and SLC22A6, where genetic variants in these transporters can alter drug plasma levels, impacting therapeutic outcomes and side effect profiles."
PA450600,"Genetic variations in the CYP2C9 enzyme significantly affect the metabolism of nateglinide, with polymorphisms such as CYP2C9*2 and CYP2C9*3 leading to decreased enzyme activity and slower drug metabolism, potentially increasing the risk of hypoglycemia. Additionally, transporter genes like ABCC4 and SLC22A6 influence the drug's pharmacokinetics by affecting drug efflux and elimination, respectively, with variations in these genes contributing to variability in drug response, impacting the effectiveness and safety of nateglinide in managing type 2 diabetes."
nan-fc46f6a4-092f-49da-913f-f42ebd7dde6f,"The pharmacogenetic interactions of Pretomanid, a drug used for drug-resistant tuberculosis, involve genes like CYP3A4, which is key to its oxidative metabolism and impacted by genetic polymorphisms altering the drug's efficacy and side effects. Additionally, the bacterial enzyme Ddn is essential for activating Pretomanid under anaerobic conditions, while human transporter genes such as SLC22A8 could influence its absorption and distribution in the body."
PA450422,"Methimazole's metabolism and subsequent efficacy and toxicity are influenced by genetic polymorphisms in several cytochrome P450 enzymes, including CYP1A2, CYP2A6, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4, and FMO3. Variations in these genes can affect the drug's metabolic rate, resulting in altered serum concentrations, differential therapeutic outcomes, and varying risk profiles for adverse effects, with specific alleles in enzymes like CYP2C19 and CYP3A4 potentially leading to higher drug concentrations that may both enhance efficacy and increase the likelihood of side effects."
PA449259,"Dexrazoxane targets the enzymatic function of TOP2A and TOP2B to mitigate the cardiotoxic effects of anthracyclines by protecting DNA structure, which is a pharmacodynamic interaction. Variants in genes related to iron metabolism or enzymes involved in hydrolysis, like dihydropyrimidine amidohydrolase, could potentially influence the efficacy and safety of dexrazoxane, particularly its cardioprotective effects."
PA449088,"Codeine's efficacy and safety are influenced by genetic variants primarily in CYP2D6, which metabolizes codeine into morphine, its active form, with variants leading to different metabolizing efficiencies and impacting therapeutic outcomes. Other genes like ABCB1, UGT2B7, OPRM1, and SLC22A1 also play roles in codeine's absorption, distribution, clearance, and pharmacodynamic interaction by encoding proteins that affect the drug's overall bioavailability and response."
PA449319,"The ABCB1 gene, which encodes P-glycoprotein, plays a crucial role in the pharmacokinetics of digoxin by affecting its absorption, distribution, and excretion, with polymorphisms in this gene altering transporter activity and thus impacting digoxin plasma levels, efficacy, and toxicity. Other genes such as ADRB1, ADRB2, ACE, NOS1AP, and NOS3 might influence pharmacodynamic interactions by affecting cardiac response and myocardial ion handling, central to digoxin's mechanism of action through ATP1A1 inhibition."
PA449686,"Genetic variants in the CYP3A4 gene can significantly alter the metabolism of fluticasone propionate, impacting its clearance and leading to variations in drug efficacy and side effect risk. Additionally, polymorphisms in transporters such as ABCB1 and SLCO1B1, along with variations in the glucocorticoid receptor NR3C1, can influence the drug's absorption, distribution, and receptor sensitivity, affecting therapeutic outcomes and side effects."
PA164742970,"The pharmacogenetics of carbimazole involves its conversion to the active form, methimazole, influenced by the enzyme CYP19A1, and the effectiveness of methimazole is modulated by genetic variations in thyroid peroxidase (TPO), which could affect drug efficacy and safety in treating hyperthyroidism. Variations in CYP19A1 may alter the activation rate of carbimazole, while TPO polymorphisms could impact the drug's ability to reduce thyroid hormone synthesis."
PA164764583,"Genetic variations in the cytochrome P450 enzymes CYP1A2, CYP2C19, CYP3A4, and CYP3A5 significantly affect the metabolism of praziquantel in the liver, influencing its pharmacokinetics. Polymorphisms in CYP2C19, for instance, can lead to either rapid or poor metabolism of the drug, affecting plasma concentrations and consequently its efficacy and safety, which may necessitate dosage adjustments based on individual genetic profiles."
PA449894,"Hydralazine metabolism and clearance are greatly influenced by the N-acetyltransferase 2 (NAT2) gene, which determines a patient's acetylator status, leading fast acetylators to process the drug quickly, reducing its efficacy, while slow acetylators may have increased drug levels and higher risk of adverse effects like drug-induced lupus. Additionally, genes such as HLA-DRB1 and MMP9 might affect immune and cardiovascular responses to the drug, though these interactions are more speculative and not directly linked to metabolism."
PA166160048,"Lacosamide's metabolism is significantly influenced by cytochrome P450 enzymes such as CYP3A4, CYP2C9, and CYP2C19, where genetic variants in these enzymes affect the drug's plasma concentration and its effectiveness in treating seizures. Additionally, the ABCC2 gene may also play a role in mediating the drug's transport mechanisms, impacting its distribution or elimination, although its specific influence on lacosamide's pharmacokinetics is less defined than that of the cytochrome P450 interactions."
PA165857067,"Variants in the DHFR gene of malaria parasites may influence the effectiveness of chlorproguanil by potentially causing resistance, and genetic variability in human drug-metabolizing enzymes, such as CYP450 isoforms, might affect the pharmacokinetics of chlorproguanil, altering its levels, efficacy, and safety. Thus, the interactions of the drug involve both pharmacodynamic actions on DHFR in the parasite and potential pharmacokinetic processes mediated by liver enzymes in humans."
nan-10cb7504-1815-48f4-9db9-1df9ce025271,"Bedaquiline's effectiveness and safety are influenced by variations in the CYP3A4 gene, which affect the drug's metabolism. Individuals with genetic variants that either enhance or reduce CYP3A4 enzyme activity may experience either reduced efficacy or increased risk of adverse effects like QT prolongation, respectively. This necessitates consideration of dose adjustments or thorough monitoring to balance therapeutic benefits and risks."
PA448519,"Genetic variations in the CYP3A4 enzyme significantly affect the metabolism of azithromycin, impacting drug levels and influencing both the drug's effectiveness and potential side effects due to differences in enzyme activity among individuals. Additionally, variants in the ABCB1 and ABCC2 genes alter the efficacy of azithromycin's transport and excretion processes, thereby affecting the drug's bioavailability, plasma concentration, and therapeutic outcomes."
PA451333,"Genetic variations in the enzymes CYP3A4, CYP2B6, CYP2C19, and CYP2D6, as well as the transporter ABCB1, significantly affect the metabolism, efficacy, and safety of sertraline, a selective serotonin reuptake inhibitor. Specifically, variants in CYP2C19, like rs4244285 and rs4986893, result in poor metabolism, leading to higher plasma levels of the drug and potentially increasing the risk of adverse effects, which highlights the importance of genotyping these variations for optimizing treatment plans."
PA166131548,"The gene CYP2D6 plays a crucial role in metabolizing noroxymorphone, leading to variations in drug levels and effects among individuals, while genetic variants in OPRM1 influence how the mu-opioid receptor interacts with noroxymorphone, affecting pain relief and adverse effects. Given their roles in the metabolism and pharmacodynamics of oxymorphone, these genetic factors logically extend their influence to noroxymorphone, underscoring their importance in determining individual responses to the drug."
PA450218,"Levonorgestrel's effectiveness and side effects are influenced by its interactions with genes such as CYP3A4 and CYP3A5, which govern its hepatic metabolism, and PGR and ESR1, which control the cellular response to the drug through hormone receptor sensitivity. Variations in these genes affect the drug's metabolic rate, efficacy, and the body's hormonal interactions, impacting contraceptive reliability and potential side effects."
PA166177484,"Enasidenib, an inhibitor targeting mutant forms of isocitrate dehydrogenase 2 (IDH2), specifically acts on mutations such as IDH2-R140Q, IDH2-R172S, and IDH2-R172K, crucial for its effectiveness in cancer therapy. Its metabolism is influenced by genes encoding cytochrome P450 enzymes (e.g., CYP1A2, CYP2B6), transport proteins (e.g., ABCB1, SLCO1B1), and UGT enzymes (e.g., UGT1A1, UGT1A3), suggesting that genetic variations in these genes can significantly affect the drug's plasma levels and patient outcomes."
PA451096,"Prednisolone interacts pharmacogenetically mainly through CYP3A4, which metabolizes the drug, affecting its dosage and side effects, and ABCB1, which influences its bioavailability by regulating cellular efflux. The drug’s action is further impacted by the NR3C1 gene, where genetic variations modify the sensitivity of the glucocorticoid receptor, thus affecting prednisolone’s anti-inflammatory and immunosuppressive efficacy."
PA165107357,"Variants of the CYP2C19 gene affect the conversion of proguanil to its active metabolite cycloguanil, impacting the drug's plasma levels and therapeutic efficacy in malaria treatment. Additionally, genetic variability in DHFR, the target enzyme of cycloguanil, influences the drug's effectiveness and potential for resistance development among different Plasmodium species."
PA449750,"Gemfibrozil's effects and metabolism are largely influenced by its interaction with genes such as CYP2C8, which is vital for its metabolic breakdown, UGT1A1 and UGT2B7, which are involved in its glucuronidation and elimination, and PPARα, which mediates its lipid-regulating effects. Variants in these genes can alter gemfibrozil's plasma concentrations and efficacy, impacting both its therapeutic outcomes and potential for drug-drug interactions."
PA166220606,"Bazedoxifene, a selective estrogen receptor modulator (SERM), interacts with estrogen receptors ESR1 and ESR2, and its metabolism is primarily through glucuronidation by UGT enzymes, notably UGT1A4, UGT1A8, and UGT1A10. Variations in these UGT genes affect the drug's metabolism rate, influencing its effectiveness, safety, and individualized therapeutic outcomes in treating menopausal symptoms and preventing postmenopausal osteoporosis."
PA451216,"Variations in the CYP2C19 gene significantly affect the metabolism of rabeprazole, with poor metabolizers having increased plasma concentrations that might enhance therapeutic outcomes or elevate side effects, whereas extensive metabolizers might experience reduced efficacy due to lower drug levels. Additionally, certain variants in the IL1B gene can modify the inflammatory response in gastric cells, potentially affecting the drug's effectiveness in treating gastric conditions."
PA166153470,"Ribociclib, primarily metabolized by the CYP3A4 enzyme, is affected by genetic variants in this enzyme, which can alter drug bioavailability and efficacy; for example, individuals with reduced function alleles of CYP3A4 may have higher levels of the drug and an increased risk of toxicity. Additionally, while genes like PGR, ERBB2, ESR1, and ESR2 are involved in pathways pertinent to breast cancer and its treatment with ribociclib, they do not directly impact its metabolism or pharmacokinetic effects."
PA451106,"Probenecid's pharmacogenetic interactions mainly involve ABCB1, a gene that influences drug transport, affecting the distribution and elimination of Probenecid and co-administered drugs like β-lactam antibiotics. Additionally, while the interaction between Probenecid and the G6PD gene, which affects glucose-6-phosphate dehydrogenase activity, is less direct, it could potentially influence metabolic balance, especially under stress or increased metabolic demand."
PA449961,"The pharmacogenetics of idarubicin involve several genes including CYP2C9 and CYP2D6, which affect the drug’s metabolism and pharmacokinetics, and TOP2A, the target gene of idarubicin that impacts DNA processes and apoptosis. Other significant genes like ABCC1, CBR3, ADH1A, SLCO1B1, ABCB1, NQO1, and DCK influence the drug's absorption, distribution, metabolic pathways, and resistance, playing a crucial role in determining individual treatment efficacy and adverse effects associated with idarubicin."
PA166179867,"Binimetinib, a drug that inhibits MEK1 and MEK2, is metabolized through glucuronidation by UGT1A1 and oxidative pathways involving CYP1A2 and CYP2C19, with genetic variations in these genes affecting drug processing, efficacy, and toxicity. Furthermore, the efficacy of binimetinib in treating conditions like melanoma and NSCLC is contingent on BRAF gene mutations (specifically V600E or V600K), making pharmacogenetic testing for these mutations critical for patient selection and predicting treatment response."
PA164781343,"Varenicline acts primarily on nicotinic acetylcholine receptors, particularly through CHRNA4 and CHRNB2, and its efficacy and side effects can be influenced by genetic variants in these receptor genes. Additionally, variations in the SLC22A2 gene, responsible for the drug's renal excretion, can affect varenicline pharmacokinetics, impacting drug levels and elimination, thus modifying the clinical response or toxicity risk."
PA449773,"Variations in genes such as **TCF7L2**, **SLC2A2**, **GCK**, **IRS1**, **INS**, and **INSR** play critical roles in influencing insulin secretion, glucose homeostasis, glucose transport, insulin release, and insulin signaling pathways, all of which impact glucose utilization and diabetes management. Gene mutations in these areas can lead to issues like insulin resistance and altered diabetes risk by affecting how glucose is handled in the body."
PA10892,"Genetic polymorphisms in CYP2C9 and CYP2C19 can significantly affect the metabolism of Gliclazide, potentially necessitating dose adjustments due to altered drug plasma levels and risk of hypoglycemia. Additionally, ABCC8 gene variants may influence the efficacy of Gliclazide by affecting insulin secretion from pancreas cells, and changes in other genes such as VEGFA may contribute to its cardiovascular effects."
PA131890625,"The metabolism of tenoxicam, an NSAID, is significantly influenced by genetic variations in the CYP2C9 enzyme which it utilizes for liver metabolism; these variations affect how the drug is processed and thus its plasma levels, posing risks of prolonged exposure in individuals with reduced CYP2C9 activity. Additionally, tenoxicam's effectiveness and side effects are also affected through its inhibition of PTGS1 and PTGS2, critical enzymes in prostaglandin synthesis, and by the transporter protein SLC22A8, which influences its renal excretion."
PA10804,"Imatinib's effectiveness and side effects in treating chronic myeloid leukemia and gastrointestinal stromal tumors are influenced by genetic variations in metabolic enzymes (CYP3A4, CYP3A5), transporters (ABCB1, ABCG2), and absorption/distribution genes (SLC22A1, SLCO1A2). Additionally, mutations in target proteins like BCR-ABL and KIT also affect the drug's efficacy, highlighting the need for genotyping these genes to optimize treatment outcomes and personalize therapy."
PA166197521,"Desethyl hydroxychloroquine metabolism largely depends on the cytochrome P450 enzymes CYP2D6, CYP2C8, and CYP3A4/5, which influence the formation and elimination of the metabolite. Additionally, genetic variants in the ABCA4 gene, affecting transporter activity, could modulate the risk of developing retinopathy by altering drug accumulation in the retina."
PA166128132,"Faldaprevir, used in treating Chronic Hepatitis C, likely interacts with the virus's replication processes, with genetic variations in interferon lambda genes IFNL3 and IFNL4 potentially influencing treatment outcomes by affecting the host's immune response to the infection. These genes, relevant in the context of Hepatitis C treatment, may play a significant role in determining the efficacy of faldaprevir through their impact on the innate antiviral response."
PA164749136,"Desflurane's pharmacokinetics are influenced by genetic variability in CYP2E1, which, although minimally involved in its metabolism, can affect anesthetic levels and recovery times. Pharmacodynamic responses to desflurane are influenced by genetic variations in the GABA(A) receptor subunits (GABRA1 and GABRA2), and susceptibility to severe reactions like malignant hyperthermia is affected by genes such as RYR1 and CACNA1S."
PA166161307,"Panobinostat's effectiveness and safety are influenced by its interaction with CYP2D6, CYP2C19, affecting its metabolism, and ABCB1, which alters its distribution and excretion. Variants in these genes can significantly modify drug plasma levels, consequently impacting therapeutic efficacy and potential toxicity, with differing effects observed in individuals with poor or rapid metabolizer phenotypes."
PA166184523,"Alpelisib targets the PIK3CA gene, where mutations enhance cancer cell growth by activating the PI3K pathway, making the drug particularly effective in cancers with these mutations. The drug is metabolized primarily by CYP3A4, with involvement from CYP2C9, CYP2C8, and CYP2C19, and polymorphisms in these enzymes can affect drug efficacy and toxicity. Additionally, alpelisib is an efflux substrate for transporters like ABCG2 and ABCB1, where genetic variants can influence drug efflux and impact its effectiveness and adverse effects."
PA451201,"Variations in the genes CYP2D6, CYP3A4, CYP3A5, ABCB1, and DRD3 significantly influence the pharmacokinetics and pharmacodynamics of quetiapine by affecting its metabolism, clearance, bioavailability, and response in neurotransmitter pathways. Differences in these genes necessitate personalized quetiapine dosing to optimize therapeutic efficacy and minimize side effects based on individual genetic profiles."
PA451341,"Sevoflurane's metabolism involves primarily CYP2E1, and to lesser extents CYP2B6, CYP2A6, and CYP3A4, with genetic variations in these enzymes potentially affecting the rate of metabolism which can influence drug sensitivity and toxicity risks, such as renal-affecting fluoride ion release. Additionally, genetic variants in the GABA_A receptor subunits targeted by Sevoflurane may alter its pharmacodynamic effects, influencing the depth and duration of anesthesia."
PA451250,"Rifampicin's interaction with genes like CYP2C9, CYP2C19, and CYP2E1 affects its metabolism, while polymorphisms in SLCO1B1 influence its hepatic uptake, impacting both the efficacy and safety of the drug. Additionally, rifampicin also influences the function of genes such as CYP2B6, ABCB1, and NR1I2, which affects drug transport and metabolism, along with other enzymes involved in detoxification like GSTT1, GSTM1, and NAT2, thereby modifying drug response or the risk of toxicity."
PA166161216,"The metabolism of aripiprazole, the active drug released from its prodrug aripiprazole lauroxil, is significantly influenced by the cytochrome P450 enzymes CYP2D6 and CYP3A4, with genetic variations in CYP2D6 playing a predominant role in determining the drug's plasma levels, efficacy, and side effect profile. This variability in metabolism due to genetic polymorphisms in CYP2D6 can lead to diverse therapeutic outcomes, necessitating tailored dosing based on the patient's specific genotype to optimize treatment efficacy and minimize adverse effects."
PA450732,"Oxcarbazepine's pharmacokinetics are influenced by ABCB1 transport proteins that manage its bioavailability and distribution, with genetic variants in ABCB1 potentially altering therapeutic levels and drug efficacy. On the pharmacodynamic front, genetic variants in the HLA gene locus, specifically HLA-B*1502 and HLA-A*3101, increase the risk of severe dermatological reactions like Stevens-Johnson Syndrome and toxic epidermal necrolysis, impacting patient safety and necessitating careful consideration of oxcarbazepine use in affected individuals."
PA449009,"Ciprofloxacin metabolism is heavily influenced by genetic variations in the CYP1A2 enzyme, where different polymorphisms can alter the drug's concentration by affecting metabolic rates, leading to variations in efficacy and safety. Variants reducing CYP1A2 activity can increase ciprofloxacin levels and toxicity risk, whereas variants enhancing enzyme function might decrease drug levels, reducing therapeutic effectiveness. Additionally, while not involved in ciprofloxacin metabolism, G6PD deficiencies can increase risks related to oxidative stress in patients using this drug, particularly at high or prolonged doses."
PA165958401,"Cabazitaxel metabolism is primarily mediated by CYP3A4 and CYP3A5 enzymes, with genetic polymorphisms in these enzymes impacting the drug's plasma levels, effectiveness, and toxicity. Additionally, genetic variations in ABCB1 and ABCG2, which are involved in drug transport, can affect cabazitaxel’s distribution and efficacy."
PA450586,"Naloxone's effectiveness in reversing opioid effects is influenced by the OPRM1 gene, which encodes the Mu-type opioid receptor where naloxone acts, with genetic variations potentially affecting receptor affinity and necessitating dosage adjustments. Furthermore, the metabolic process of naloxone is affected by variations in the UGT1A1, CYP3A4, and CYP2C19 genes, impacting its clearance and potentially requiring dose modifications to achieve effective plasma levels."
PA450464,"Methylphenidate, used for ADHD and narcolepsy, is metabolized by CES1, with genetic variants of CES1 affecting its plasma concentration and efficacy. Additionally, genes such as CYP2D6, SLC6A3 (DAT1), and DRD4 influence the drug's pharmacodynamics by altering neurotransmitter reuptake or receptor sensitivity, ultimately impacting its effectiveness and side effect profile."
PA450524,"Mitomycin's pharmacogenetic interactions involve its activation by the enzyme POR, which is essential for converting the drug into its active form that can alkylate DNA, with variability in the POR gene affecting the drug's efficacy and toxicity. Additionally, the gene NQO1, which participates in the activation of quinone-containing compounds, also influences mitomycin’s activation; variants in NQO1 that reduce enzyme activity may alter the drug's therapeutic outcomes and toxicity, reflecting the significant impact of these gene variations on mitomycin’s pharmacodynamics and anti-cancer effects."
PA448033,"Acetylcysteine, used as a mucolytic agent and an antidote for acetaminophen overdose, interacts with genes like glutathione synthetase (GSS) for detoxification and Aminoacylase-1 (ACY1) for its metabolism into cysteine. Variants in transporter genes such as SLCO1B1 and SLC22A6, as well as in the carrier protein Albumin (ALB), can alter its pharmacokinetics and affect acetylcysteine's efficacy and safety in clinical use."
PA451609,"The effectiveness of Temozolomide (TMZ) in treating tumors is significantly affected by the MGMT gene, where the methylation status of the MGMT promoter determines the expression of the MGMT enzyme, impacting the repair of TMZ-induced DNA damage and consequently tumor sensitivity to the drug. Additionally, pharmacokinetics influenced by genes such as ABCB1 and ABCG2, which encode proteins involved in drug transport, alter TMZ's distribution and clearance, further affecting the drug's therapeutic efficacy and side effects."
PA451749,"Triamcinolone, a synthetic corticosteroid, functions by binding to the glucocorticoid receptor (NR3C1) to diminish pro-inflammatory cytokines and its metabolism is primarily mediated by CYP3A4, CYP3A5, and CYP3A7 enzymes. Genetic variations in these enzymes, as well as in carrier proteins like SERPINA6 and ALB, influence the drug's clearance, plasma concentration, distribution, and bioavailability, thereby affecting therapeutic efficacy and side effect profiles."
PA451718,"Tolbutamide metabolism is primarily mediated by CYP2C9, with variants like CYP2C9*2 and CYP2C9*3 leading to slower metabolism and increased risk of adverse effects such as hypoglycemia due to higher and prolonged plasma drug levels. Other genes such as CYP2C19 and G6PD also interact with tolbutamide; CYP2C19 influences its metabolism to a lesser extent, and while G6PD may increase the risk of hemolytic anemia, its direct impact on tolbutamide's pharmacokinetics or pharmacodynamics remains unclear."
PA166249401,"Genetic variations in the CYP3A4 gene affect the metabolism of teneligliptin, a DPP-4 inhibitor, potentially influencing the drug's plasma levels, dosing requirements, and risk of adverse effects due to altered enzyme activity. Variants in the DPP-4 gene might also impact the efficacy of teneligliptin in inhibiting the DPP-4 enzyme, thus affecting therapeutic outcomes in managing Type 2 Diabetes Mellitus."
PA166182881,"Migalastat works effectively as a pharmacological chaperone for treating Fabry disease only in the presence of specific mutations in the GLA gene, termed ""amenable variants."" These variants affect the structural compatibility of the drug with the enzyme alpha-galactosidase A, facilitating its proper folding and transport to the lysosome, crucial for its therapeutic action in degrading glycosphingolipids."
PA143487910,"Aliskiren, used to manage hypertension, pharmacodynamically inhibits the function of the gene REN, affecting the renin-angiotensin-aldosterone system that regulates blood pressure. Pharmacokinetically, aliskiren is minimally metabolized by CYP3A4 and is a substrate of the transporter protein encoded by ABCB1; variations in these genes may influence the drug's metabolism, absorption, and overall efficacy."
PA450633,"Nimodipine's effectiveness and safety are influenced by its interaction with pharmacogenetic components such as the CYP3A5 gene and the CACNA1C gene. Genetic variations in CYP3A5 can affect the metabolism rate of nimodipine, leading to alterations in drug concentration and potential side effects, while variants in CACNA1C can affect the sensitivity of calcium channels to nimodipine, impacting its therapeutic efficacy in treating cerebral vasospasm."
PA164748726,"Entacapone's interactions with genes such as COMT, CYP2D6, and UGT1A9 influence its effectiveness and tolerability in the treatment of Parkinson's disease. Variations in COMT affect dopamine degradation and thus the drug’s pharmacodynamic response, while polymorphisms in CYP2D6 and UGT1A9 alter its metabolism and elimination, impacting drug levels, efficacy, and potential side effects."
PA166213482,"Raloxifene metabolism, particularly into raloxifene 6-glucuronide, is significantly influenced by the UGT1A1 gene, which regulates the glucuronidation process affecting drug plasma levels and thus its safety and efficacy. Additionally, genetic variations in estrogen receptor genes, ESR1 and ESR2, can modify the pharmacodynamic effects of raloxifene, impacting outcomes such as bone density and breast cancer risk reduction."
PA449048,"Clomipramine's pharmacogenetics involves key genes such as CYP2D6, CYP2C19, CYP1A2, CYP3A4, and ABCB1 that affect its pharmacokinetics through variations in drug metabolism, bioavailability, and distribution. Additionally, pharmacodynamic interactions involve genes like HTR2A, HTR2B, HTR2C, and SLC6A4, which influence the drug's effectiveness by affecting serotonin receptor function and serotonin reuptake, crucial for treating depressive and obsessive symptoms."
PA166182720,"Erdafitinib's pharmacogenetic interactions are influenced by metabolism via CYP2C9 and CYP3A4 enzymes, with variants like CYP2C9*3 potentially causing increased plasma concentrations and toxicity, which suggests the need for genotyping to guide dosage adjustments. Additionally, its therapeutic efficacy is dependent on the presence of mutations in FGFR2 and FGFR3 genes, thereby requiring their genetic testing to predict treatment response in patients."
PA451300,"The pharmacogenetics of salmeterol involves its interaction with the ADRB2 gene and metabolism by the CYP3A4 enzyme; genetic variations in ADRB2 can alter beta-2 adrenergic receptor function, affecting the drug's efficacy and side effect profile, while polymorphisms in CYP3A4 and other CYP enzymes influence the drug's plasma concentration and duration of action by affecting its metabolic degradation, thereby impacting safety and effectiveness."
PA166114961,"The metabolism and transport of the drug dolutegravir are significantly impacted by genetic variations in genes such as UGT1A1, CYP3A4, CYP3A5, ABCG2, ABCB1, SLC22A1, and NR1I2. Polymorphisms in these genes affect the drug’s plasma concentration, bioavailability, and distribution, thereby influencing the efficacy and potential side effects of the treatment, which assists clinicians in customizing dosages to optimize treatment outcomes and minimize toxicity."
PA165110439,"Ixabepilone's pharmacokinetic interactions involve the CYP3A4 enzyme and the ABCB1 transporter. Genetic variations in CYP3A4 can alter ixabepilone's plasma levels, impacting its efficacy and toxicity, while variations in ABCB1 can affect the drug's cellular distribution and elimination, potentially leading to decreased effectiveness due to increased drug resistance."
PA166184562,"Tafamidis treats transthyretin-mediated amyloidosis by binding to the tetrameric form of the transthyretin protein, which is encoded by the TTR gene, preventing its dissociation into disease-causing monomers. The drug's pharmacokinetics involve interactions with the ABCG2, SLC22A6, and SLC22A8 genes, which encode transport proteins affecting its excretion and bioavailability, hence influencing its plasma levels and overall efficacy and safety."
PA449646,"The metabolism of flecainide is primarily influenced by the CYP2D6 gene, where genetic variants can lead to differences in enzyme activity, affecting drug levels and efficacy. Other genes such as CYP3A5, CYP1A2, SCN4A, and ADRB1 also play roles in its metabolism and pharmacodynamics, impacting heart rhythm and drug response variability."
PA449586,"Famotidine's clearance and pharmacokinetics are significantly impacted by genetic variations in renal organic ion transporters including SLC22A6 (OAT1), SLC22A8 (OAT3), SLC22A2 (OCT2), and SLC47A1 (MATE1), which are crucial for its renal excretion. While the CYP1A2 enzyme plays a minimal role in its metabolism and is impacted by genetic differences, this is likely clinically insignificant due to the primary excretion pathway being renal rather than metabolic."
PA166184711,"Mephedrone's pharmacodynamic effects may relate to monoamine-related genes such as SLC6A4, which encodes the serotonin transporter, influenced by its role in enhancing monoamine neurotransmitter release and inhibiting reuptake. Additionally, variations in genes like CYP2D6, which may impact mephedrone's metabolism, could modify how individuals are affected by the drug, though direct research confirming these pharmacogenetic interactions is lacking."
PA166151992,"Dapoxetine, an SSRI used for treating premature ejaculation, has pharmacogenetic variability influenced by CYP3A4 and CYP2D6 enzymes. Variants in CYP2D6 categorize individuals into different metabolizer types—poor, intermediate, extensive, ultrarapid—altering the drug's plasma concentration and effectiveness, with poor metabolizers at risk of severe side effects and ultrarapid metabolizers seeing reduced efficacy. Genetic variations in CYP3A4 further affect dapoxetine's pharmacokinetics, indicating the importance of pharmacogenetic testing for personalized medication dosing to optimize efficacy and safety."
PA448499,"Atenolol's effects are primarily mediated through the ADRB1 gene, which codes for the Beta-1 adrenergic receptor, influencing heart rate and myocardial contractility. Genetic variations in ADRB1, CYP2D6, ABCB1, and ABCB11 can affect the drug's efficacy, side effects, metabolism, and overall pharmacokinetics, impacting individual responses to atenolol."
PA166163226,"Cavosonstat, designed to treat cystic fibrosis patients with the F508del mutation in the CFTR gene, may have its efficacy and safety influenced by variations in the CFTR gene itself, primarily impacting pharmacodynamics due to the gene's role in protein function which the drug aims to modulate. The absence of specific interaction data makes it hard to determine how other pharmacokinetic genes might affect Cavosonstat’s action."
PA450149,"Variations in the CYP2C9 and CYP2C8 genes significantly influence the metabolism of ketoprofen in the liver, affecting the drug's plasma levels and potentially altering risk of side effects. Additionally, genetic variants in transporters like ABCC4 and SLCO1A2, as well as in ALB, impact the renal excretion, hepatic uptake, and plasma protein binding of ketoprofen, respectively, highlighting the necessity of tailoring dosing based on individual genetic profiles to optimize efficacy and reduce adverse effects."
PA451365,"Sirolimus pharmacogenetics is heavily influenced by the genes CYP3A4 and CYP3A5, which control the drug's metabolism, and variations in these genes necessitate dosage adjustments to prevent toxicity and achieve therapeutic effects. Additionally, the ABCB1 gene affects the drug's absorption and distribution, while genes such as POR and NR1I2 further influence sirolimus by modifying the activity of enzymes and drug transporters involved in its handling, with non-CYP genes like IL10, PPARA, and TCF7L2 impacting its effects through immune and metabolic pathways."
PA166225041,"Variations in the genes CYP3A4, CYP2C9, ABCB1, and ABCG2 significantly influence the pharmacokinetics of rimegepant, a CGRP receptor antagonist used to treat migraines. Polymorphisms in these genes affect the drug's metabolism, clearance, bioavailability, and distribution, consequently impacting its efficacy and safety."
PA449982,"Indomethacin’s metabolism and effects are significantly influenced by genetic variations in the enzymes CYP2C9 and UGT1A1, which affect its metabolic rate and clearance, and by variations in the PTGS1 gene, which can alter the drug's anti-inflammatory effectiveness. Variants in CYP2C9 can lead to altered blood concentrations of indomethacin, potentially increasing efficacy and toxicity, while UGT1A1 polymorphisms can affect drug clearance, impacting accumulation and side effects, and PTGS1 variants vary the response to indomethacin's inhibition of COX enzymes."
PA166153431,"The pharmacogenetics of flibanserin involve key genes like CYP3A4 and CYP2C19 that influence its metabolism, affecting drug efficacy and safety, while ABCB1 gene variations alter its distribution and elimination, impacting drug exposure and response. These genetic interactions are crucial for understanding individual differences in treatment outcomes with flibanserin."
PA164764584,"Rasagiline, a drug used to treat Parkinson's disease, is metabolized by the enzyme CYP1A2, and genetic variants in CYP1A2 can significantly affect the drug's plasma levels and efficacy; higher activity of this enzyme may reduce drug effectiveness, while lower activity can increase adverse effects. Additionally, other genes like COMT and DRD2 may indirectly influence rasagiline's therapeutic effects by modulating dopamine metabolism and receptor signaling, respectively, although their specific interactions need more specific investigation."
PA449421,"Dronabinol, a synthetic Δ⁹-THC, interacts with cannabinoid receptors and is metabolized by cytochrome P450 enzymes such as CYP2C9 and CYP3A4, with variations in these genes affecting its metabolism, efficacy, and safety. Additionally, genetic differences in transporters like ABCB1 can influence the drug's distribution and excretion, further affecting individual responses and side effects."
PA449470,"Genetic variations in key enzymes such as COMT, MAOA, and MAOB, which metabolize epinephrine into metanephrine and normetanephrine, can significantly affect the drug’s pharmacokinetics by altering the intensity and duration of its effects. Additionally, polymorphisms in adrenergic receptors, particularly ADRB2, influence how patients respond to epinephrine, which is critical for managing conditions like asthma and stabilizing cardiovascular function during anaphylactic reactions. Variants in additional enzymes like CYP2C9 and CYP3A4, though less directly involved, may also subtly affect epinephrine's systemic clearance rates."
PA166128167,"Daclatasvir is primarily metabolized by CYP3A4, and genetic variations in the CYP3A4 gene can significantly influence its metabolism, affecting drug efficacy and safety. The drug's pharmacokinetics are also affected by other cytochrome P450 family enzymes (CYP3A5, CYP3A43, CYP3A7) and interactions with various drug transporters (ABCB1, SLCO1B1, SLCO1B3, ABCG2), which can alter drug absorption and distribution due to genetic differences in these genes."
PA166014703,"Etravirine, a Non-Nucleoside Reverse Transcriptase Inhibitor for HIV-1, has pharmacogenetic interactions primarily involving its metabolism by cytochrome P450 enzymes, specifically CYP3A4, CYP2C9, and CYP2C19. Variants in these genes can affect drug levels and efficacy, with certain alleles potentially leading to increased toxicity or altered effectiveness due to changes in metabolism speed. Additionally, transporter genes like ABCB1 also play a role by influencing the drug's absorption and distribution, impacting its pharmacokinetics."
PA451205,"The pharmacogenetic profile of quinapril, an ACE inhibitor, is influenced by variants in genes such as ACE, CES1, SLC15A1, SLC15A2, and SLC22A8 which affect its pharmacokinetics and pharmacodynamics. Variants in the ACE gene can alter the drug's efficacy by affecting enzyme inhibition levels and angiotensin II reduction, while CES1 variants impact the conversion of quinapril to its active form, quinaprilat; additionally, genetic differences in SLC15A1, SLC15A2, and SLC22A8 affect the drug’s cellular uptake and renal excretion, impacting its overall distribution and elimination."
PA449900,"Hydrocodone's interaction with the enzymes CYP2D6 and CYP3A4 and the OPRM1 opioid receptor gene significantly impacts its metabolism and effects. Variations in CYP2D6 affect the conversion of hydrocodone into hydromorphone, influencing pain control, while differences in CYP3A4 alter drug clearance. Additionally, genetic differences in OPRM1 can modify the sensitivity to hydrocodone's analgesic and euphoric effects, thus impacting its overall therapeutic efficacy and side-effect profile."
PA166151864,"The pharmacogenetics of Ataluren is influenced by the liver and intestinal metabolism via UGT1A9 enzyme, and variations in this gene may alter Ataluren's metabolism, affecting its plasma levels, efficacy, and safety. Additionally, the renal excretion handled by SLC22A6 and SLC22A8, and hepatic uptake by SLCO1B3 are genetically variable, which can further impact the drug's clearance, blood concentrations, and overall effectiveness in treating Duchenne Muscular Dystrophy."
PA166114460,"The effectiveness of icotinib in treating non-small cell lung cancer relies significantly on interactions between its metabolic pathways, influenced by genetic polymorphisms in enzymes such as CYP3A4, and the presence of specific activating mutations in the EGFR gene, such as exon 19 deletions or the L858R mutation. These genetic factors affect the drug's plasma concentration and its therapeutic efficacy, highlighting the importance of tailored treatment based on individual genetic profiles."
PA165111697,"The pharmacogenetics of artesunate are influenced by its metabolism through esterases, glucuronidation by UGT1A9 and UGT2B7, minor metabolism by CYP2A6, and interactions with transporter proteins such as ABCB1, ABCG2, SLCO1B1, and SLC22A8. Variations in these genes affect the pharmacokinetics of artesunate, altering drug efficacy and safety, with G6PD and IKBKG gene variants impacting treatment outcomes due to their roles in red blood cell stability and immune response, respectively."
PA449726,"Galantamine's effectiveness and potential for toxicity are influenced by genetic variations in the enzymes CYP2D6 and CYP3A4, which affect drug metabolism, and the transporter ABCB1, which moderates drug distribution across the blood-brain barrier. Specifically, variations in CYP2D6 categorize individuals into different metabolizer types (poor, intermediate, extensive), altering galantamine's systemic concentrations and risk of adverse effects, while variability in CYP3A4 and ABCB1 also contributes to differences in drug plasma levels and efficacy."
PA451260,"Ritonavir's pharmacogenetics are influenced by its interactions with metabolic enzymes such as CYP3A4 and CYP2D6, which play crucial roles in the drug's metabolism, affecting its plasma levels and interaction with other protease inhibitors. Transporter genes like ABCB1 also modify ritonavir's pharmacokinetics by affecting its distribution and elimination, while variations in other genes such as SLCO1B1, CYP3A5, UGT1A1, and additional members of the UGT and ABC transporter families impact its absorption, metabolism, and excretion."
PA131887008,"Variants in the CYP2D6 gene significantly influence the metabolism of MDMA, with ultrarapid metabolizers potentially experiencing diminished psychoactive effects and increased formation of harmful metabolites, while poor metabolizers may see enhanced and prolonged effects. Additional genes like CYP2B6, CYP2C19, and SLC6A2 also contribute to MDMA's metabolic and pharmacodynamic profiles, affecting drug clearance and noradrenaline uptake, though their impacts vary in magnitude compared to CYP2D6."
PA450801,"Paroxetine metabolism is influenced by variations in several genes, including CYP2D6, which substantially affects its plasma levels and the risk of side effects, especially in individuals with polymorphisms that lead to poor metabolism. Additionally, genes like ABCB1, which affects drug efflux from the brain, and SLC6A4, which encodes the serotonin transporter targeted by paroxetine, along with serotonin receptor genes HTR1A and HTR2A, contribute to variations in drug efficacy and pharmacodynamics, potentially impacting the clinical response to treatment."
PA166165203,"Carfilzomib works by irreversibly inhibiting specific proteasome subunits (PSMB5, PSMB8, PSMB1, PSMB9, PSMB2, and PSMB10) essential for the proteolytic activities crucial in cancer cell apoptosis and cell cycle control. It is metabolized in the liver independently of the cytochrome P450 system, with the transporter gene ABCB1 playing a role in drug resistance by influencing drug efflux from cells, indicating that variations in ABCB1 could affect carfilzomib's effectiveness."
PA10079,"Variations in the ADRB2 gene, which encodes for the beta-2 adrenergic receptor, significantly affect the efficacy and safety of Fenoterol, a drug used for bronchodilation. Specific polymorphisms in ADRB2 can alter the receptor's structure or function, leading to differences in how patients respond to the drug, including changes in receptor sensitivity and regulation, which impacts clinical outcomes such as the effectiveness of bronchodilation and severity of side effects."
PA450767,"Pamidronate inhibits osteoclast-mediated bone resorption by targeting enzymes such as farnesyl pyrophosphate synthase (FDPS) and geranylgeranyl pyrophosphate synthase (GGPS1) in the mevalonate pathway, disrupting lipid attachments necessary for osteoclast function and facilitating apoptosis in hematopoietic tumor cells through the activation of caspases CASP3 and CASP9. Genetic variability in FDPS, GGPS1, CASP3, and CASP9 genes can influence the drug's efficacy and apoptotic response, while variations in genes related to renal function may affect its renal elimination and overall drug levels and activity."
PA452633,"Genetic variants in the UGT2B7 gene can influence the metabolism of morphine into Morphine-6-glucuronide (M6G), altering its plasma levels and impacting its analgesic effectiveness and side effects like respiratory depression. Additionally, variations in opioid receptor genes (OPRM1, OPRD1, OPRK1) can modify how M6G interacts with these receptors, affecting the drug’s efficacy and tolerance by altering receptor binding affinity and signaling pathways."
PA164746412,"Tigecycline, a glycylcycline antibiotic, shows minimal pharmacogenetic interactions as it is not significantly metabolized and excreted largely unchanged, and its mechanism of action—targeting the bacterial 30S ribosomal subunit—is not notably affected by human genetic variations that typically influence drug metabolism or transport. Major genes involved in drug levels and effects, such as those for cytochrome P450 enzymes or transport proteins like P-glycoprotein, do not alter tigecycline's pharmacokinetic or pharmacodynamic properties, making genetic considerations in its clinical use straightforward."
PA450555,"Moxifloxacin's metabolism primarily occurs via glucuronide and sulfate conjugation involving the UGT gene family (UGT1A1, UGT1A5, UGT1A9, UGT1A8, UGT1A4, UGT1A3, UGT1A6, UGT1A10), and variants in these genes can affect the drug’s pharmacokinetics such as metabolism and excretion. Additionally, the ABCB1 gene, coding for P-glycoprotein, influences moxifloxacin’s absorption and elimination, while G6PD relates to oxidative stress response, and CYP1A2 has a minor role in its pharmacokinetics."
PA451728,"Topiramate's pharmacogenetic interactions are influenced by its metabolism through CYP3A4 and CYP2C19 enzymes, with genetic variants in these enzymes affecting its plasma levels and efficacy, necessitating possible dose adjustments. Additionally, genetic variations in pharmacodynamic targets such as SCN1A, GABRA1, CA12, GRIK1, and UGT2B7 can impact its antiepileptic effectiveness and overall pharmacological profile by affecting key receptors and metabolic pathways."
PA451668,"Thiotepa's pharmacogenetic interactions are significantly influenced by its metabolizing enzymes CYP3A4 and CYP2B6, where genetic variants lead to different metabolic rates that affect drug efficacy and toxicity; increased activity results in faster metabolism reducing thiotepa's effectiveness, while decreased activity can cause drug accumulation and increase toxicity. Additionally, polymorphisms in GSTP1, ALDH1A1, and ALDH3A1 genes also impact thiotepa's pharmacodynamics and pharmacokinetics, altering its detoxification process and the balance of reactive aldehyde species, which can affect tolerance and side effects."
PA448320,"Allopurinol’s pharmacogenetic interactions involve the genes XDH and AOX1 in its metabolism, ABCG2 and SLC22A2 affecting its pharmacokinetics, and UGT family genes impacting the bioavailability and clearance of its active metabolite oxipurinol. Additionally, the HLA-B*5801 allele is crucial for predicting the risk of severe cutaneous adverse reactions like Stevens-Johnson syndrome, particularly in certain populations, which highlights the drug's varied response based on genetic makeup."
PA450965,"The pharmacogenetics of pimozide, an antipsychotic drug, show that variations in genes such as CYP2D6, CYP3A4, CYP1A2, and transporter gene ABCB1 affect its metabolism and efficacy. For example, different genetic profiles in CYP2D6 can lead to altered plasma levels of pimozide, influencing its effectiveness and side effect profile, thus suggesting that genotype-specific dosing might improve therapeutic outcomes."
PA166272921,"The pharmacokinetic profile of abrocitinib, a JAK1 selective inhibitor, is significantly influenced by genetic variants in cytochrome P450 enzymes CYP2C19 and CYP2C9, which are crucial in its metabolism, and by the transporter ABCB1, involved in its absorption and distribution. These genetic variations can lead to differences in drug concentration, affecting efficacy, toxicity, and overall therapeutic outcomes, making pharmacogenetic testing essential to customize treatment approaches for individual safety and effectiveness."
PA166163418,"Rucaparib, a PARP inhibitor effective in BRCA1 or BRCA2 mutant cancers, interacts pharmacokinetically and pharmacodynamically with several genes. Variants in the genes BRCA1, BRCA2, CYP2D6, CYP1A2, CYP3A4, ABCB1, and ABCG2 influence its metabolism, efficacy, and toxicity by affecting the drug's processing, distribution, and elimination in the body."
PA166131260,"The efficacy of the drug clopidogrel and its active metabolite, clopidogrel thiol metabolite H4, is significantly influenced by genetic variations in the CYP2C19 gene which encodes an enzyme vital for converting clopidogrel into its active form. Specific alleles, such as CYP2C19*2 and CYP2C19*3, lead to reduced enzyme activity, resulting in decreased production of the active metabolite, poorer drug activation, reduced platelet aggregation inhibition, and a higher risk of thrombotic events."
PA164760843,"The pharmacogenetics of deferasirox involves key enzymes like UGT1A1, UGT1A3, UGT1A9, which are crucial for its glucuronidation and clearance, as well as CYP1A2, CYP2C8, and CYP3A4 which impact drug levels through metabolism. Additionally, transporter proteins such as ABCC2 and ABCG2, along with the VDR gene, influence the drug’s pharmacokinetics, efficacy, and safety through their roles in drug excretion and metabolic pathways, suggesting the potential for personalized dosing based on genetic differences."
PA166183788,"Metabutethamine's interaction with the G6PD gene suggests pharmacodynamic concerns, particularly posing a risk of drug-induced hemolysis in individuals with a G6PD deficiency. This observation arises from the enzyme defect in G6PD-deficient individuals that increases vulnerability to oxidative stress leading to red blood cell breakdown."
PA10069,"The pharmacokinetics and efficacy of emtricitabine, a nucleoside reverse transcriptase inhibitor, are influenced by several genes: SLC47A1 impacts its renal secretion and potentially drug levels and toxicity; DCK is essential for the drug's activation; ABCC2 might affect transport and elimination; and NR1I2 could indirectly alter pharmacokinetics by regulating expression of enzymes and transporters. Furthermore, the gene HLA-B may influence immune responses related to emtricitabine, though its role is more speculative."
PA450530,"Modafinil's metabolism is influenced by polymorphisms in several cytochrome P450 enzymes such as CYP2C19, CYP3A4, and others, affecting its efficacy and risk of side effects. Its pharmacodynamic effects involve interactions with genes like SLC6A3, which mediates dopamine reuptake, ADRA1B, which impacts adrenergic signaling, and the COMT gene where specific polymorphisms can modulate patient responses to the drug."
PA450603,"Genetic variations in CYP3A4 significantly impact the metabolism of nefazodone, affecting drug concentrations and the risk of hepatic injury, while variations in ABCB1, which encodes P-glycoprotein, influence the drug's efflux and bioavailability. Furthermore, genetic differences in the SLC6A4 and SLC6A2 genes, which are involved in serotonin and norepinephrine reuptake, respectively, are crucial in determining the antidepressant efficacy and side-effect profile of nefazodone, with additional pharmacodynamic interactions possibly affected by variations in HTR1B, which modulates serotonergic signaling."
PA450840,"The pharmacokinetics of penicillamine, used for Wilson's disease and cystinuria, are influenced by the transporter gene SLCO1B1, where genetic variants can affect drug absorption and elimination, impacting its effectiveness and safety. Additionally, in the context of autoimmune diseases like rheumatoid arthritis, the HLA-DRB1 gene plays a pharmacodynamic role by affecting the immune response to the drug, which can alter the treatment's effectiveness and potential drug reactions."
PA166127651,"N-desmethyltamoxifen, a vital metabolite of tamoxifen, interacts significantly with the CYP2D6 enzyme, which is crucial for its conversion from tamoxifen and influences its effectiveness in breast cancer therapy. Variants in the CYP2D6 gene affect the levels of this metabolite, impacting its therapeutic efficacy or potential side effects, while CYP3A4's role in its metabolism is less definitive."
PA449676,"Fluphenazine's interactions are influenced by the CYP2D6 gene, which impacts its metabolism and plasma concentration, leading to variations in drug exposure that can cause increased adverse effects or reduced efficacy depending on the individual's metabolic rate. Additionally, genetic differences in DRD2 and ABCB1 affect fluphenazine’s binding affinity to dopamine receptors and its penetration through the blood-brain barrier, respectively, which alters therapeutic outcomes and side effects."
PA166114483,"Lumacaftor works by targeting the F508del mutation in the CFTR gene, which helps stabilize and improve the function of the mutated protein crucial for chloride transport in cystic fibrosis patients. It is metabolized by several enzymes including CYP3A4, CYP2B6, and others, and interacts with proteins such as ABCB1 and SLC26A9; variations in these genes influence lumacaftor's metabolism, distribution, and efficacy, affecting therapeutic outcomes."
PA449627,"Finasteride's efficacy and side effects are influenced by genetic variances in the SRD5A2 gene, which codes for the Type II 5α-reductase enzyme that finasteride targets to reduce DHT production. Additionally, variants in the CYP3A genes (CYP3A4, CYP3A5, and CYP3A7), which are responsible for metabolizing finasteride, can affect the drug's pharmacokinetics, altering its plasma levels and clinical effectiveness."
PA451221,"Raloxifene's effectiveness and safety are influenced by genetic variations in estrogen receptor genes (ESR1 and ESR2) which affect its pharmacodynamics, and in metabolic enzymes (UGT1A1 and UGT1A8) and transporters (SLCO1B1, ABCB1, ABCG2) which impact its pharmacokinetics, altering the drug's metabolism, bioavailability, and therapeutic outcomes. These gene-drug interactions highlight the critical role of individual genetic makeup in modulating both the effects and metabolism of raloxifene."
PA166123407,"Variants in genes such as CYP3A4, CYP3A5, and SLCO1B1 directly influence the metabolism and transport of abiraterone, affecting its efficacy and toxicity by altering drug metabolism rates and plasma levels. Additionally, non-pharmacokinetic genes like HSD3B1 and others indirectly impact treatment outcomes by affecting biological pathways involved in prostate cancer and response to hormone levels, thereby influencing the response to abiraterone treatment in prostate cancer therapies sensitive to androgen levels."
PA449685,"Polymorphisms in the AR gene may affect the efficacy of flutamide, an antiandrogen for prostate cancer, by altering its binding affinity and its antiandrogenic effects. Additionally, genetic variants in cytochrome P450 enzymes like CYP1A2 and CYP3A4 influence the metabolism of flutamide, impacting its effectiveness and toxicity by altering drug levels in the body."
PA451112,"Genetic variations in the MAOA and MAOB genes affect both the psychotropic side effects and possibly the antineoplastic activity of procarbazine due to their role in neurotransmitter breakdown. Variations in the XDH gene influence the hepatic metabolism of procarbazine, affecting the drug's metabolism rate, resulting in different drug levels and related toxicity among individuals."
PA451283,"The efficacy and safety of rosiglitazone are influenced by its metabolism through CYP2C8 enzyme variants such as CYP2C8*3, and its pharmacodynamics are affected by polymorphisms in PPARG, the drug's direct target. Other genes like SLCO1B1 and CYP3A4 also impact the drug’s distribution and secondary metabolism, potentially modulating the clinical response and underscoring the importance of personalized medication based on genetic profiles."
PA449753,"Gentamicin's interactions with human genes like SLC22A2, LRP2, and ABCC2 influence its pharmacokinetics by affecting its transport, renal uptake, excretion, and secretion, which may alter its nephrotoxicity and efficacy. Additionally, variants in mitochondrial genes MT-RNR1 and MT-ND1 impact susceptibility to ototoxicity by affecting mitochondrial functions, as these genes are involved in encoding components of the mitochondrial ribosome and respiratory chain enzymes, respectively."
PA449493,"Erythromycin metabolism is significantly influenced by genetic variations in the CYP3A4 and CYP3A5 enzymes, affecting drug efficacy and risk of toxicity. Additionally, transporter genes such as SLCO1B1 and ABCB1, which regulate drug absorption, distribution, and efflux in various tissues, along with ABCC2 which is involved in drug excretion, also play crucial roles in the pharmacokinetics of erythromycin, influencing its levels and side effects."
PA450128,"Variability in the CYP3A4 gene affects the metabolism rate of isotretinoin, a vitamin A derivative, influencing its systemic concentrations which could alter therapeutic and adverse effects such as teratogenicity or hyperlipidemia. Additionally, gene variants in RARA and RARG, encoding retinoic acid receptors, could impact isotretinoin's effectiveness in activating these receptors, thus affecting clinical responses and skin-related side effects like differentiation and apoptosis of skin cells."
PA10810,"Pemetrexed pharmacogenetics involves the impact of genetic polymorphisms in various genes on the drug's uptake, metabolism, and effectiveness. Transporters such as SLC19A1 and ABCG2, and enzymes like DHFR, TYMS, GART, and ATIC influence how pemetrexed is absorbed, distributed, metabolized, and excreted, as well as how it interacts with target enzymes, affecting its antiproliferative effects and overall efficacy."
PA135057240,"The metabolism of bupivacaine is significantly influenced by genetic variations in cytochrome P450 enzymes such as CYP3A4, CYP2C19, and CYP2D6, which can impact its clearance rates and pharmacokinetics. Variants that reduce enzyme activity can lead to prolonged exposure to the drug and increased risk of toxicity, while other polymorphisms can affect metabolic speed, influencing drug efficacy and safety. Non-P450 genes like CYB5R3 and G6PD also play roles in modifying the pharmacodynamic response to bupivacaine through their involvement in cellular processes like electron transport and glucose metabolism."
PA164747170,"Fulvestrant's pharmacogenetic interactions are primarily influenced by CYP3A4 and potentially UGT1A1, which govern its metabolism. Variations in CYP3A4 affect drug levels, impacting Fulvestrant's safety and efficacy, while UGT1A1 might alter the drug's pharmacokinetics through its role in glucuronidation. Additionally, genetic variants in ESR1, the drug's target, alter the expression or function of estrogen receptors, thereby influencing Fulvestrant's pharmacodynamics and its effectiveness in treating breast cancer."
PA166182348,"Genetic variations in the metabolic enzymes CYP3A4, CYP3A5, CYP2D6, and CYP2C8 can significantly affect the pharmacokinetics of elagolix, potentially influencing its metabolism rate, blood levels, effectiveness, and risk of side effects. Additionally, genetic differences in transporter genes ABCB1 and SLCO1B1, which affect drug absorption and distribution, could modify the therapeutic outcomes and bioavailability of elagolix."
PA165946122,"Gene variants in CYP3A4 and CYP3A5 affect the metabolism of crizotinib, with the presence of the CYP3A5*1 allele leading to faster drug metabolism, possibly necessitating dose adjustments. Additionally, polymorphisms in ABCB1, which encodes for the P-glycoprotein efflux transporter, impact how crizotinib is distributed within cells, affecting its efficacy and side effects, such as hepatotoxicity and gastrointestinal issues. Furthermore, the effectiveness of crizotinib depends on targeting specific gene alterations like the EML4-ALK fusion in tumors, thereby guiding the use of the drug in treatments."
PA166128166,"Ledipasvir, an antiviral drug treating Hepatitis C, primarily interacts with genes ABCB1 and ABCG2, which are involved in drug transport and can significantly influence the drug's absorption and distribution in the body. Variations in these genes, as well as in IFNL3 and IFNL4 that affect immune response, can alter the effectiveness or safety of ledipasvir, potentially requiring dose adjustments or close monitoring."
PA451255,"Risedronate inhibits the enzyme FDPS in bone cells, impacting osteoclast function and bone resorption; genetic variability in FDPS may alter the drug's effectiveness in inhibiting bone resorption. Variations in the gene PTGS2, involved in prostaglandin synthesis, could affect the drug's secondary effects on inflammation and bone metabolism, potentially influencing its efficacy in conditions like osteoporosis and Paget's disease."
PA449653,"Fluconazole inhibits the fungal enzyme ERG11 and interacts with human cytochromes P450 including CYP2C9, CYP2C19, and CYP3A4, affecting drug metabolism and increasing plasma levels of other drugs metabolized by these enzymes. Genetic variations in these cytochromes and the transporter ABCB1 can alter fluconazole's metabolism, efficacy, and toxicity, impacting therapeutic outcomes."
PA451344,"Sibutramine's metabolism through the CYP3A4 enzyme leads to the production of active metabolites M1 and M2, which inhibit the reuptake of neurotransmitters such as serotonin, norepinephrine, and dopamine by interacting with their respective transporters (SLC6A4, SLC6A2, SLC6A3). Additionally, genetic variations in genes like GNB3 may affect the drug’s efficacy in weight loss, indicating a role in differential patient responses to sibutramine treatment in obesity management."
PA166114925,"The drug mafenide's pharmacogenetic relevance is linked to its inhibition of the enzyme CA6 during metabolic transformation, affecting drug efficacy and safety by potentially varying among individuals due to differences in CA6 activity and expression. This interaction could influence the therapeutic outcomes and adverse effects in the treatment of burn wounds and related metabolic issues. Additionally, caution is advised in G6PD-deficient patients, as the general risks associated with sulfonamides might suggest possible hemolytic anemia, though direct evidence specific to mafenide is lacking."
PA449841,"Haloperidol metabolism is significantly influenced by genetic variations in the CYP2D6 enzyme, affecting the drug's concentration and resulting in different clinical responses and side effects; poor metabolizers experience higher drug levels and more adverse effects, while ultra-rapid metabolizers have lower levels potentially leading to reduced efficacy. Additionally, genetic variations in the D2 dopamine receptor (DRD2) can affect haloperidol's therapeutic effects and side effect profile by altering receptor sensitivity and density."
PA166197681,"Genetic variations in VKORC1 and CYP4F2 significantly influence the pharmacokinetics and pharmacodynamics of phylloquinone, a form of vitamin K1. VKORC1 mutations impact the recycling of vitamin K necessary for clotting factor activation, while CYP4F2 variations affect the catabolism of vitamin K1, altering its availability and thus influencing coagulation processes. These interactions are essential for determining the effectiveness of vitamin K1 in clotting and for adjusting dosages in treatments involving coagulation control."
PA451103,"Primaquine's pharmacogenetics are heavily influenced by its interactions with cytochrome P450 enzymes such as CYP2D6, CYP1A2, CYP3A4, CYP1A1, and CYP1B1, where genetic polymorphisms especially in CYP2D6 can lead to variable drug metabolism, affecting the drug’s efficacy and toxicity. Additionally, in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, Primaquine can cause hemolytic anemia due to increased red blood cell vulnerability to oxidative damage, highlighting the need for genetic testing for G6PD deficiency before treatment to ensure safety and efficacy."
PA165111696,"The metabolism of artemisinin is significantly influenced by the cytochrome P450 enzyme system, particularly CYP2B6, and to a lesser extent, CYP2C8 and CYP3A4. Variations in CYP2B6 due to genetic polymorphisms can affect the metabolic efficiency of artemisinin, altering drug levels in the plasma and thus impacting both the efficacy and safety of the treatment."
PA166114911,"Dabrafenib's effectiveness as a kinase inhibitor in cancer treatment is primarily influenced by its interaction with BRAF mutations (V600E, V600K, V600D) and is metabolized by the cytochrome P450 enzymes, CYP3A4 and CYP2C8. Genetic variations in these enzymes, as well as transport proteins ABCB1 and ABCG2, can significantly affect the drug's plasma concentration, efficacy, and safety, necessitating potential dose adjustments based on individual genetic profiles. Additionally, genes like NRAS, HRAS, and KRAS, while not directly involved in dabrafenib's primary mechanism, can affect BRAF signaling pathways and hence the drug's cellular context."
PA449964,"The pharmacogenetics of ifosfamide are significantly influenced by variations in genes encoding CYP450 enzymes like CYP2B6 and CYP3A4, which control its metabolism into active metabolites that bind to DNA and produce cytotoxic effects. Additionally, polymorphisms in the ALDH1A1 gene affect the detoxification of these metabolites, impacting the drug's toxicity profile, while variations in genes like ERCC2 and KLC3 could influence the effectiveness and adverse effects of the treatment by modulating DNA repair and cellular transport."
PA166128370,"Salvianolic acid B, used in treating cardiovascular conditions, interacts pharmacodynamically through its antioxidant effects, influencing pathways related to oxidative stress and inflammation involving genes such as NOS3 and ACE. NOS3 facilitates nitric oxide production affecting vascular tone and myocardial demand, while ACE is integral to blood pressure and vascular function regulation; polymorphisms in these genes could thus affect the drug's efficacy and safety by altering how it modulates these critical cardiovascular processes."
PA450911,"Phenobarbital's pharmacogenetics is influenced by its metabolism through enzymes such as CYP2C19, CYP2C9, CYP1A2, and CYP3A4, where genetic polymorphisms in these enzymes can alter drug metabolism rates, affecting its efficacy and toxicity. Additionally, UGT family enzymes involved in drug elimination, and genetic variations in transporter protein ABCB1 and other non-enzyme factors like MTHFR and HLA genes, can also impact the pharmacokinetics and pharmacodynamics of phenobarbital, influencing individual drug responses and potential adverse reactions."
PA166124478,"The gene CYP2D6 plays a crucial role in the metabolism of endoxifen, an active metabolite of tamoxifen used in ER+ breast cancer therapy. Variations in the CYP2D6 gene affect the plasma levels and therapeutic effectiveness of endoxifen, with different alleles like CYP2D6*4 or CYP2D6*5 impacting patients' responses to treatment by altering metabolizer phenotypes, leading to either reduced or elevated drug levels in the body."
PA164749649,"Dicloxacillin metabolism is significantly influenced by the CYP3A4 gene, which determines the activity of the enzyme crucial for its hepatic metabolism, impacting the drug's clearance, effectiveness, and potential toxicity. Additionally, genetic variations in the peptide transporters SLC15A1 and SLC15A2 affect dicloxacillin’s absorption and bioavailability, while variations in albumin (ALB) could influence its distribution in the bloodstream."
PA450626,"Nicotine pharmacogenetics is influenced by key genes such as CYP2A6, which is primarily responsible for metabolizing nicotine into cotinine, and to a lesser extent by CYP2B6 and CYP2E1, leading to individual variations in metabolism rates that affect smoking cessation efficacy and tobacco dependence. Additionally, genes like CHRNA3, which affect nicotine's pharmacodynamic interactions by mediating receptor sensitivity, and SLC22A2, which influences nicotine's cellular uptake, further contribute to variations in individual responses to nicotine-based therapies."
PA451898,"Genetic variations in the SLC23A1 and SLC23A2 genes, which encode sodium-dependent vitamin C transporters, significantly affect the absorption and plasma levels of vitamin C, impacting its effectiveness and potential deficiency outcomes such as scurvy. Additionally, mutations in the G6PD gene influence the metabolism of vitamin C by affecting its antioxidative functions and retention in cells, contributing to increased oxidative stress levels in the body."
PA166187141,"Lacidipine's metabolism by CYP3A4, which exhibits genetic variability, affects its efficacy and safety by altering drug blood levels; this variability can result in either faster metabolism, potentially leading to inadequate blood pressure control, or slower metabolism, increasing the risk of side effects. Additionally, lacidipine acts on various L-type calcium channel subunits such as CACNA1C, and genetic variations in these channel genes could theoretically influence the drug's effectiveness in managing hypertension by affecting calcium flux in vascular smooth muscle."
PA448360,"Genetic variations in genes such as SLC22A1, SLC22A2, DRD2, GRIN3A, CHRNA7, CHRNA4, and CHRNA3 affect the pharmacokinetics and pharmacodynamics of amantadine, potentially influencing its absorption, distribution, and interaction with dopaminergic and cholinergic receptors. Consequently, these genetic polymorphisms can modify the drug’s effectiveness and tolerability in the treatment of conditions like influenza A, Parkinson’s disease, and drug-induced extrapyramidal reactions."
PA166184379,"The pharmacogenetic profile of Letermovir involves significant interactions with UGT1A1, which is pivotal in its minor metabolic pathways affecting drug clearance and efficacy, and SLCO1B1, which affects the hepatic uptake and bioavailability of the drug through its genetic variants such as UGT1A1*28 and SLCO1B1*5. These gene-drug interactions highlight the impact of individual genetic variability on the pharmacokinetics, effectiveness, and tolerability of Letermovir, emphasizing the importance of personalized dosing strategies."
PA452632,"The pharmacogenetics of acenocoumarol involve key genes like VKORC1, which impacts drug efficacy and bleeding risks due to variations that modify enzyme sensitivity, and CYP2C9, whose polymorphisms significantly alter the drug's metabolism, affecting plasma levels and bleeding risks, necessitating different dosing. Other genes like CYP4F2, CYP1A2, CYP2C19, CYP3A4, ABCB1, and GGCX also influence the metabolism and effect of acenocoumarol, although their roles and impacts vary, with some like ABCB1 affecting drug bioavailability and GGCX involved in processes crucial for the drug’s pharmacodynamics."
PA450684,"Genetic variants of the enzyme CYP1A2, which metabolizes ofloxacin, can significantly alter the drug's pharmacokinetics—variants decreasing enzyme activity may increase toxicity risk by reducing metabolism, while those increasing activity could reduce drug efficacy by enhancing metabolism. Additionally, variations in genes encoding transporter proteins such as SLC22A5, SLC22A6, SLC22A4, ABCC1, ABCC2, and ABCB11 influence ofloxacin's absorption, distribution, and excretion, affecting its bioavailability and clearance, while G6PD deficiency might predispose patients to hemolytic anemia, although its direct connection to ofloxacin requires further evidence."
PA166247601,"The CYP3A4 gene is crucial for converting atorvastatin to its active metabolite, 2-hydroxyatorvastatin; variations in this gene can lead to differing drug levels, impacting efficacy and safety. Additionally, the SLCO1B1 gene, encoding the OATP1B1 transporter, affects hepatic uptake of statins and its polymorphisms are linked to variations in drug concentration and increased risk of statin-induced myopathy."
PA448383,"Amiodarone's efficacy and safety are affected by genetic variations in metabolizing enzymes such as CYP3A4, CYP2C8, CYP2C9, and CYP4F2, and transporters like ABCG2, which influence its plasma concentration, distribution, and elimination. Additionally, genetic variants in KCNH2 and KCNE1, which are involved in cardiac repolarization, can alter the drug's pharmacodynamic effects, particularly impacting the risk of arrhythmias like prolonged QT interval and torsades de pointes in patients."
PA166183939,"The pharmacogenetics of dextropropoxyphene is significantly influenced by the activity of the CYP3A4 enzyme, where genetic polymorphisms alter the drug's metabolism, impacting its efficacy and safety. Genetic variations in CYP3A4 can lead to either increased or decreased drug plasma levels, posing risks of toxicity or inadequate pain management, respectively. Additionally, variations in opioid receptors like OPRM1 may also affect the drug’s analgesic efficacy and addiction potential, although these interactions are less clearly defined compared to other opioids."
PA451729,"Topotecan pharmacokinetics is influenced by genetic variations in the ABCG2 and ABCB1 genes, which affect the drug's efflux and hence its intracellular levels, impacting overall efficacy and toxicity. Similarly, variations in SLC47A1 and SLC47A2 genes alter topotecan clearance, influencing both pharmacokinetics and patient response."
PA164744895,"Gliquidone's effectiveness and risk of side effects, such as hypoglycemia, are influenced by genetic variations in the CYP2C9 gene, which affect how the drug is metabolized in the liver. Additionally, genetic variants in the ABCC8 and KCNJ8 genes, which regulate pancreatic beta-cell potassium channels, can alter how effectively gliquidone triggers insulin release by affecting cellular depolarization and calcium influx."
PA151958574,"Posaconazole's effectiveness and safety are affected by its interactions with the CYP3A4 enzyme and ABCB1 transporter through genetic variations. Variants in the *CYP3A4* gene can lead to altered enzyme activity affecting the drug's metabolism, while *ABCB1* gene variants can modify the activity of the efflux transporter, impacting posaconazole's absorption, distribution, and excretion. These gene-drug interactions are crucial for determining individual responses to the treatment, optimizing dosing, and minimizing adverse effects."
PA166249521,"Nintedanib's metabolism is significantly influenced by polymorphisms in **UGT1A1**, **UGT1A7**, **UGT1A8**, and **UGT1A10** genes which affect its glucuronidation, and by **ABCB1** and **ABCG2** that alter drug efflux, impacting its pharmacological effects and toxicity. Additionally, **CYP3A4** plays a role, albeit minor, in metabolizing nintedanib, and its genetic variants can also modify the drug’s plasma levels and therapeutic response."
PA450935,"Phenylephrine's pharmacogenetic interactions involve its metabolism by genes MAOA, MAOB, and SULT1A3, where variations can alter drug concentration and effectiveness, and its effects are mediated by receptors ADRA1A, ADRA1B, and ADRA1D, where genetic differences impact patient response such as sensitivity to its vasoconstrictive actions. Variants in these metabolic genes can lead to different rates of metabolism, affecting the drug's duration and safety, while variants in receptor genes influence the therapeutic effects and individual tolerance to the drug."
PA164924493,"Axitinib’s metabolism and transport are significantly influenced by genetic variations in enzymes such as CYP3A4, CYP3A5, CYP1A2, CYP2C19, and UGT1A1, as well as transporters like ABCB1 and SLCO1B1. These genetic factors can dramatically alter axitinib's plasma levels, effectiveness, and toxicity, thereby requiring dosage adjustments to balance therapeutic benefits against adverse effects."
PA166182740,"Talazoparib's efficacy predominantly relies on its ability to inhibit PARP1 and PARP2, which disrupts DNA repair mechanisms, particularly in cancer cells with BRCA1 and BRCA2 mutations—these mutations impair the homologous recombination repair pathway, increasing vulnerability to PARP inhibition, a condition known as ""synthetic lethality."" Additionally, gene transporters like ABCB1 and ABCG2 affect the drug’s pharmacokinetics by altering its distribution and excretion, but talazoparib is less affected by interactions with metabolic enzymes, focusing its pharmacogenetic profile more on the dynamics of these genetic interactions."
PA449028,"Variants in the genes CYP3A4 and CYP3A5 affect the metabolism of clarithromycin, potentially altering its efficacy and risk of toxicity, such as drug-induced hepatotoxicity or prolonged QT interval. Additionally, polymorphisms in the transporter genes SLCO1B1, SLCO1B3, and ABCB1 can impact the drug's hepatic uptake, clearance, bioavailability, and efflux from cells, which influences clarithromycin's plasma concentration and exposure to target tissues, affecting therapeutic outcomes and side effects."
PA164769056,"Tiotropium is influenced by pharmacogenetic interactions involving minimal metabolism by CYP2D6 and CYP3A4 variants, and variability in muscarinic receptor genes such as CHRM3, which might impact the drug's efficacy and side effects due to alterations in drug levels and receptor responses. Additionally, genes like SLC22A5 and SLC22A4 can affect its renal clearance, further influencing individual therapeutic outcomes and variability in patient response."
PA452616,"The metabolism and efficacy of the drug debrisoquine are primarily influenced by variations in the CYP2D6 gene, which causes individuals to metabolize the drug at different rates, categorized as poor, intermediate, extensive, or ultrarapid metabolizers. This variation leads to differential drug plasma levels, affecting the risk of adverse effects and the necessity for dosage adjustments. Additionally, debrisoquine interacts with P-glycoprotein 1 (ABCB1), impacting its distribution and systemic concentration, although SLC6A2's effect on the drug does not contribute to pharmacogenetic variability."
PA448084,"The pharmacogenetic interactions of Alfentanil largely depend on its metabolism by the CYP3A family genes (CYP3A4, CYP3A5, CYP3A7), where genetic variations can lead to altered enzyme activity affecting drug levels and safety. Furthermore, genetic polymorphisms in the ABCB1 gene, encoding the P-glycoprotein transporter, influence Alfentanil's distribution and clearance, thereby impacting its pharmacokinetics and overall effects, while variations in OPRM1, encoding opioid receptors, may modify the analgesic response to the drug."
PA451271,"The metabolism of ropivacaine is significantly influenced by genetic variations in CYP1A2, CYP3A4, and CYP2B6, with CYP1A2 playing a major role in its metabolic degradation, which affects the drug's plasma concentration, duration, and effectiveness of anesthesia. Additionally, variations in CYP3A4 and CYP2B6 affect the pharmacokinetics of ropivacaine to a lesser degree, influencing both the rate and extent of metabolism, while interactions with proteins like ORM1 can alter its distribution and availability, impacting its pharmacodynamics."
PA166179872,"Encorafenib, a BRAF kinase inhibitor used in cancer therapy, is most effective against tumors with the BRAF V600E mutation, a key target of its action. The drug's metabolism is primarily governed by CYP3A4, with minor roles for CYP2C19 and CYP2D6, and its pharmacokinetics can be altered by polymorphisms in these enzymes and transporter proteins such as ABCB1 and ABCG2, affecting drug levels, tissue penetration, and excretion. Moreover, mutations in NRAS, HRAS, and KRAS genes could modify the therapeutic efficacy of encorafenib by influencing downstream signaling pathways."
PA166179720,"Tapentadol's efficacy and safety are affected by genetic variations in the OPRM1 gene, which impact the mu-opioid receptor binding affinity, altering the drug's analgesic and side effect profile. Additionally, its metabolism is primarily influenced by the UGT2B7 and UGT1A9 genes, where genetic polymorphisms can alter pharmacokinetics, affecting drug levels and potentially modifying effectiveness and risk of side effects."
PA165291472,"Variations in the CYP3A4 gene affect the metabolism of neratinib, impacting its plasma levels, efficacy, and toxicity, with changes in activity levels leading to different drug exposure and potential adverse effects like diarrhea and hepatotoxicity. Additionally, polymorphisms in the ABCB1 gene influence the distribution and excretion of neratinib, affecting therapeutic outcomes and side effects, while genes like ESR1, ESR2, PGR, and ERBB2, although not involved in its pharmacokinetics, are crucial in determining tumor response due to their role in hormone and receptor signaling pathways related to the drug's targets."
PA166208561,"Ulinastatin may interact with the genes MMP9 and MMP2, which are involved in the breakdown of extracellular matrix proteins, potentially affecting inflammation and tissue remodeling processes that impact vascular and tissue integrity during inflammatory responses. However, the exact effects of genetic variability in MMP9 and MMP2 on the efficacy or safety of ulinastatin remain speculative, as these interactions are inferred and not well-documented or directly evidenced by research."
PA165107052,"Rupatadine, which acts on the histamine H1 receptor and the platelet-activating factor receptor, is metabolized primarily by CYP3A4, with contributions from CYP2C9, CYP2C19, and CYP2D6. Genetic polymorphisms in these cytochrome P450 enzymes affect the drug's pharmacokinetics, altering its concentration in the bloodstream, which can impact its effectiveness and safety, necessitating possible dosage adjustments."
PA166177606,"Variations in genes such as CYP3A4 and CYP2B6, which are involved in the metabolism of methadone into S-EDDP, along with UGT2B7 that affects methadone's further metabolism, play significant roles in determining the pharmacokinetics of S-EDDP. These genetic differences can lead to variations in methadone and S-EDDP levels, affecting individual drug responses and necessitating personalized dosing to manage effects and avoid adverse reactions."
PA451305,"Variants in the CYP3A4 gene significantly affect the metabolism of saquinavir, altering its levels, efficacy, and safety, whereas polymorphisms in CYP3A5 and the ABCB1 gene also modify saquinavir's metabolism and its bioavailability respectively. These genetic variations in metabolizing enzymes and transport proteins are crucial for determining the personalized dosing and effectiveness of the HIV treatment involving saquinavir."
PA449461,"The pharmacogenetics of enflurane primarily involves its metabolism by the liver enzyme CYP2E1 and interactions with neural receptors like GABA(A) receptor subunits and calcium channel subunits. Gene variations in CYP2E1 affect the metabolic rate of enflurane, which can alter the anesthetic effects and risk of toxicities such as hepatotoxicity and neurotoxicity, while variability in genes coding for GABA(A) receptor subunits and calcium channels influences the drug’s CNS depressant effects, sedation depth, muscle relaxation, and cardiovascular impacts."
PA166114414,"Cotinine pharmacogenetics is influenced by variations in the CYP2A6 gene, which affects how quickly nicotine is metabolized to cotinine, thereby impacting nicotine withdrawal and dependence. Other genes such as CYP2B6, NAT1, and UGT2B10 also play roles in the metabolism and excretion of nicotine and its derivatives, while genes like OPRM1, PSMA4, CHRNB4, CHRNA3, and CHRNA5 are involved in the pharmacodynamic effects by influencing how nicotine interacts with nicotinic acetylcholine receptors, affecting addiction and withdrawal symptoms."
PA166153471,"Variability in the CYP3A4 gene primarily affects the metabolism of abemaciclib, influencing its plasma levels, efficacy, and toxicity. Additionally, polymorphisms in the ABCG2 and ABCB1 genes, which encode efflux transporters, impact the transport and clearance of the drug, thereby affecting drug exposure and potential side effects."
PA166114434,"Genetic variations in the PPARG gene, which codes for the PPAR-gamma receptor, can influence the pharmacodynamics of sipoglitazar, impacting its efficacy and safety profiles in treating conditions like type 2 diabetes and hyperlipidemia. Such polymorphisms might affect the therapeutic response by altering gene expression levels and consequentially metabolic outcomes related to the drug's action as a dual agonist of PPAR-alpha and PPAR-gamma."
PA451156,"The efficacy and toxicity of Propylthiouracil (PTU) in treating hyperthyroidism are influenced by genetic variations in the thyroid peroxidase (TPO) and CYP1A1 genes. TPO gene variants can lead to differing responses to PTU, affecting the suppression of thyroid hormone synthesis, while CYP1A1 gene variants impact PTU metabolism, influencing both the drug's effectiveness and side effect profile."
PA449441,"Genetic polymorphisms in the cytochrome P450 enzymes, particularly CYP2B6, and in other enzymes and transporters such as CYP3A5, CYP2C19, CYP3A4, UGT2B7, and ABCB1 significantly influence the metabolism and disposition of efavirenz, a drug used for HIV-1 treatment. These genetic variations can affect drug levels and toxicity, underscoring the need for genotyping in patients to tailor dosing regimens and optimize therapeutic outcomes."
PA449690,"Fluvoxamine, an SSRI, is metabolized by enzymes such as CYP2D6, CYP1A2, and CYP3A4, where genetic variations can impact its pharmacokinetics, influencing patient responses in terms of efficacy and side effects. Pharmacodynamically, genetic polymorphisms in SLC6A4 affect its effectiveness in enhancing serotonin activity, crucial for its antidepressant action, and variations in KCNH2 could impact cardiological side effects."
PA166177865,"The pharmacogenetics of metoprolol, and its metabolite alpha-hydroxymetoprolol, are significantly influenced by variations in the CYP2D6 gene, which affects the enzyme’s activity. These variations can lead to substantial differences in drug plasma levels and responses, where poor metabolizers may experience higher concentrations and potential toxicity, and ultra-rapid metabolizers might have lower drug concentrations and reduced effects."
PA166225141,"Tucatinib, a treatment for HER2-positive metastatic breast cancer, undergoes pharmacogenetic interactions that can affect its metabolism and transport. The enzymes CYP2C8, CYP3A4, CYP3A5, CYP3A7, and CYP3A43 are involved in its metabolism, with genetic variations in CYP2C8 playing a significant role in altering tucatinib's efficacy and safety. Transport proteins such as ABCG2, ABCB1, SLC22A2, SLC47A1, and SLC47A2 also affect the drug’s absorption and disposition, potentially impacting drug concentration at target sites and therapeutic outcomes."
PA451234,"Repaglinide's pharmacogenetic interactions are influenced by several genes that affect its metabolism and efficacy. CYP2C8 and CYP3A4 are crucial for its hepatic metabolism, impacting drug clearance and the risk of hypoglycemia, while SLCO1B1 affects its hepatic uptake, influencing plasma levels and pharmacodynamic effects. Additionally, ABCC8, which encodes an ATP-sensitive potassium channel in pancreatic β-cells, directly alters the drug's efficacy in insulin stimulation, highlighting the importance of genetic testing in optimizing therapy and managing patient-specific responses."
PA164768835,"Maraviroc's effectiveness in treating CCR5-tropic HIV-1 infection is influenced by genetic variants of the CCR5 gene, such as the CCR5-Δ32 mutation, which can modify the receptor's structure or expression and affect drug efficacy. Additionally, the drug's metabolism is largely dependent on CYP3A4, an enzyme whose activity varies due to genetic polymorphisms, altering the drug’s pharmacokinetics, effectiveness, and side effect profile."
PA165291922,"Doxorubicinol, an active metabolite of doxorubicin, is influenced by the gene CBR1, which governs its formation from doxorubicin and affects its efficacy and toxicity. Additionally, the transporter gene SLC22A16 may impact the cellular uptake of doxorubicinol, further influencing its therapeutic effectiveness and patient response to treatment."
PA166163161,"The genes CYP3A4 and SLCO1B1 play significant roles in the pharmacogenetic interactions with lovastatin and its precursor, mevinolinic acid. CYP3A4 is involved in the drug's metabolism to its active form, affecting its efficacy and safety, while SLCO1B1 impacts lovastatin’s hepatic uptake and is linked to a higher risk of statin-induced myopathy due to variants like c.521T>C, which reduce its transport activity and increase systemic drug exposure."
PA449905,"Hydrocortisone's effectiveness and safety are influenced by interactions with the glucocorticoid receptor gene NR3C1, metabolism by CYP3A4 and CYP3A5 enzymes, and transport mechanisms involving the ABCB1 gene, with variations in these genes affecting drug exposure and response. Other genes such as SLCO1A2, SLC22A8, SERPINA6, and SHBG also contribute to its pharmacokinetics and systemic availability, but their specific roles are less defined."
PA166123566,"Genes such as HLA-DQB1 and HLA-DRB1, which are crucial components of the immune system's Major Histocompatibility Complex class II, could potentially influence how patients react to bucillamine, a drug used for rheumatoid arthritis and gout. Since variations in these genes impact the immune response, they might affect the drug’s effectiveness or the occurrence of adverse reactions, though this link is hypothesized based on the drug’s application and the general functions of these genes, not on concrete pharmacogenetic interaction data with bucillamine."
PA166049180,"Variations in the genes CYP3A4, CYP3A5, and UGT2B7, which are involved in the metabolism of loxoprofen, can lead to significant differences in how individuals process the drug, affecting both its effectiveness and safety. Genetic polymorphisms in these enzymes can lead to increased drug toxicity or reduced efficacy, influenced by altered levels of hydroxylated metabolites and glucuronidation rates."
PA451251,"Riluzole's metabolism is primarily influenced by the CYP1A2 gene, with additional involvement from CYP2D6, CYP2C19, CYP3A4, and CYP2E1, which affect the drug's hydroxylation and glucuronidation processes. Additionally, the ABCG2 transporter protein influences riluzole's absorption and distribution, while genes SCN5A and SLC7A11 impact its pharmacodynamics, crucial for understanding its therapeutic effects in ALS treatment."
PA450970,"Pioglitazone, a type 2 diabetes medication, interacts with the PPARG gene to modulate insulin sensitivity directly and relies on metabolic enzymes like CYP2C8 and CYP3A4, along with transporters SLCO1B1 and SLCO1B3, for its pharmacokinetics. Genetic variations in these enzymes and transporters can significantly affect the drug's metabolism, levels, efficacy, and risk of adverse effects, altering its therapeutic effectiveness in patients."
PA450921,"Phenprocoumon's effectiveness and safety are significantly influenced by genetic variations in several key genes essential to its metabolic pathways and mechanisms. The primary target gene, VKORC1, along with polymorphisms in CYP2C9 (rs1799853 and rs1057910), heavily dictates the anticoagulant activity and metabolic rate of the drug, respectively, necessitating dosage adjustments to mitigate increased bleeding risks and optimize therapeutic outcomes. Other genes like CYP4F2 and CYP2C19 also contribute to its metabolism but to a lesser extent, while STX4 and PPARA impact its pharmacodynamics indirectly."
PA165945763,"Cangrelor directly inhibits the P2Y12 receptor, and its effectiveness or safety may be influenced by genetic variants in the P2RY12 gene that encode this receptor. Variations in P2RY12 could affect the receptor’s binding affinity or expression levels, potentially altering cangrelor's antiplatelet effect."
PA450616,"Nevirapine's pharmacogenetic interactions are primarily influenced by genetic polymorphisms affecting its metabolism and clearance; key enzymes like CYP2B6 and CYP3A4 significantly modulate its hepatic processing. Variants in CYP2B6 can slow metabolism leading to higher drug concentrations and increased adverse effects, while genes such as HLA-DRB1 and HLA-B impact pharmacodynamics by linking to hypersensitivity reactions. These genetic variations are crucial for tailoring therapy to maximize efficacy and minimize risks in treating HIV-1 infections."
PA450496,"Midazolam's pharmacogenetics is affected by its metabolism involving CYP3A5 and CYP3A4 enzymes and its transport mediated by the ABCB1 gene. Genetic variations in these enzymes and transporter genes alter midazolam’s clearance rates, plasma concentrations, and brain access, influencing its sedative effects and side effects. Furthermore, genes like POR, NR1I2, and possibly VDR support these processes through various regulatory and enabling roles, impacting midazolam's overall pharmacokinetic behavior."
nan-dd19a3ae-626b-486b-8448-9961ea333971,"Delamanid's metabolism in humans is predominantly governed by the CYP3A4 enzyme, with variations in the CYP3A4 gene affecting the drug's pharmacokinetics through altered enzyme activity, impacting its efficacy and safety. Additionally, genetic variations in the proteins albumin (ALB) and alpha-1-acid glycoprotein 1 (ORM1) might affect delamanid's distribution and half-life, while mutations in the mycobacterial enzyme required for activating delamanid can lead to drug resistance by altering enzyme efficiency."
PA450434,"Genes such as CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP3A4, and CYP2E1 influence the pharmacokinetics of methoxyflurane by affecting its liver metabolism, impacting drug clearance and varying toxicity profiles. On the pharmacodynamic side, variations in genes related to neurotransmitter receptors (GABRA, GLRA) and potassium channels (KCNA1), as well as calcium channels and sensitivity genes (CACNA1S, RYR1), can affect the anesthetic and sedative effects of methoxyflurane and susceptibility to adverse reactions like malignant hyperthermia."
PA166129535,"Mizolastine is metabolized by the enzyme CYP2D6, and genetic variations in the CYP2D6 gene can significantly alter the drug's pharmacokinetics, affecting its efficacy and safety. Poor metabolizers may have higher blood levels and increased risk of adverse effects due to slower metabolism, while ultrarapid metabolizers may experience reduced effectiveness due to faster drug clearance."
PA450475,"The pharmacogenetic profile of metoclopramide is significantly affected by genes involved in its metabolism and transport, particularly the enzyme CYP2D6, which influences drug plasma concentration and therapeutic outcomes due to genetic polymorphisms leading to variable enzymatic activity. Additionally, CYP3A4, CYP1A2, and transporter proteins like ABCB1 also impact its metabolism and distribution, while genetic variations in dopamine D2 receptors (DRD2) can affect the drug's pharmacodynamics, altering its effectiveness and side-effect profile."
PA166131340,"Genetic variability in the UGT2B7 enzyme can significantly alter the metabolism of morphine into morphine-3-glucuronide (M3G), affecting both morphine's efficacy and side effects like hyperalgesia and allodynia. Additionally, the transporter protein ABCC3 influences the excretion and bioavailability of M3G, potentially modifying its pharmacokinetic profile."
PA450657,"Nortriptyline metabolism is significantly influenced by genetic variations in CYP2D6, which primarily demethylates the drug, affecting its plasma levels and clinical efficacy or side effects. Other genes like CYP2C19 and ABCB1 also modulate its therapeutic responses by altering its metabolism and transport, whereas genes such as BDNF and ADRA2A are involved in pharmacodynamic responses, thereby influencing the drug's overall impact and adverse effects profile."
PA166115364,"Trametinib, a MEK1 and MEK2 inhibitor, is more effective in cancers with certain BRAF mutations (V600E or V600K) due to its targeting of the MAPK/ERK pathway; however, its efficacy is reduced by mutations in NRAS, HRAS, or KRAS, which can activate alternate pathways and negate the effect of MEK blockade. Pharmacokinetic interactions are less prominent, involving minimal metabolism by CYP3A4 and CYP2C8, but the drug primarily undergoes deacetylation via carboxylesterases."
PA450606,"Nelfinavir, an HIV-1 protease inhibitor, is metabolized by CYP3A4, CYP3A5, and CYP2C19, with genetic variants in these enzymes affecting its plasma concentration and efficacy. Additionally, the ABCB1 efflux transporter influences nelfinavir's cellular uptake and distribution, which can alter drug concentrations at target sites and impact therapeutic outcomes. Understanding these gene-drug interactions is key for individualizing dosages to optimize treatment efficacy and minimize toxicity."
PA450882,"Variants in the CYP2D6 gene significantly influence the metabolism of perphenazine, affecting its clearance from the body and thus impacting both its effectiveness and side effect profile. Other CYP enzymes such as CYP1A2, CYP2C19, and CYP3A4 also contribute to its metabolism, which underscores the need for dose adjustments based on individual genetic differences to optimize therapeutic outcomes."
PA166180985,"The effectiveness and toxicity of the chemotherapy drug cytarabine and its active metabolite ara-CTP in treating AML are influenced by genetic variants in key enzymes such as DCK, which is crucial for ara-CTP formation, and CDA, which is responsible for cytarabine catabolism. Additionally, genes such as CTPS1, RRM1, SLC28A1, and SLC28A3 affect ara-CTP activity by modifying substrate availability, DNA synthesis, and cellular drug uptake."
PA450550,"Morphine's efficacy and safety are influenced by pharmacogenetic interactions involving genes such as UGT2B7, UGT1A1, and UGT1A3 that affect its metabolism, and OPRM1, OPRK1, and OPRD1 that affect opioid receptor function. Additionally, ABCB1 gene variants impact the drug's distribution and elimination, highlighting the necessity for personalized medicine in morphine therapy to optimize treatment outcomes and minimize side effects."
PA450931,"The pharmacogenetic profile of phenylalanine is largely determined by its interactions with the PAH gene, responsible for encoding phenylalanine hydroxylase, which is essential for converting phenylalanine into tyrosine. Deficiencies in this enzyme activity, due to genetic variations in PAH, can lead to phenylketonuria (PKU), affecting the severity of the condition and the effectiveness of dietary treatments designed to limit phenylalanine intake. Other genes like SLC7A8 and SLC16A10, involved in the amino acid's transport, along with enzymes such as TAT and TH that participate in downstream tyrosine metabolism, may also influence phenylalanine's pharmacogenetics and its effects on disorders like depression and vitiligo."
PA164743150,"Labetalol metabolism and efficacy are significantly influenced by genetic variations in cytochrome P450 enzymes (CYP2D6, CYP2C19) and UGT enzymes (UGT1A1, UGT2B7, UGT1A9). Polymorphisms in these genes affect how individuals metabolize labetalol, leading to variations in drug clearance, plasma concentrations, and potential toxicity, which are critical for tailoring treatment to individual patient needs in managing hypertension."
PA451241,"The pharmacogenetics of ribavirin are influenced by genes like IFNL3, ADK, NT5C2, SLC28A3, SLC29A1, and IMPDH2, which govern how it is metabolized, transported, and modulates the host's immune system response. Specifically, IFNL3 affects therapeutic outcomes through different variants such as rs12979860, while ADK and NT5C2 are involved in its metabolism outside the cytochrome P450 system, and IMPDH2 is essential in its target pathway, affecting ribavirin's efficacy and side effects like anemia."
PA152241907,"Lapatinib's metabolism is predominantly handled by CYP3A4, CYP3A5, CYP2C8, and CYP2C19, with genetic variations in these enzymes influencing its pharmacokinetics, which could require dose adjustments due to altered drug exposure. Moreover, variants in the HLA genes HLA-DQA1, HLA-DRB1, and HLA-DQB1 are linked to a heightened risk of lapatinib-induced hepatotoxicity, necessitating enhanced liver monitoring and potentially modified dosing to prevent severe adverse effects in susceptible individuals."
PA451123,"Genetic variations in CYP2C19 can significantly alter the metabolism of progesterone, affecting its efficacy and safety by influencing drug exposure and side effect risks. Additionally, variants in receptor genes such as PGR, NR3C2, ESR1, and ESR2, and transporter genes like ABCB1 and SLCO1B1, impact progesterone's effectiveness and bioavailability, which are crucial for therapeutic outcomes in reproductive processes."
PA449762,"The metabolism and effectiveness of the diabetes drug glipizide are significantly impacted by genetic variations, particularly in the CYP2C9 gene. Polymorphisms in CYP2C9, notably variant rs1057910, lead to slower drug metabolism and increased risk of hypoglycemia, necessitating dosage adjustments for affected patients. Other genes such as NOS1AP, TCF7L2, and G6PD may influence the drug's pharmacodynamics and risk of adverse effects, though their interactions with glipizide are less explicitly established."
PA449673,"Fluoxetine's metabolic processing is primarily influenced by the cytochrome P450 enzyme CYP2D6, the polymorphisms of which affect individuals' metabolic rates, impacting drug efficacy and safety. Additionally, CYP2C9 and ABCB1 also play roles in its metabolism and distribution, respectively, while fluoxetine's inhibition of CYP3A5 and CYP2C19 affects the clearance and efficacy of other medications administered concurrently."
PA166175791,"Cannabidiol (CBD) metabolism is primarily influenced by CYP3A4 and CYP2C19 enzymes, where genetic variants in these enzymes can alter its plasma levels, efficacy, and safety. Additionally, genetic variations in ABCC5 and SLC15A1 transporters, as well as the AOC1 enzyme, may impact CBD's distribution, excretion, and pharmacodynamics, thus affecting its therapeutic outcomes."
PA166182279,"Variations in the EGFR gene, specifically exon 19 deletions or the exon 21 L858R substitution, enhance the sensitivity of non-small cell lung cancer (NSCLC) to dacomitinib, making it an effective treatment option. Furthermore, genetic variants in metabolic enzymes like CYP2D6, CYP3A4, CYP2C9, and transporters such as ABCB1 and ABCG2 influence the metabolism and tissue distribution of dacomitinib, affecting drug exposure and patient response, which assists in individualizing therapy to maximize efficacy and minimize toxicity."
PA451627,"The pharmacogenetic profile of testosterone is influenced by interactions with genes such as the androgen receptor (AR), which affects the physiological response to the hormone, and metabolic enzymes like CYP3A4, CYP3A5, and CYP19A1, which play roles in its metabolism and subsequent plasma levels and effects. Additionally, genetic polymorphisms in transport proteins like SHBG and ALB can impact the transport and bioavailability of testosterone, thereby affecting hormone levels and activity."
PA451835,"Urofollitropin mainly interacts with the FSHR gene, which influences its effectiveness in fertility treatments by affecting the binding capacity of the FSH receptor involved in ovulation induction. Genetic variations in the FSHR gene can significantly alter the drug's action by affecting follicular response, critical in therapies like IVF where this drug stimulates follicular growth."
PA166178378,"The pharmacogenetic interactions of uric acid are primarily associated with its transport through solute carriers like SLC22A6, SLC22A8, and SLC2A9, which govern the renal excretion and reabsorption of uric acid, thus affecting its plasma levels and influence on diseases like gout and its role in neuroprotection during stroke. Variations in these genes alter uric acid levels, impacting the pharmacokinetics of absorption, distribution, metabolism, and excretion, influencing disease risk, progression, and response to therapies."
PA449283,"Genetic variations in CYP2C19 and CYP3A4 enzymes primarily influence the metabolism of diazepam, affecting the drug's clearance and plasma levels, with CYP2C19 having a more pronounced impact. Additionally, ABCB1 transporter variations modify the distribution and elimination of diazepam, while differences in GABA(A) receptor genes might alter its therapeutic efficacy by affecting pharmacodynamics."
PA451545,"Sulfanilamide, a sulfonamide antibiotic, functions by inhibiting bacterial dihydropteroate synthase, an enzyme crucial for folic acid synthesis in bacteria. The drug's interaction with the human G6PD gene, which encodes for glucose-6-phosphate dehydrogenase, does not directly alter sulfanilamide's pharmacological action but is significant for patient risk assessment due to the potential for hemolytic anemia induced by oxidative stress from such medications in individuals with G6PD deficiency."
PA448068,"Variants in the ADRB2 gene, such as Arg16Gly and Gln27Glu, impact the pharmacodynamics of salbutamol by altering the beta-2 adrenergic receptor's binding affinity or downregulation rate, influencing bronchodilation efficacy and side effects. The pharmacokinetics of salbutamol, primarily involving metabolism by CYP3A4, shows no direct interactions with the other genes listed, which relate more broadly to physiological pathways concerning lung function and inflammation."
PA448039,"Acitretin's efficacy and safety are influenced by its interactions with specific retinoid receptors (RXRA, RXRB, RXRG, RARA, RARB, RARG) and other proteins (RBP1, ALB), where genetic variations in these encoding genes can affect the drug's action and patient response by altering skin cell growth, differentiation, drug distribution, and bioavailability. These interactions underscore the importance of understanding individual genetic differences to optimize treatment in psoriasis management."
PA10026,"The pharmacokinetics of Aripiprazole, an atypical antipsychotic, are significantly affected by genetic polymorphisms in the CYP2D6 enzyme, leading to variations in drug metabolism that necessitate dose adjustments: poor metabolizers may require lower doses due to higher plasma concentrations, while ultra-rapid metabolizers might need increased doses to attain therapeutic effects. Additionally, the ABCB1 transporter gene influences the absorption and distribution of Aripiprazole, though its clinical impact is less clear compared to CYP2D6."
PA10204,"Tenofovir's pharmacokinetic behavior, including its activation, transport, and elimination, is significantly influenced by the genetic variations in genes such as ABCB1, SLC22A6, ABCC2, ABCC10, ABCG2, and ABCC4, which encode for different transporters affecting the drug's bioavailability, distribution, and toxicity. Additionally, genetic markers like HLA-B can predispose individuals to hypersensitivity reactions, highlighting the importance of considering individual genetic profiles to optimize efficacy and minimize adverse effects of tenofovir therapy."
PA10344,"Acamprosate interacts with genes encoding central nervous system receptors including NMDA receptor subunits (GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B), the metabotropic glutamate receptor 5 (GRM5), and inhibits the Gamma-aminobutyric acid type B receptor subunit 1 (GABBR1), affecting both excitatory and inhibitory neurotransmission pathways. Additionally, the transporter gene SLC22A6, crucial for acamprosate's renal excretion, plays a significant role in its pharmacokinetics, highlighting the importance of these genetic interactions in modulating individual responses to the drug for alcohol dependence treatment."
PA449177,"The efficacy and toxicity of the drug cytarabine are heavily influenced by genetic variants in the DCK and CDA genes, where DCK activates cytarabine into its effective form and reduced activity variants can lower the drug's effectiveness, while CDA deactivates it and variants that decrease its function can increase toxicity from longer active drug exposure. Additionally, transport genes like SLC29A1 and ABCC10 affect cytarabine’s pharmacokinetics by managing its uptake and efflux from cells, respectively, further impacting its therapeutic effectiveness and side effects."
PA10084,"Fosamprenavir's pharmacogenetic interactions are significantly influenced by genetic variants in CYP3A4, an enzyme critical for metabolizing its active form, amprenavir. These variants can alter CYP3A4 activity, thereby affecting amprenavir's plasma concentrations and influencing either an increased risk of toxicity or reduced drug efficacy, which underscores the potential benefit of genotype-based dosing in treatment optimization."
PA166160055,"Genetic variations in genes such as CYP7A1, CYP27A1 (involved in cholic acid biosynthesis), ABCB11, SLC10A1 (critical in bile acid transport), and NR1H4, GPBAR1 (related to receptor function) significantly influence the pharmacogenetic interactions of Cholic Acid, affecting its therapeutic effectiveness and safety. Additionally, genes like HSD3B7, DHCR7, AMACR, and AKR1D1 are crucial in different stages of bile acid metabolism, further impacting Cholic Acid's pharmacodynamics and the patient's response to this treatment."
PA165958382,"Genetic variations in muscarinic receptor genes such as CHRM1, CHRM2, CHRM3, CHRM4, and CHRM5 impact the function and expression of receptors, influencing the sensitivity and response to methacholine in asthma diagnosis through bronchoconstriction. Additionally, genetic variants in ADRB2, which mediates bronchodilation, may alter responses by modifying airway relaxation pathways during the methacholine challenge test, and while SLC22A5 might affect methacholine's pharmacokinetics, its influence on clinical outcomes remains unclear."
PA166235321,"Pralsetinib's metabolism is predominantly influenced by CYP3A4, with CYP2D6 and CYP1A2 also playing roles, much that genetic variations in these enzymes can alter the drug's efficacy and toxicity. Additionally, pralsetinib interacts with transport proteins like ABCB1, ABCG2, SLCO1B1, and SLCO1B3, where gene variants might affect the medication's absorption and distribution, potentially modifying therapeutic outcomes and side effects."
PA165110775,"SN-38, the active metabolite of irinotecan, is primarily metabolized by UGT1A1 through glucuronidation to SN-38G, reducing toxicity and aiding excretion, with variants like UGT1A1*28 leading to higher toxicity due to reduced enzyme activity. Other genes such as ABCC1, ABCB1 (involved in efflux), UGT1A9, and SLCO1B1 (implicated in hepatic uptake) also play roles in the pharmacokinetics and pharmacodynamics of SN-38, influencing its efficacy and safety."
PA448561,"The pharmacogenetics of benazepril involves the metabolism of the drug to its active form benazeprilat primarily through esterase-mediated hydrolysis in the liver, and its pharmacodynamics are influenced by polymorphisms in the ACE gene, which can affect the drug's effectiveness in inhibiting ACE. Additionally, variants in the SLC15A1 and SLC15A2 transporter genes impact the drug’s absorption and bioavailability, while CYP11B2 may indirectly affect benazepril's pharmacodynamics related to blood pressure regulation through aldosterone pathways."
PA166122590,"Simeprevir, used in treating HCV, is influenced by genetic variations such as polymorphisms in the HCV NS3 protease (e.g., Q80K) that affect drug binding and resistance, and by genetic differences in metabolic enzymes like CYP3A4 that impact drug plasma levels. Additionally, carrier genes like SLCO1B1, IFNL3, and IFNL4 can alter the drug’s hepatic uptake and the host's immune response, respectively, thereby affecting treatment efficacy and safety."
PA165958345,"Nilotinib, a drug used for chronic myeloid leukemia, primarily inhibits ABL1 and KIT, while its pharmacokinetics are influenced by metabolic enzymes CYP3A4, CYP2C8, CYP2C9, CYP2D6, and CYP2B6, and transport proteins ABCB1 and ABCG2. Additionally, polymorphisms in the UGT1A1 gene, especially the UGT1A1*28 allele, can predispose patients to hyperbilirubinemia, affecting the drug's conjugation process and highlighting the need for personalized dosing based on individual genetic profiles."
PA166131561,"The pharmacogenetic interactions of cotinine glucuronide are influenced by genetic variations in UGT2B10 and UGT2B17 enzymes, which catalyze its formation affecting its solubility and renal excretion. These variations can significantly alter the metabolic rate of cotinine into cotinine glucuronide, impacting its effectiveness as a biomarker for measuring nicotine exposure."
PA166223601,"Oliceridine's pharmacodynamics involve acting as a biased agonist at the μ-opioid receptor (OPRM1), affecting pain signaling through changes in ion conductivity in neurons, while its pharmacokinetics are influenced by cytochrome P450 enzymes, particularly CYP3A4 and CYP2D6. Variations in these genes, notably CYP2D6, significantly impact the metabolism rate of oliceridine, thereby affecting drug plasma levels, efficacy, and safety, with implications for tailoring dosage to minimize risks like respiratory depression or constipation."
PA450085,"Irinotecan's interactions with genes like UGT1A1, ABCC2, NR1I2, and SLCO1B1 significantly influence its pharmacokinetics and toxicity. Variations in these genes affect the metabolism, transportation, and cellular efflux of the drug and its metabolites, altering the effectiveness and adverse effects of the treatment, with the most notable being the impact of UGT1A1*28 polymorphism on the glucuronidation and toxicity profile of its active metabolite SN-38."
PA166268841,"Asciminib, a tyrosine kinase inhibitor for chronic myeloid leukemia, is metabolized by enzymes CYP3A4, UGT2B7, and UGT2B17, where genetic variants in these enzymes can alter the drug's metabolism, affecting its efficacy and safety. Additionally, transporters like ABCG2 and ABCB1, influenced by genetic variations, modulate the drug's cell efflux and bioavailability, impacting potential dose adjustments."
PA164774763,"Latanoprost targets the PTGFR and its efficacy can be affected by genetic variations in this receptor, influencing receptor sensitivity or expression. Furthermore, polymorphisms in transporter genes such as SLC22A6, SLC22A8, and ABCC4, as well as the prostaglandin synthesis gene PTGS1, can alter the drug's pharmacokinetics and pharmacodynamics, impacting concentration, availability, and ultimately the clinical outcomes of latanoprost treatment."
PA450205,"Genes involved in immune response modulation and drug metabolism significantly influence the efficacy and safety of Levamisole. Variations in genes encoding immune system components, such as cytokines (e.g., IL1, TNF), could impact therapeutic outcomes and the risk of adverse reactions like agranulocytosis, while genetic differences in liver enzymes, specifically in the cytochrome P450 family, and detoxification genes like GSTP1 may affect Levamisole's metabolism, altering drug exposure and side effects."
PA166131493,"Pharmacogenetic variations in the CYP2D6 gene significantly affect the metabolism of tramadol into its active metabolite, n-desmethyltramadol, influencing therapeutic outcomes and side effects. Variations in CYP2D6 can lead to different metabolic rates; for instance, ultra-rapid metabolizers might experience increased effects and toxicity, while poor metabolizers may find tramadol less effective due to impaired conversion into n-desmethyltramadol. Additionally, the CYP3A4 gene also contributes to the metabolism of tramadol, though its role is less significant than CYP2D6."
PA164742949,"Dexpramipexole primarily interacts with the DRD3 gene, which is responsible for encoding the dopamine receptor D3, affecting neurological functions that might influence the drug's efficacy and side effects in the neural system. Although the drug is also associated with effects on the QTc interval, which implies potential interactions with cardiac ion channel genes like KCNH2 or SCN5A, these interactions remain speculative as they are not explicitly confirmed in existing studies."
nan-54504531-9cf0-4b63-b356-1beb564c3c73,"Clofazimine interacts pharmacogenetically with multiple enzymes and transporters that affect its pharmacokinetics and pharmacodynamics. Key metabolic enzymes such as CYP3A4, CYP3A5, CYP2C8, and CYP2D6, influenced by genetic variants like CYP3A4*22 and CYP3A5*3, alter its plasma levels and potentially its efficacy and toxicity, while genetic variations in transporters like ABCB1, ABCG2, and ABCC1 may impact tissue distribution, absorption, and elimination. Additionally, genetic differences in clofazimine's molecular targets, such as PPARG and KCNA3, can modify its anti-inflammatory and immunomodulatory effects."
PA450126,"Isosorbide mononitrate's effectiveness and patient response can be influenced by genetic variations in key metabolizing enzymes such as GSTM1, XDH, and ADH5, which are responsible for converting the drug into nitric oxide and its inactive metabolites. Variants in these genes can impact drug pharmacokinetics by altering clearance rates and serum concentrations, while genes like CYB5R1-4, though not directly involved in primary metabolism, may affect secondary metabolic pathways and the synthesis of nitric oxide, further influencing the drug’s efficacy."
PA166179849,"Variations in the genes encoding for the enzymes CYP2C9, CYP3A4, and CYP2C8 can lead to differences in the metabolic rate of avatrombopag, necessitating potential dosage adjustments. Similarly, genetic differences in the transporters ABCB1, ABCG2, and SLC22A8 affect the drug's distribution and elimination, which could influence avatrombopag's bioavailability, therapeutic outcomes, and adverse effects."
PA164744372,"Amikacin interacts with the MT-RNR1 gene, which encodes mitochondrial 12S ribosomal RNA similar to bacterial ribosomal RNA, increasing susceptibility to ototoxicity due to cellular damage in the cochlea. Additionally, genetic variations affecting renal function can influence amikacin-induced nephrotoxicity by impacting drug accumulation, due to its primary excretion via the kidneys, which may present varying toxicity risk profiles in patients with such genetic predispositions."
PA161199368,"Iloperidone metabolism is heavily influenced by variations in the CYP2D6 and CYP3A4 genes, impacting drug efficacy and side effects due to differences in plasma levels and metabolic clearance. Additionally, genetic variations in receptor-related genes like HTR2C may influence iloperidone's pharmacodynamic interactions, affecting how the drug interacts with dopamine and serotonin receptors, which can also alter its efficacy and side effect profile."
PA449899,"Variations in genes such as SLC12A3, which encodes for the sodium-chloride symporter, and others related to renal transport like SLC22A6 (OAT1), SLC22A8 (OAT3), SLC22A11 (OAT4), and ABCC4 (MRP4), directly alter the effectiveness of hydrochlorothiazide by influencing its absorption, secretion, and the reabsorption capabilities of sodium and chloride in the kidneys. Other genes like KCNJ1, NEDD4L, and WNK1, which are involved in potassium and sodium balance, may also play a role, albeit more speculatively, in modulating the drug's diuretic effect and its impact on electrolyte management."
PA10888,"Clobazam's metabolism is significantly affected by interactions with the CYP2C19 enzyme, where genetic variants like CYP2C19*2 can lead to reduced enzymatic activity. This reduction increases plasma levels of N-desmethylclobazam, clobazam's active metabolite, thus affecting therapeutic outcomes and potentially increasing the risk of adverse reactions, which impacts dosing requirements and the overall risk-benefit ratio of using the drug. Other enzymes, like POR, and genes like SCN1A, may influence its metabolism or pharmacodynamics, but clear evidence of their impact on clobazam's pharmacogenetics is lacking."
PA448897,"Variants in the cytochrome P450 enzymes CYP3A4, CYP3A5, CYP2C8, and CYP2C9 significantly influence the metabolism of cerivastatin, affecting its efficacy and safety by altering metabolic rates and increasing risks of adverse effects like rhabdomyolysis. Additionally, variations in the SLCO1B1 gene, which encodes the solute carrier organic anion transporter family member 1B1, are associated with the risk of statin-induced myopathy, highlighting the impact of genetic differences in both the transport and metabolism of cerivastatin on its adverse effect profile."
PA448405,"Amoxapine's pharmacogenetic interactions primarily involve the CYP2D6 enzyme, which due to its genetic variability, impacts drug metabolism and consequently, its efficacy and safety. Individuals with different CYP2D6 genetic profiles (poor or ultra-rapid metabolizers) may experience higher risks of side effects or diminished therapeutic effects, respectively, which can necessitate dosage adjustments."
PA448794,"Carbidopa inhibits DDC (dopa decarboxylase) to prevent the peripheral conversion of levodopa to dopamine, a crucial mechanism for treating Parkinson’s disease, while polymorphisms in DDC could hypothetically affect its efficacy. Furthermore, DBH (Dopamine beta-hydroxylase), which converts dopamine to norepinephrine, may also influence responses to carbidopa, although direct genetic associations are unspecified, highlighting potential individual variability in response due to genetic differences in enzymes linked to dopamine synthesis and metabolism."
PA450112,"Isoniazid pharmacogenetics is significantly influenced by the NAT2 gene, which encodes for the enzyme responsible for the acetylation of isoniazid, causing variability in drug metabolism rates; this variability categorizes individuals as rapid or slow acetylators, affecting their risk for adverse effects such as hepatotoxicity and peripheral neuropathy. Other genes like CYP2E1, GSTT1, GSTM1, GSTP1, CYP2C9, CYP2C19, and SLCO1B1 also affect isoniazid’s metabolism and detoxification, influencing the drug’s pharmacokinetics and the susceptibility to its toxicity."
PA448685,"Buprenorphine's pharmacogenetic interactions are influenced by its metabolism through enzymes CYP3A4 and CYP3A5, where genetic variations can alter drug clearance, affecting both efficacy and safety. Additionally, genetic variants in opioid receptor genes like OPRM1 and OPRK1, and the transporter gene ABCB1, affect its binding and distribution, influencing individual responses in terms of analgesic effects and addiction treatment efficacy. Other genes such as COMT and SLC6A4 also play roles in impacting pain perception and mood, respectively, further affecting treatment outcomes."
PA452619,"Genetic variations in CES1 affect the rate at which heroin is metabolized to morphine, impacting the drug’s efficacy and safety, while polymorphic genes like OPRM1, OPRK1, and OPRD1 influence how morphine interacts with opioid receptors, affecting pain perception, addiction risk, and opioid sensitivity. Additionally, genes such as MAOA, COMT, and transporters like SLC6A3 indirectly modulate heroin’s effects through their roles in neurotransmitter pathways, contributing further to individual differences in drug response and potential side effects."
PA164754814,"Pregabalin's pharmacogenetics are significantly influenced by genetic variations in the SLC1A1 and SLC7A5 transporter genes, which play crucial roles in the drug's absorption, distribution, and elimination, thereby affecting its efficacy and safety profiles. While the drug's interaction with metabolic enzymes is minimal, these transporters impact pregabalin's pharmacokinetic characteristics, and variations in these genes can lead to individual differences in drug levels."
PA449027,"The efficacy and safety of cladribine are influenced by the deoxycytidine kinase (DCK) enzyme, which activates the drug into its cytotoxic form, and variations in the DCK gene can impact this process. Additional genes such as ABCG2 and SLC28A3, affecting drug transport, and genes like RRM1, RRM2, RRM2B, POLA1, and POLE, involved in DNA synthesis and repair, play crucial roles in the pharmacodynamics and bioavailability of cladribine, ultimately affecting therapeutic outcomes."
PA451900,"The pharmacogenetics of Vitamin E mainly involves the cytochrome P450 system, particularly genes like CYP4F2, CYP3A4, and CYP3A5 that participate in its metabolism. CYP4F2 specifically catalyzes the omega-hydroxylation of tocopherols and tocotrienols, critical for Vitamin E catabolism, while polymorphisms in these genes can cause variations in Vitamin E metabolism, impacting its plasma levels, tissue concentrations, and overall antioxidant effectiveness."
PA166163740,"Genetic variations in CYP3A4 and CYP3A5 enzymes notably impact the metabolism of apixaban, affecting its plasma levels, efficacy, and safety through altered enzymatic activity. Additionally, genetic polymorphisms in the transporters ABCB1 and ABCG2 influence the absorption and excretion of apixaban, thus altering its bioavailability and plasma concentrations, which are crucial for its pharmacological effect and response to therapy."
PA451483,"The pharmacogenetic profile of spironolactone is influenced by genes impacting its pharmacokinetics and pharmacodynamics. Variants in CYP2C8 alter its metabolism and efficacy, affecting its diuretic and antihypertensive effects, while CYP11B2 variations can modify spironolactone's effectiveness by influencing aldosterone production. Moreover, genetic differences in NR3C2, which encodes the mineralocorticoid receptor, crucially affect the drug's response in managing hypertension and heart failure. Other genetic factors including NOS3, CYP4A11, CYP4F2, ADD1, ADRB1, ADRB2, and ACE also potentially impact its efficacy, primarily through mechanisms related to blood pressure regulation and renal function."
PA451996,"Azacitidine's effectiveness and safety are influenced by its interaction with the CDA gene, which encodes cytidine deaminase responsible for the drug's metabolism, and DNMT1, the target enzyme inhibited by azacitidine affecting DNA methylation. Variations in these genes can alter drug pharmacokinetics and pharmacodynamics, influencing efficacy and toxicity in treating myelodysplastic syndrome and acute myeloid leukemia. Additionally, mutations in genes like PTPN11, CBL, NRAS, KRAS, TYMS, MTHFR, and XRCC1, which are involved in oncogenic pathways and DNA synthesis and repair, may also modify treatment outcomes through effects on cancer pathology and drug resistance mechanisms."
PA449293,"Diclofenac’s pharmacogenetic interactions mainly involve CYP2C9, CYP2C8, ABCC2, and UGT2B7 genes, regulating its metabolism, excretion, and elimination. Variants in these genes can lead to differences in diclofenac's systemic concentrations and excretion rates, consequently affecting the drug's efficacy and toxicity, notably increasing the risk of side effects such as gastrointestinal issues and liver toxicity."
PA451666,"Thioridazine metabolism is primarily influenced by CYP2D6 genetic polymorphisms, which cause variations in drug levels impacting its efficacy and side effect profile. Poor metabolizers have higher plasma concentrations increasing side effect risks, such as cardiac arrhythmias, while ultra-rapid metabolizers may experience subtherapeutic drug levels, reducing effectiveness."
PA165948902,"Boceprevir's metabolism is significantly influenced by CYP3A4 and CYP3A5 enzymes, with genetic variants in these genes resulting in different enzyme activities and, therefore, altering drug metabolism. For instance, CYP3A5 expressers process the drug quicker which might require dose adjustments, whereas non-expressers may face higher drug exposure and potential adverse effects. Additionally, boceprevir is a substrate of P-glycoprotein, impacted by ABCB1 gene polymorphisms, affecting its distribution and elimination, and IFNL3 and IFNL4 gene variations can influence treatment response, including therapy duration and outcome in HCV treatment."
PA449211,"Variations in genes such as CYP2E1, which is crucial for dapsone's hepatic metabolism, along with other enzymes like CYP3A4, CYP2C9, CYP2C19, CYP3A5, CYP3A7, NAT2, MPO, and FMO3, affect the drug's metabolism and pharmacokinetics, potentially influencing its efficacy and toxicity. Genetic differences in the acetylation by NAT2 or metabolic oxidation by MPO and FMO3 particularly can lead to variations in dapsone's systemic exposure and pharmacological outcomes, impacting adverse effects and therapeutic effectiveness."
PA10251,"Atazanavir's pharmacokinetic profile is influenced by its interaction with various genes related to its metabolism and transport, such as CYP3A4 and CYP3A5, which are crucial for its metabolism, and UGT1A1, whose polymorphisms can lead to adverse reactions like hyperbilirubinemia by affecting bilirubin processing. Other notable genes include NR1I2, which influences the transcription of metabolism enzymes; ABCB1, affecting absorption through P-glycoprotein; and ABCC2 and SLCO1B1, which play roles in the drug's distribution and excretion."
PA166204001,"Zanubrutinib's metabolism is primarily mediated by CYP3A4, with additional involvement from CYP2B6, CYP3A5, and CYP3A7, where genetic variants like CYP3A4*22 could significantly impact its pharmacokinetics by altering enzyme activity, affecting the drug’s efficacy and toxicity due to altered drug concentrations in the blood. Furthermore, the drug transporter ABCB1, influenced by genetic variations such as the C3435T polymorphism, moderates zanubrutinib’s absorption and elimination, affecting its bioavailability and distribution, while MYD88 affects pharmacodynamic responses related to mutations prevalent in certain diseases like Waldenström’s macroglobulinemia."
PA450588,"Naltrexone's effectiveness in treating alcohol and opioid dependence hinges on its interactions with specific opioid receptor genes, such as OPRM1, OPRK1, and OPRD1, which influence how the drug impacts mu, kappa, and delta opioid receptors, and the metabolic enzyme gene UGT1A1, which affects the drug’s conversion into its active metabolite 6-beta-naltrexol. These genetic variations alter naltrexone’s pharmacodynamics and metabolism, thus affecting individual patient responses and treatment outcomes."
PA449334,"Diltiazem metabolism is significantly affected by polymorphisms in the CYP3A4 and CYP3A5 genes, impacting the oxidation process and altering the drug's plasma levels and safety profile. Variants in the ABCB1 gene also alter diltiazem's absorption and distribution, while polymorphisms in the ADRB1 gene can influence the heart rate response to the drug, which is crucial for conditions like atrial fibrillation, indicating the potential need for tailored dosages based on individual genetic makeup."
PA162372878,"Dasatinib's pharmacogenetic interactions are influenced primarily by the CYP3A4 enzyme, which metabolizes the drug, affecting its plasma levels and thus impacting both efficacy and toxicity. Additionally, transporter genes like ABCB1 and ABCG2 regulate dasatinib's efflux from cells, altering bioavailability and distribution, while genetic variations in the pharmacodynamic target gene ABL1 and related kinases can also affect treatment response and clinical outcomes."
PA163518919,"Genetic variations in CYP2D6 can lead to different plasma levels of the antipsychotic drug paliperidone, affecting its side effect severity, while variants in the ABCB1 gene can alter the drug's absorption and distribution, impacting its therapeutic efficacy and side effects. Other genes like NFIB, SH2B1, RABEP1, and MC4R may also influence the drug's effectiveness and safety through mechanisms not directly related to its primary metabolism or transport pathways."
PA450132,"Itraconazole's metabolism and efficacy are influenced by genetic variations in several cytochrome P450 enzymes and transporters, particularly CYP3A4, CYP3A5, and CYP2B6, which metabolize the drug, and ABCB1, which affects its bioavailability and distribution. These genetic differences can lead to variability in drug plasma levels, impacting both the effectiveness and potential toxicity of the drug."
PA450163,"Lamivudine interacts with genes related to transport and phosphorylation; transporter genes like ABCC1-4, ABCG2, and SLC22A1-6 affect its cellular uptake and efflux, impacting drug distribution and elimination, while phosphorylation by enzymes such as deoxycytidine kinase (DCK) and UMP-CMP kinase (CMPK1) influences its activation rate. Genetic variations in these genes can lead to differences in lamivudine activation, levels, and efflux, thereby affecting the drug’s efficacy and potential toxicity in treating HIV and HBV."
PA448780,"Captopril's interaction with the ACE gene causes variability in its effectiveness to reduce blood pressure by influencing enzyme activity that controls angiotensin I conversion to angiotensin II. Additionally, the drug's pharmacokinetics are affected by genetic variations in ABCB1 and SLC22A6, which alter captopril's absorption, elimination, and renal excretion, consequently impacting the drug's plasma levels, efficacy, and likelihood of side effects."
PA448883,"The pharmacokinetics of cephalexin, notably its absorption and excretion, are significantly influenced by the genetic variations in transporter genes such as SLC22A6 and SLC15A1, which are responsible for its renal excretion and intestinal absorption respectively. Variants in these genes, as well as others like SLC22A5, SLC15A2, SLC22A8, and SLC47A1, can affect the levels of cephalexin reaching the systemic circulation and its subsequent excretion, potentially impacting therapeutic outcomes and drug tolerability due to altered drug exposure. Additionally, variations in the ALB gene, which codes for albumin that carries cephalexin in the serum, might modify the drug’s distribution and availability by affecting binding efficiency."
PA448500,"Genetic variations in several key genes, including SLCO1B1, CYP3A4, CYP3A5, UGT1A1, ABCB1, ABCG2, HMGCR, and KIF6, significantly affect the pharmacokinetics and pharmacodynamics of atorvastatin. These gene variants influence how atorvastatin is absorbed, metabolized, and eliminated from the body, as well as how effectively it targets its main enzymatic site, HMGCR, to reduce cholesterol, thereby impacting its overall efficacy and safety in treating cardiovascular conditions."
PA448691,"Busulfan's metabolism is chiefly controlled by glutathione S-transferases (GSTs), including GSTM1, GSTA1, GSTP1, and GSTA2, which detoxify the drug by catalyzing its conjugation with glutathione, thereby impacting its toxicity and clearance based on genetic variations within these genes. The cytochrome P450 enzyme CYP3A4 also metabolizes busulfan, though to a lesser extent, with its genetic variability affecting busulfan's plasma levels and side effects; other CYP enzymes like CYP2C9 and CYP2C19 may influence metabolism, but their roles are less clearly defined."
PA450106,"Isoflurane is minimally metabolized by cytochrome P450 enzymes, notably CYP2E1, with genetic variability in this enzyme affecting isoflurane clearance to some extent. Additionally, isoflurane modulates pharmacodynamics through interactions with neurotransmitter systems, involving genes such as GABRA1, GABRA2, GABRG2, and KCNA1, which influence the drug's effects on neural excitability and anesthetic efficacy, while genes like CACNA1S and RYR1 may also impact sensitivity through muscle excitation and calcium signaling pathways."
PA166211181,"Tepotinib, a MET tyrosine kinase inhibitor used in treating NSCLC, interacts primarily with the MET gene and is metabolized significantly by CYP3A4 and CYP2C8. Variants in these and other related genes, including CYP2C9 and multiple drug transport genes like ABCB1, ABCG2, and others, influence the drug’s pharmacokinetics and pharmacodynamics, affecting its plasma concentrations, efficacy, and safety profiles."
PA450264,"Genetic variations in enzymes CYP3A4 and CYP3A5 affect the metabolism of lopinavir, a protease inhibitor used in HIV treatment, influencing its plasma concentration and effectiveness, with underactive enzyme variants leading to higher plasma levels and potential adverse effects. Additionally, polymorphisms in the ABCB1 gene, encoding P-glycoprotein, affect lopinavir’s absorption and distribution, highlighting the importance of personalized dosing based on individual genetic profiles to optimize treatment outcomes."
PA451108,"Procainamide's metabolism and effectiveness are significantly influenced by genetic variations in the CYP2D6, NAT2, and SCN5A genes. Variants in CYP2D6 and NAT2 can alter procainamide clearance rates, leading to higher plasma levels and increased toxicity risks, while genetic differences in SCN5A may affect the drug's efficacy in treating arrhythmias by altering cardiac sodium channel function."
PA164743977,"Arformoterol, targeting the ADRB2 gene, is metabolized primarily through glucuronidation and to a lesser extent by cytochrome P450 enzymes including CYP2D6 and CYP2C19. Genetic variations in these metabolic enzymes can significantly impact the drug's plasma levels, efficacy, and side-effect profiles, making personalized dosing essential for optimal therapeutic outcomes in COPD management."
PA448681,"Budesonide's pharmacogenetic interactions involve crucial genes impacting both its pharmacokinetics and pharmacodynamics. The cytochrome P450 enzymes CYP3A4, CYP3A5, and CYP3A7 primarily influence its metabolism, while genes like NR3C1 (a glucocorticoid receptor), TBX21, FCER2, GLCCI1, CRHR1, ADRB2, and ZNF432 play significant roles in its pharmacodynamics by affecting drug sensitivity, responsiveness, and side effect profiles."
PA448497,"The genes CYP2C9 and CYP2C19 are involved in the metabolic transformation of aspirin into salicylic acid, with CYP2C9 polymorphisms, such as rs1799853, impacting its metabolic rate, effectiveness, and side effect profile. ITGB3 gene, through the rs5918 polymorphism, influences platelet response and the efficacy of aspirin's antiplatelet effects, while LTC4S gene variant rs730012 is associated with aspirin-induced urticaria, indicating a risk for hypersensitivity reactions."
PA166268804,"Mobocertinib's effectiveness and safety are influenced by genetic variations, particularly through the interaction with EGFR exon 20 insertion mutations which enhance its pharmacodynamic efficacy in NSCLC by targeting resistant receptors. Pharmacokinetically, the drug's metabolism is primarily governed by CYP3A4, CYP3A5, and CYP3A7, while transporters like ABCB1 and ABCG2 impact its plasma levels and toxicity by affecting drug distribution and elimination, highlighting the importance of genetic variations in these enzymes and transporters in optimizing mobocertinib’s dosage and minimizing risks."
PA450180,"Genetic variants in CYP2C19 significantly affect the metabolism and efficacy of lansoprazole, impacting its plasma levels and leading to variability in drug response among individuals. Other genes such as ABCB1, influencing drug absorption, and CYP3A5, which contributes to lansoprazole's hepatic breakdown, also modulate its pharmacokinetics, while IL1B's role is less related to metabolism and more to gastric mucosal processes."
PA164752425,"Nelarabine's pharmacogenetic interaction involves the drug's metabolism by adenosine deaminase (ADA), which activates it to ara-G, followed by further activation steps mediated by deoxycytidine kinase (DCK) and deoxyguanosine kinase (DGUOK). The variability in ADA, DCK, DGUOK, and the drug transporter gene SLC29A1 influence nelarabine's activation, efficacy, and toxicity by affecting both the drug's metabolism and the cellular uptake of its active forms."
PA452629,"The metabolism of zuclopenthixol, a drug used in treating psychosis, is significantly influenced by variations in the CYP2D6 gene, leading to classifications such as poor, intermediate, extensive, or ultra-rapid metabolizers. These genetic variations affect the drug levels and clearance rates in individuals, thereby impacting the effective dosage and potentially altering therapeutic outcomes and the incidence of side effects, which necessitates tailored clinical management to enhance treatment efficacy and safety."
PA164748728,"Genetic polymorphisms in UGT1A9 and UGT2B7 significantly affect the metabolism of mycophenolic acid, influencing drug clearance rates, efficacy, and toxicity. Additionally, genes like SLCO1B1 and ABCC2 impact the drug's pharmacokinetics through hepatic processes, whereas HPRT1, NFATC1, and genetic variations in IMPDH1, the drug's target, potentially alter pharmacodynamics, impacting the drug's effectiveness and safety."
PA10364,"The genes NR1I2 and BCHE are significant in understanding the pharmacogenetics of memantine: NR1I2 affects the drug's metabolism and excretion by regulating various enzymes and transporters, while BCHE's role, though not directly involved in memantine's primary metabolism as an NMDA receptor antagonist, could indirectly alter treatment outcomes in Alzheimer's disease due to its involvement in cholinergic mechanisms."
PA448388,"Amlodipine targets the CACNA1C gene encoding L-type calcium channels to provide vasodilation and is metabolized by CYP3A4 and CYP3A5 enzymes, where genetic variants can alter drug metabolism and efficacy. Additionally, variants in the ABCB1 gene affect the drug's transport, impacting its effectiveness and side effect profile, emphasizing the need for personalized dosing based on genetic makeup to optimize therapeutic outcomes and minimize adverse effects."
PA166131388,"The pharmacogenetics of 4-hydroxycyclophosphamide, a metabolite of cyclophosphamide, depends significantly on enzymes CYP2B6 and CYP3A4/5 for its activation, with variations in these genes affecting the drug's metabolism and thus its therapeutic efficacy and toxicity. Additionally, genetic differences in aldehyde dehydrogenase genes ALDH1A1 and ALDH3A1 influence the detoxification of its byproducts, possibly leading to increased toxicity risks such as hemorrhagic cystitis."
PA451565,"Sulindac, a nonsteroidal anti-inflammatory drug, is metabolized by CYP1A1 into its active form and eliminated via SLC22A6, with genetic variations in these genes affecting its bioavailability, efficacy, and risk of toxicity. Additionally, its pharmacodynamic effects are influenced by genetic differences in PTGS1 and PTGS2, which it targets to reduce inflammation, as well as by genes like PPARD, PTGDR2, AKR1B1, and AKR1B10 that modulate inflammatory and metabolic responses. These genetic interactions could guide individualized therapeutic strategies and minimize adverse effects."
PA166118041,"Variations in the UGT1A6 gene significantly influence the metabolism of deferiprone by affecting the conversion of the drug to its inactive form, deferiprone 3-O-glucuronide, which can alter the drug's effectiveness in iron chelation and the incidence of side effects. The genetic influences on the pharmacodynamics of deferiprone are less significant due to its specific role in iron chelation without direct interaction with cellular targets or involvement in complex signaling pathways."
PA449072,"Cocaine’s effects and addiction potential are significantly influenced by genetic variations impacting its pharmacokinetics and pharmacodynamics. Genes like CYP3A4 and CYP2D6 affect the metabolic rate of cocaine, while CES1 influences its hydrolysis. Additionally, transporter genes such as SLC6A3, SLC6A2, and SLC6A4, along with neurotransmitter-related genes like DRD2, OPRM1, and CNR1, alter the drug’s psychostimulatory effects and addiction risks by modifying neurotransmitter reuptake and receptor interactions."
PA451955,"The pharmacogenetics of zileuton are significantly influenced by genes such as CYP1A2, CYP2C9, and CYP3A4, which are critical in the drug's hepatic metabolism and notably affect its clearance and plasma concentrations. Variants in these genes can alter enzyme activity, impacting the drug's efficacy and safety, with certain variants potentially necessitating dose adjustments. Additionally, zileuton acts pharmacodynamically by selectively inhibiting ALOX5, preventing the formation of pro-inflammatory leukotrienes, thereby contributing to its anti-inflammatory effects in treating asthma. Although variability in ALOX5 might hypothetically affect drug effectiveness, such associations are not well-established."
PA163522472,"Darunavir's pharmacogenetic interactions are influenced by genes crucial for its metabolism and transport, particularly CYP3A4 and CYP2D6, which are responsible for its oxidative biotransformation. Variants in these genes alter enzyme activity, thereby affecting darunavir's levels, efficacy, and toxicity. Additionally, transporter genes like ABCB1 and SLCO1B1 play roles in the drug’s distribution and cellular uptake, impacting its plasma concentrations and effectiveness."
PA134687924,"Erlotinib, an EGFR-targeting tyrosine kinase inhibitor, has its efficacy and metabolism influenced by genetic variations in the EGFR, CYP3A4, CYP1A2, CYP1A1, ABCG2, and ABCB1 genes. These genetic factors affect drug response, clearance, toxicity, absorption, and efflux, making molecular profiling essential for tailoring personalized cancer therapies to optimize outcomes and minimize adverse effects."
PA451616,"Terbutaline's efficacy and safety are influenced by genetic variations in the ADRB2 gene, which affect its bronchodilatory function, as well as in metabolic genes like SULT2A1, SULT1A1, UGT1A1, and UGT1A4, which impact its plasma concentration and side effect profiles through altered drug metabolism. Additionally, genetic polymorphisms in transporters SLC22A5 and SLC22A2 can change cellular uptake and distribution, affecting the drug's pharmacokinetics."
PA161925594,"Tropisetron's effectiveness and side effect profile are influenced by genetic variations in HTR3A, the gene coding for its primary target, the 5HT3 receptor, which affects receptor binding or activity. Additionally, variations in the CYP2D6 gene, crucial for the drug's metabolism involving hydroxylation and conjugation, impact metabolic rates and thereby affect its plasma levels, efficacy, and toxicity."
PA449301,"Variations in the gene encoding Purine nucleoside phosphorylase (PNP) affect the metabolism of didanosine, altering its antiviral efficacy and toxicity by influencing intracellular concentrations of its active metabolites. Similarly, genetic variability in transport proteins such as SLC29A1 and SLC29A2 impacts didanosine's absorption and distribution, thereby modifying its therapeutic outcomes by altering bioavailability and intracellular levels."
PA451647,"The metabolism of the drug theophylline is heavily influenced by cytochrome P450 enzymes, notably CYP1A2 and, to a lesser extent, CYP2E1. Genetic variations in CYP1A2 can alter enzyme activity, thereby affecting the drug’s plasma levels, efficacy, and risk of adverse effects, necessitating dose adjustments based on individual genetic profiles."
PA10072,"Epoetin alfa, a drug used to stimulate erythropoiesis, operates primarily through the interaction with the erythropoietin receptor (EPOR) gene and may also interact with the JAK2/STAT5 pathway genes, influencing the drug's effectiveness and the risk of adverse effects like thromboembolism. Additionally, the HFE gene, related to iron metabolism, may indirectly affect the drug's response due to its role in erythropoiesis."
PA166121346,"Ibrutinib's effectiveness and safety are influenced by genetic variants in the CYP450 enzymes (including CYP3A4, CYP3A5, and CYP2D6), which affect how the drug is metabolized, thus altering its concentration and the potential risk of side effects. Specific polymorphisms, such as CYP3A5*3, play a crucial role in determining the levels of ibrutinib available for its intended action on the BTK protein. Additionally, genetic differences in proteins like ALB and ORM2 could further modify ibrutinib’s distribution and plasma protein binding, which are key factors in its pharmacologic profile."
PA166163437,"Grazoprevir, a direct-acting antiviral drug for Hepatitis C, is significantly affected by pharmacogenetic interactions involving the CYP3A4 gene, which is crucial for its metabolism. Variants in this gene can alter drug levels and efficacy, while genetic differences in transporters like ABCB1, SLCO1B1, and SLCO1B3 impact its bioavailability, distribution, and elimination, thereby influencing the drug's plasma concentrations and duration of action."
PA451733,"The metabolism of torasemide is significantly affected by genetic variants in CYP2C9 and, to a lesser extent, CYP2C8, with variations like CYP2C9*2 and CYP2C9*3 leading to reduced enzyme activity and potentially higher drug concentrations, increasing the risk of side effects such as hypotension or electrolyte imbalances. Additionally, genetic factors may also influence the role of transporters like SLCO1B1 in torasemide's hepatic uptake, though these interactions are less clearly understood."
PA451540,"Sulfadoxine, an antimalarial drug, interacts pharmacodynamically with human genetics primarily through considerations of glucose-6-phosphate dehydrogenase (G6PD) deficiency, which can increase risks of hemolysis when patients with this genetic condition are treated with sulfadoxine. Additionally, while not thoroughly documented, interactions might exist with the cytochrome P450 enzyme system, potentially affecting drug metabolization in combination therapies like Fansidar, although this is more speculative and relevant to the pyrimethamine component of the drug."
PA164745442,"The HLA-B gene affects the immune response to phenoxymethylpenicillin (Penicillin V), particularly predisposing individuals to allergic reactions, which impacts the drug's safety and efficacy due to hypersensitivity concerns. The SLC15A1 gene influences the absorption of the drug, affecting its bioavailability and potentially altering therapeutic effectiveness and toxicity levels. These genetic interactions are crucial for determining both the pharmacodynamic and pharmacokinetic profiles of phenoxymethylpenicillin."
PA451791,"Trimipramine's metabolism is heavily influenced by its interaction with cytochrome P450 enzymes, specifically CYP2D6 and CYP2C19, which are significant in processing the drug in the liver, affecting both its efficacy and potential side effects. Additionally, the ABCB1 transporter plays a role in the drug's distribution and elimination, further impacting its systemic exposure and therapeutic outcomes."
PA10235,"Zoledronic acid interacts pharmacogenetically primarily through the inhibition of key enzymes GGPS1 and FDPS in the mevalonate pathway, essential for osteoclast function, and also with the ABCC1 gene, which affects the drug’s distribution and elimination. Genetic variations in these genes can influence the drug’s effectiveness and safety, impacting bone resorption and osteoclast apoptosis, and potentially altering the therapeutic outcomes in treating bone diseases."
PA166180939,"The metabolism of phenazepam is significantly influenced by the CYP2C19 gene, with variants leading to different metabolic rates that affect the drug's plasma concentration and duration of action. Additionally, genetic variations in the GABA_A receptor subunits impact the drug's efficacy in modulating GABAergic inhibition, which influences therapeutic outcomes and side effect profiles through its pharmacodynamics."
PA166184233,"Vernakalant, a class III antiarrhythmic agent, undergoes metabolism predominantly via the CYP2D6 enzyme, where differences in metabolic rates between extensive metabolizers (EMs) and poor metabolizers (PMs) due to genetic polymorphisms may affect the drug's efficacy and safety, influencing dosing strategies. Additionally, Vernakalant interacts with various ion channels such as SCN5A-encoded sodium channels, KCNA5 and KCND3-encoded potassium channels, and KCNH2-encoded hERG channels, which are instrumental in its effects on atrial electrophysiology and cardiac safety."
PA449719,"Furosemide's effectiveness and safety are influenced by genetic variations in SLC12A1, which regulates sodium and chloride reabsorption in the kidneys, directly affecting the drug's mechanism of action. Additionally, genes such as UGT1A1, SLC22A6, and SLC22A8 impact its metabolism and excretion, altering furosemide's clearance and plasma levels, while CYP4F2, CYP11B2, and SCNN1G indirectly influence its pharmacodynamic properties. Understanding these genetic interactions can help tailor individualized dosing and therapeutic strategies to optimize treatment outcomes."
PA166122595,"Vortioxetine is metabolized primarily by the CYP2D6 enzyme, and genetic variations in this enzyme significantly influence the drug’s plasma concentration, affecting its efficacy and safety. While other enzymes like CYP3A4/5 and CYP2C19 also participate in its metabolism, CYP2D6's role is crucial, and its genotyping could help customize treatment plans. Additionally, vortioxetine interacts with various serotonin receptors, which contributes to its pharmacodynamic profile, although the pharmacogenetic impact on these receptor interactions is less defined."
PA449599,"Fentanyl's interaction with genetic variants primarily impacts its metabolism and receptor binding, influencing both its effectiveness and safety profile. Variations in metabolic enzymes such as CYP3A4, CYP3A5, and CYP2D6 affect the rate of fentanyl metabolism, altering drug exposure and activity. Additionally, genetic differences in the transporter gene ABCB1 and the opioid receptor gene OPRM1 modify how fentanyl is distributed within the body and how it interacts with opioid receptors, respectively, consequently affecting drug efficacy and the risk of dependency or adverse effects."
PA449748,"Genetic variations in key enzymes and transporters such as DCK, CDA, SLC29A1, SLC28A1, and RRM1 significantly influence the pharmacokinetics and pharmacodynamics of gemcitabine. These variations affect the drug's activation, breakdown, cellular uptake, and DNA synthesis disruption, thereby impacting its efficacy and toxicity in cancer treatment."
PA134308647,"Rosuvastatin metabolism is influenced by CYP2C9 and its pharmacokinetics are significantly affected by SLCO1B1 and ABCG2 gene variants, with the *15 allele of SLCO1B1 increasing hepatic uptake and plasma levels, potentially raising myopathy risk, and the c.421C>A polymorphism in ABCG2 altering intestinal absorption, affecting dose requirements. Additionally, efficacy in cholesterol reduction is influenced by polymorphisms in the HMGCR gene, which are central to the drug's pharmacodynamics."
PA164768738,"Ethionamide, a drug used against tuberculosis, is metabolized in the liver with varying efficacy due to genetic variations in the FMO2 enzyme, which can affect its activation and thus its overall effectiveness. Additionally, Ethionamide's action on tuberculosis bacteria involves targeting specific bacterial enzymes like inhA and can be compromised by resistance mutations in katG, affecting its therapeutic efficacy and potential cross-resistance with similar drugs such as isoniazid."
PA448717,"The pharmacogenetics of calcitriol involves genes such as VDR, CYP24A1, and CYP3A4. VDR genetic polymorphisms affect calcitriol's therapeutic efficacy by influencing gene transcription related to calcium balance and metabolic processes, while CYP24A1 mutations affect calcitriol's degradation rates and hence its dosage and effectiveness; variability in CYP3A4 also impacts calcitriol’s metabolism but to a lesser extent."
PA165958374,"Desvenlafaxine metabolism is primarily influenced by UGT enzymes (notably UGT1A1 and UGT1A3), leading to variable drug clearance and efficacy due to polymorphisms in these genes, while minor metabolism pathways involve CYP3A4 and CYP2C19, also affected by genetic variations. Furthermore, its pharmacodynamics are affected by neurotransmitter transporter genes (SLC6A4, SLC6A2, SLC6A3), ABC transporter genes (ABCB1, ABCC1), and the serotonin receptor gene HTR7, all of which contribute to differences in therapeutic outcomes due to variations in drug transport and receptor function."
PA166160050,"Alectinib's effectiveness and safety are influenced by its pharmacogenetic interactions with CYP3A4, where genetic variations affect its metabolism and plasma levels, and with ABC transporters like ABCG2 and ABCB1, which modify its absorption, distribution, and cellular efflux. These genetic interactions determine individual variabilities in therapeutic outcomes and toxicity risks, highlighting the importance of genetic testing to tailor alectinib treatment."
PA166152901,"The efficacy and safety of 5-HTP in treating symptoms like anxiety and mood swings are influenced by genetic variations in several serotonin modulating genes. The SLC6A4 gene affects serotonin reuptake, potentially altering 5-HTP pharmacokinetics, while variations in HTR2A and HTR3A genes can modify how 5-HTP stimulates serotonin receptors, affecting its pharmacodynamic response. Additionally, the SLC22A2 gene, involved in organic cation transport, could influence 5-HTP's cellular uptake and distribution, contributing to interindividual differences in drug response."
PA450374,"Genetic variations in enzymes CYP2C19 and CYP2B6 significantly influence the metabolism of methylphenobarbital into phenobarbital, affecting the drug’s efficacy and safety due to differing metabolic rates that can lead to underdosing or toxicity. Moreover, genetic variations in GABA_A receptor subunits may cause pharmacodynamic variability, although the specific polymorphisms and their impacts are not thoroughly documented."
PA448871,"Celecoxib metabolism primarily depends on the CYP2C9 enzyme and its genetic variants, such as CYP2C9*2 and CYP2C9*3, which reduce metabolic activity and can increase the drug’s plasma concentrations, affecting its safety profile. Other genes including CYP2C8, ABCB1, and ABCC4 also influence celecoxib's pharmacokinetics, while genes such as ALOX12 and PTGS2 may affect its pharmacodynamic responses in inflammation-related pathways."
PA166152940,"Tolperisone is metabolized by the CYP1A2 enzyme, and genetic variations in the CYP1A2 gene affect its metabolism, influencing the drug's efficacy and safety which may require dose adjustments. While CYP2D6 was mentioned, its significant role in the metabolism of Tolperisone is not clearly supported, highlighting a potential error unless further verified by specific studies."
PA164774901,"The pharmacogenetics of darifenacin is significantly influenced by interactions with the enzymes CYP2D6 and CYP3A4, which are vital for its hepatic metabolism. Genetic variations in CYP2D6 can lead to different metabolic rates, causing either higher plasma concentrations and potential adverse effects in poor metabolizers, or reduced efficacy in ultra-rapid metabolizers due to faster clearance of the drug. Variants in CYP3A4 can similarly affect darifenacin levels and outcomes, though its implications are generally less significant than those of CYP2D6."
PA448970,"Chlorthalidone's effectiveness in managing hypertension can be influenced by genetic variants in SLC12A1, affecting sodium and chloride reabsorption in renal distal convoluted tubules which impacts the drug's pharmacodynamics. Additionally, variations in ALB could alter Chlorthalidone's binding and transport, affecting its pharmacokinetics and modifying dosage requirements and effectiveness in individual patients."
PA450146,"Levoketoconazole is primarily metabolized by the CYP3A4 enzyme, but its efficacy and safety can also be influenced by genetic variations in the CYP3A5 gene, which can lead to different levels of drug exposure and thereby affect both therapeutic and adverse effects. Although the CYP4F2 gene is involved in other metabolic pathways such as vitamin K metabolism, its direct impact on levoketoconazole's metabolism or efficacy remains speculative and less established."
PA166268805,"Odevixibat interacts pharmacogenetically with proteins like the ileal sodium/bile acid cotransporter (SLC10A2) and P-glycoprotein (ABCB1), where SLC10A2 facilitates bile acid reabsorption and its inhibition by odevixibat is key to treating pruritus in PFIC. Variations in SLC10A2 and ABCB1 genes can affect the drug's efficacy and pharmacokinetics, respectively, influencing odevixibat's absorption, distribution, and overall effectiveness, necessitating potential dosing adjustments."
PA166115441,"Pridopidine, a drug targeting Huntington's Disease by modulating dopaminergic signaling, may interact with genes involved in these pathways, such as DRD2 and HTT. These interactions could potentially influence both the pharmacodynamics and pharmacokinetics of pridopidine, affecting its efficacy and how it is processed in the body, although specific pharmacogenetic interactions have not been officially documented yet."
PA451690,"Timolol metabolism is significantly influenced by genetic polymorphisms in the CYP2D6 and CYP2C19 genes, where CYP2D6 plays a primary role. Variants that cause poor metabolism in CYP2D6 can lead to higher plasma levels of Timolol, increasing the risk of side effects like bradycardia or respiratory issues during systemic use for cardiovascular purposes, while ultra-rapid metabolizers may require higher doses for therapeutic effectiveness. Although CYP2C19 also affects Timolol's metabolism, its impact is less pronounced, and genetic variations in this gene may require dosage adjustments."
PA451550,"Sulfinpyrazone's metabolism is influenced by the CYP2C9 gene, where polymorphisms can alter drug efficacy and toxicity, necessitating potential dose adjustments. The drug also interacts with transporter genes like SLC22A12 and ABCB11, affecting its uricosuric action in promoting urate excretion, therefore impacting its effectiveness in reducing serum urate levels."
PA451871,"Verteporfin's pharmacogenetic interactions are minimal as it primarily works outside classical metabolic pathways affected by genetic variations and does not interact directly with specific genetic targets like enzymes or receptors. However, genetic variations in genes encoding plasma lipoproteins, which are responsible for verteporfin's transport, might theoretically influence the drug’s distribution and efficacy, and the ARMS2 gene might indirectly affect treatment outcomes through susceptibility to age-related macular degeneration, the primary condition treated by verteporfin."
PA448018,"Acetazolamide interacts pharmacogenetically mainly through the modulation of carbonic anhydrase isoforms (CA1, CA2, CA3, CA4, CA7, CA12, CA14) affecting its pharmacodynamics, while its pharmacokinetics involve CYP3A4, crucial for its metabolism, and SLC22A6, an organic anion transporter important for renal clearance. Genetic variations in CYP3A4 and SLC22A6 can modify the drug's metabolism and excretion rates, respectively, impacting the drug’s efficacy and side-effect profile."
PA164784021,"Genetic polymorphisms in NAT2 significantly influence the metabolism of ethambutol, where ""slow"" alleles can lead to increased drug exposure and risks, including optic neuritis. Additionally, variations in CYP enzymes (e.g., CYP1A2, CYP2E1, CYP2C19, CYP2C9) and transporter genes such as SLCO1B1 and ABCB1 might also affect the drug’s pharmacokinetics and distribution, although detailed interactions are less understood."
PA451663,"Thioguanine requires activation through HPRT1 and its metabolism is significantly influenced by genetic variants in TPMT (e.g., rs1800460 and rs1142345) that modulate the drug's toxicity, notably causing severe bone marrow suppression due to reduced TPMT enzyme activity. Additionally, the ABCC4 gene affects thioguanine’s pharmacokinetics by mediating the drug metabolites’ efflux, while other genes like XDH, UGT1A1, NAT1, and NUDT15 could potentially affect its metabolism and efficacy based on their roles in metabolic pathways, though their specific interactions with thioguanine are less well-defined."
PA450608,"Neomycin toxicity such as ototoxicity and nephrotoxicity may be influenced by genetic factors including variations in mitochondrial genes like MT-RNR1 and MT-ND1, and genes like ALDH2. The MT-RNR1 gene interacts with aminoglycosides to impair mitochondrial protein synthesis, potentially increasing susceptibility to toxicity, while MT-ND1 and ALDH2 could influence cellular energy processes and aldehyde metabolism in renal tissues, although these interactions are speculative."
PA450748,"Genetic variants in the mu-opioid receptor (OPRM1) affect the analgesic and sedative responses to oxymorphone due to changes in receptor structure and function, impacting both therapeutic outcomes and adverse effects. Additionally, variations in the enzymes CYP2D6 and CYP3A4 alter the drug's metabolism and plasma levels, leading to differences in efficacy and side effect profiles, which necessitates personalized dosing to accommodate these genetic differences."
PA450488,"Mexiletine metabolism is predominantly influenced by the CYP2D6 enzyme, with variations in this gene affecting its plasma levels, potentially leading to adverse effects in poor metabolizers or therapeutic ineffectiveness in ultrarapid metabolizers. The drug targets the sodium channel protein encoded by SCN5A, and variations in this gene might also impact its effectiveness and safety in controlling arrhythmias."
PA451954,"Zidovudine's pharmacogenetic profile is mainly influenced by its metabolism through glucuronidation by enzymes like UGT2B7, where genetic variations affect drug plasma levels and toxicity, potentially influencing treatment outcomes. Additionally, interactions with transporters such as ABCB1 and ABCC4 and other genes like DDRGK1, HLA-B, and ITPA impact the drug's efficacy, distribution, and toxicity, specifically concerning adverse effects like bone marrow suppression."
PA163522473,"The pharmacogenetic profile of Tipranavir is influenced by its interactions with metabolic enzymes, such as CYP3A4, CYP2C19, and CYP2D6, as well as transporters including ABCB1, which affect the drug's metabolism and cellular efflux, respectively. Variants in these genes can lead to significant alterations in Tipranavir's plasma concentrations, impacting drug efficacy and potential for adverse effects."
PA451974,"Ziprasidone's effectiveness and safety are influenced by genetic variations in the CYP3A4 gene which affects its metabolism, and the ABCB1 gene which impacts its transport across the blood-brain barrier. Additionally, genetic differences in neurotransmitter receptor genes like HTR2A and DRD2 influence the drug's antipsychotic efficacy and its risk of causing side effects such as akathisia, extrapyramidal symptoms, and tardive dyskinesia."
PA451737,"Genetic variations in CES1 affect the metabolism of trandolapril to its active form, trandolaprilat, impacting the drug's efficacy and safety by altering the available drug levels. Simultaneously, variations in the ACE gene influence trandolapril’s ability to inhibit ACE and reduce blood pressure by modifying the enzyme's expression or activity, crucial for understanding individual drug responses and potential adverse effects."
PA164777036,"Hydroxychloroquine metabolism is significantly affected by genetic polymorphisms in the enzymes CYP3A4, CYP2D6, and CYP2C8, influencing the drug's levels and potential toxicity, while the efficacy can also vary based on genetic variations in these enzymes. Additionally, genetic variations in immune receptors like TLR7 and TLR9, as well as transporters such as ABCB1 and SLCO1A2, can influence the drug's pharmacodynamics, distribution, and excretion rates. G6PD genetic variations, while not involved in metabolism, can predispose individuals to hemolysis when taking hydroxychloroquine, highlighting the importance of considering genetic diversity when administering the drug."
PA449053,"Clopidogrel's efficacy is significantly influenced by genetic variants in the CYP2C19 gene, which affect the enzyme's activity in metabolizing clopidogrel into its active form, impacting the antiplatelet effect and increasing cardiovascular risk. Additionally, enzymes like CES1 and genetic variations in transport proteins such as ABCB1 also modify clopidogrel's concentration and bioavailability, further influencing the drug's effectiveness in individual patients."
PA451544,"Sulfamethoxazole metabolism is influenced by NAT2 and CYP2C9 gene polymorphisms, which affect its pharmacokinetics through N-acetylation and oxidation processes, respectively. NAT2 gene variations categorize individuals as slow or rapid acetylators, impacting drug efficacy and side effects such as hypersensitivity or hemolytic anemia, while CYP2C9 variations alter drug oxidation rates. Additionally, G6PD polymorphisms affect sulfamethoxazole sensitivity, particularly in relation to oxidative stress-induced hemolytic anemia, marking a vital consideration for therapeutic strategies and dosing adjustments."
PA162565877,"Genetic variations in transporter genes ABCB1 and ABCG2 can influence the pharmacokinetics of amisulpride, affecting its plasma concentrations and distribution, while variants in dopamine receptor genes DRD2 and DRD3, as well as serotonin receptor-related genes like HTR2C and HTR1A, could alter how patients respond to the drug in terms of efficacy and side effects. This reveals the importance of considering genetic profiles to optimize the use of amisulpride in treating psychiatric conditions."
PA165946747,"Hydroxyamitriptyline's metabolic conversion from amitriptyline is catalyzed by the CYP2D6 enzyme, and genetic variations in CYP2D6 affect the drug's plasma concentration. Individuals with poor metabolizer variants of CYP2D6 may have increased plasma levels leading to potential side effects and toxicity, whereas ultra-rapid metabolizers could experience reduced antidepressant effects due to faster drug metabolism."
PA166278021,"Mitapivat interacts pharmacogenetically with genetic variants in PKLR, its direct enzymatic target, affecting therapeutic efficacy due to differential enzyme activation. Furthermore, variations in genes such as CYP3A4, which influences mitapivat's metabolism and clearance, as well as other cytochrome P450 enzymes, CYP19A1, and the transporter gene ABCB1, impact its pharmacokinetics, effectiveness, and potential drug-related outcomes like bone density effects, necessitating personalized dosage adjustments."
PA451583,"Tamsulosin metabolism is significantly influenced by the genetic variations in CYP2D6 and CYP3A4 enzymes. Polymorphisms in CYP2D6 can lead to higher plasma concentrations of the drug, increasing risks of side effects such as hypotension and dizziness, whereas multiple gene copies can decrease drug levels, undermining its therapeutic effects. Although CYP3A4 also affects tamsulosin metabolism, its impact is generally less pronounced due to its broader substrate specificity and various genetic and environmental influences."
PA154410481,"Prasugrel is metabolized into its active form through a series of reactions involving CES2, CYP3A4, CYP2B6, CYP2C9, and CYP2C19 enzymes, with CES2 initiating the conversion in the intestine and the other enzymes subsequently processing the intermediary metabolite to the active antiplatelet agent, R-138727. Polymorphisms in the genes encoding these enzymes may affect prasugrel’s efficiency of metabolism, thereby influencing its effectiveness and safety, suggesting a potential benefit from genetic testing to adjust dosing and reduce adverse effects."
PA164779050,"Sulfapyridine metabolism is chiefly managed by the enzyme CYP2C9, and genetic variations like CYP2C9*2 and CYP2C9*3 can lead to reduced enzyme activity, resulting in slower drug metabolism. This decreased metabolic rate may increase drug levels, prolonging exposure and potentially heightening the risk of adverse effects such as toxicity."
PA451521,"Succimer functions by forming complexes with heavy metals through its chemical properties, without direct interactions with biological targets like enzymes or receptors. Although there is limited pharmacogenetic data regarding succimer, one relevant gene, G6PD, may influence treatment outcomes as its deficiency can exacerbate oxidative stress during chelation, potentially impacting patients with G6PD deficiency who undergo therapy with succimer."
PA166212681,"Genetic variations in the OPRM1 gene can affect the binding and response to piritramide, an opioid analgesic, impacting its effectiveness and side effect profile. Additionally, variants in the CYP2D6 and ABCB1 genes can alter the metabolism and transport of piritramide, respectively, influencing the drug's concentration, efficacy, and elimination, thereby potentially modifying pain management outcomes and the risk of adverse effects."
PA448997,"Cidofovir's effectiveness and safety are influenced by genetic variations in the TYMP enzyme, which affects the drug's activation or degradation, and in the SLC22A6 transporter, which modulates its renal clearance and toxicity. These genetic factors impact cidofovir's pharmacokinetics, altering both its therapeutic effectiveness and nephrotoxic risk in individuals."
PA448505,"Atropine interacts pharmacogenetically mainly through its impact on muscarinic acetylcholine receptors (CHRM1-5) and neuronal acetylcholine receptors (CHRNA4 and CHRNB2), where genetic variations can affect its pharmacodynamic effects such as heart rate and neurological responses. Additionally, genetic differences in the transporter gene ABCB11 and the plasma carrier protein ORM1 can modify atropine's pharmacokinetic properties, impacting its distribution, bioavailability, and excretion."
PA448785,"Carbamazepine metabolism involves various cytochrome P450 enzymes like CYP3A4, CYP2C8, CYP1A2, CYP2C9, and CYP2C19, where genetic polymorphisms in these enzymes can affect the drug's metabolic rates, impacting its efficacy and toxicity. Additionally, the efficacy of carbamazepine in controlling seizures is influenced by variants in the SCN1A gene, and the risk of severe skin reactions such as Stevens-Johnson syndrome is associated with the HLA-B*1502 and HLA-A*3101 alleles, highlighting the importance of genetic testing in optimizing treatment and reducing adverse effects."
PA164746384,"Variations in the CYP1A2 gene influence the metabolism of nalidixic acid in the liver, affecting drug levels and toxicity; while polymorphisms in SLC22A6 impact its renal excretion, thus modifying drug response. Additionally, TDO2 variations may affect the formation of nalidixic acid metabolites, but their impact on overall drug metabolism is less significant compared to CYP1A2."
PA134688071,"Atomoxetine's metabolism and clinical response are significantly influenced by genetic variability, primarily involving the CYP2D6 gene, which determines metabolizer status (poor, intermediate, extensive, or ultrarapid) and affects atomoxetine's plasma concentrations and side effect risks. Additionally, the CYP2C19 gene plays a secondary role in its metabolism, while the SLC6A2 gene impacts its pharmacodynamics through norepinephrine reuptake inhibition, crucial for its effectiveness in treating ADHD; HTR7 may also influence treatment outcomes through serotonergic pathways, though its role is less clearly defined."
PA165111698,"Artemether is metabolized by several cytochrome P450 enzymes, including CYP3A4, CYP3A5, CYP2B6, CYP2C19, and CYP2C9, into its active metabolite dihydroartemisinin, which is essential for its antimalarial effects. Genetic variations in these enzymes can significantly affect the metabolism of artemether, impacting its efficacy and toxicity, and suggest the importance of tailored dosing based on individual genetic backgrounds to optimize treatment outcomes."
PA448964,"Chlorpromazine's effectiveness and safety are influenced by genetic variations in its metabolic enzymes and receptor targets. Specifically, polymorphisms in the CYP2D6 enzyme impact drug plasma concentrations and efficacy, with additional metabolic effects from CYP1A2 and possibly CYP3A4, while genetic variants in the DRD2 receptor can modify therapeutic responses and the risk of side effects like extrapyramidal symptoms."
PA450137,"Kanamycin's pharmacogenetic interactions emphasize resistance mechanisms in bacteria, involving genes like aac, knt, and aphA1 that produce enzymes acetylation, adenylation, and phosphorylation respectively, leading to drug inactivation and bacterial resistance. Additionally, human gene MT-RNR1 might be linked to heightened ototoxic effects through mitochondrial damage in cochlear cells, a known side effect of kanamycin."
PA166223903,"Avapritinib's efficacy is significantly influenced by pharmacogenetic interactions, chiefly through mutations in the PDGFRA gene, especially the exon 18 D842V mutations, which crucially determine the likelihood of response in GIST patients. Additionally, its metabolism is primarily governed by the cytochrome P450 enzymes CYP3A4 and CYP2C9, where genetic variations can modulate drug plasma levels, thus impacting both its efficacy and potential toxicity."
PA166128168,"Asunaprevir's metabolism is significantly influenced by genetic variations in enzymes CYP3A4 and CYP3A5, with polymorphic variants affecting drug metabolism and plasma levels, potentially impacting its efficacy and toxicity. Additionally, genetic polymorphisms in transporters SLCO1B1 and ABCB1, which facilitate drug uptake and efflux, can alter the bioavailability, therapeutic effectiveness, and safety profile of asunaprevir."
PA450084,"Irbesartan’s effectiveness and safety are influenced by genetic interactions, where CYP2C9 variants impact its metabolism and plasma concentration, and variations in AGTR1 and other related genes like EDN1 and AGT affect its efficacy in blood pressure regulation. This understanding can aid in tailoring individual treatment plans in conditions like hypertension and diabetic nephropathy."
PA164776964,"Desloratadine interacts with the HRH1 gene by acting as an antagonist at the Histamine H1 receptor, reducing allergic symptoms by blocking histamine action, which influences pharmacodynamics. Additionally, the drug's pharmacokinetics are affected by the P-glycoprotein transporter encoded by the ABCB1 gene, where variants within this gene can alter the transport, bioavailability, and distribution of desloratadine, potentially affecting its effectiveness and safety due to variations in absorption and clearance among different genotypes."
PA451168,"Protriptyline's interaction with genetic components such as SLC6A2 and SLC6A4 affects its pharmacodynamics by altering serotonin and norepinephrine uptake, influencing the drug’s effectiveness and side effects. Additionally, the ABCB1 gene impacts its pharmacokinetics by encoding the P-glycoprotein, which affects the drug’s distribution and elimination; variations in these genes can significantly influence individual responses, potentially necessitating dose adjustments to optimize therapy and minimize adverse effects."
PA450344,"Medroxyprogesterone acetate (MPA) pharmacogenetics interacts with metabolic enzymes, including CYP3A4 and CYP2C8, affecting drug clearance and plasma concentrations through genetic variations such as CYP3A4*22, which may decrease enzyme efficiency leading to increased drug levels. Additionally, variations in hormone receptors like progesterone receptor (PGR) and estrogen receptor alpha (ESR1), as well as the impact of other genes such as HSD3B2 on steroid metabolism, ABCB1 on drug distribution, and ALB on drug bioavailability, influence the efficacy and therapeutic outcomes of the drug."
PA450354,"The pharmacokinetics of melphalan, a cancer treatment drug, can be influenced by genetic variations in solute carriers (SLC22A3, SLC7A5, SLC7A10) which are integral to its cellular uptake, and proteins (ALB and ORM1) that transport it in plasma. These genetic differences affect the drug's distribution, availability at target sites, and thus its efficacy and toxicity, highlighting the importance of considering genetic factors when administering the drug to optimize therapy and predict possible adverse effects."
PA450214,"Genetic variations in the CYP2C9 enzyme can minimally impact the metabolism of the fluoroquinolone antibiotic levofloxacin, while variants in ABCB1, coding for P-glycoprotein, can affect the drug’s cellular efflux, impacting its concentration in target tissues, thus influencing efficacy and safety. Furthermore, genes such as SLC22A1, SLC22A2, SLC22A4, SLCO1A2, and SLCO4C1, which are involved in renal secretion and organic anion transport, may also influence levofloxacin's excretion and overall pharmacokinetics."
PA164778866,"Liothyronine's metabolism is significantly affected by UGT1A1, which aids in its conjugation and excretion, while its transport involves various SLCO and ABC transporters such as SLCO1A2, ABCB1, which can impact its absorption, distribution, and elimination due to genetic polymorphisms. Furthermore, genetic differences in thyroid hormone receptors THRA and THRB influence the pharmacodynamics of liothyronine, affecting its therapeutic effects on metabolic rates and growth development. These genetic interactions highlight how variations can lead to differing patient responses and guide personalized treatment strategies."
PA448492,"Asparaginase, used in treating acute lymphoblastic leukemia, does not interact directly through typical drug-metabolizing enzymes, but genetic predispositions, particularly from genes like HLA-DRB1, MTHFR, SOD2, GATA3, and NFATC2, influence its therapeutic outcomes and hypersensitivity reactions. These genes, related to immune responses and metabolic pathways, might affect the drug’s efficacy and toxicity, suggesting that genetic variations could impact treatment results, though direct gene-drug interactions are speculative."
PA166268801,"Variants in the CYP3A4 and CYP2D6 genes can affect the activity of enzymes that metabolize glycerol phenylbutyrate into phenylbutyric acid (PBA) and phenylacetic acid (PAA), influencing the drug's effectiveness and safety by altering levels of PAA and the formation of phenylacetylglutamine in patients with urea cycle disorders (UCDs). These genetic differences might require pharmacokinetic adjustments to manage the drug's efficacy and avoid toxicity, while genes directly involved in the urea cycle such as CPS1, NAGS, ASS1, ASL, ARG1, and OTC, though essential for the conditions treated by the drug, do not interact with its pharmacokinetic or pharmacodynamic pathways."
PA165958354,"Telaprevir, a drug for chronic HCV infection, is metabolized mainly by the CYP3A4 enzyme, and genetic variants of this enzyme can affect the drug's plasma concentration and overall efficacy. Additionally, polymorphisms in the ABCB1 gene, which affects drug absorption and efflux, can also alter how effectively the drug is utilized, further influencing patient outcomes."
PA166185957,"Genetic variations in key genes such as estrogen receptors (ESR1 and ESR2) and metabolic enzymes (sulfatase - STS, and aromatase - CYP19A1) influence the effectiveness and safety of estrone sulfate therapy. Polymorphisms in these genes can modulate receptor affinity and expression, and alter the metabolic conversion rates of estrone sulfate, impacting its pharmacodynamics and pharmacokinetics, which affects therapeutic outcomes and side effect profiles."
PA166131626,"Osimertinib, a drug for NSCLC, targets mutations in the EGFR gene, including T790M, exon 19 deletions, and L858R, which are critical for its therapeutic effectiveness by influencing cancer cell sensitivity. The drug's metabolism involves mainly CYP3A4 and to a lesser extent CYP1A2, while its distribution and elimination are affected by ABCB1 and ABCG2 transporters, with genetic variations in these enzymes and transporters impacting osimertinib's efficacy and toxicity."
PA166160044,"Cobimetinib's effectiveness and safety are influenced by its interaction with various genes crucial for its metabolism and transport. Specifically, the presence of BRAF mutations (V600E or V600K) is essential for its efficacy in melanomas. Enzymes like CYP3A4 and UGT2B7, and transporters such as SLCO1B1, SLCO1B3, ABCG2, and ABCB1 play vital roles in modifying the drug's plasma levels and cellular disposition, affecting both its therapeutic results and potential toxicity. Personalizing dosing based on these genetic variations can help optimize treatment outcomes and reduce adverse effects."
PA165958360,"Rivaroxaban's pharmacogenetics involve key interactions with CYP3A4, CYP3A5, and ABCB1 genes that influence its metabolism and transport. Variants in CYP3A4 and CYP3A5 affect the enzyme's ability to biotransform rivaroxaban, altering its plasma levels and anticoagulant efficacy; whereas, ABCB1 gene variations impact rivaroxaban's bioavailability and elimination by encoding P-glycoprotein which modulates drug's cellular efflux."
PA448404,"The pharmacogenetic interactions of the drug amodiaquine involve several genes, notably CYP2C8, CYP1A1, CYP1B1, CYP2D6, CYP2C9, and ABCB1, which affect its metabolism, transport, efficacy, and toxicity. Polymorphisms in genes like CYP2C8 and CYP2D6 impact how the drug is metabolized, while the ABCB1 gene influences its distribution in the body, affecting both its effectiveness and side effects."
PA448515,"The efficacy and safety of azathioprine are considerably affected by genetic variations in TPMT, NUDT15, XDH, ITPA, SLC29A1, and HLA genes. Polymorphisms in TPMT and NUDT15 genes directly impact the metabolism and toxicity of its active metabolite, 6-mercaptopurine, leading to different therapeutic outcomes and risks like myelosuppression, while genes like XDH and ITPA influence other metabolic pathways, and HLA variants are linked to hypersensitivity reactions."
PA7000,"Sorafenib metabolism involves multiple enzymes such as CYP3A4, CYP2C9, and CYP2C8, as well as glucuronidation by UGT1A9, where genetic variants can affect drug clearance, metabolism speed, and efficacy. Additionally, its pharmacodynamics are influenced by interactions with kinases like BRAF and RAF1 and transporters like ABCB1 and ABCG2, where genetic variations can alter drug targeting, distribution, and excretion, affecting overall therapeutic outcomes and potential for adverse reactions."
PA166123346,"The UGT1A1 gene, crucial in bilirubin metabolism through its role in glucuronidating unconjugated bilirubin, also influences the metabolism of drugs like irinotecan due to polymorphisms such as the UGT1A1*28 allele which can reduce enzyme activity and lead to higher levels of unconjugated bilirubin. This necessitates clinical considerations for adjusting drug dosages to prevent toxicity. The potential role of SOD2 in bilirubin metabolism remains speculative, linked indirectly through its function in oxidative stress defense and liver health."
PA166184060,"Carbocisteine is metabolized by enzymes CDO1 and PAH, where CDO1 helps in catabolizing cysteine and PAH in hydroxylating phenylalanine, both essential for the drug's breakdown and efficacy. Another gene, ST3GAL5, affects the drug's functionality by altering glycoprotein content in mucus, with genetic variations in these genes impacting the metabolic process and the balance of sialomucins and fucomucins in mucus, thus influencing the effectiveness of carbocisteine as a mucolytic."
PA10066,"Duloxetine's metabolism is significantly regulated by the CYP2D6 and CYP1A2 enzymes, where variations in these genes can lead to different pharmacokinetic outcomes; CYP2D6 affects Duloxetine's plasma levels, influencing its efficacy and side effects in individuals with varying metabolic capacities (poor to ultrarapid metabolizers), while CYP1A2 alterations can modify drug metabolism rates impacting its efficacy and safety. Additionally, the ABCB1 gene, by affecting cellular uptake and distribution, can also influence the pharmacokinetics of Duloxetine, further affecting drug exposure and therapeutic outcomes."
PA166182939,"L-Methylfolate is particularly effective in individuals with the MTHFR C677T gene variant, which reduces the enzyme conversion efficiency of folates, leading to higher homocysteine levels; this drug effectively bypasses this compromised pathway, directly serving as a cofactor for methionine synthase to lower homocysteine levels and reduce cardiovascular risks. This gene-drug interaction underscores the value of personalized medicine, allowing for tailored supplementation based on individual genetic profiles to more effectively manage conditions like depression and hyperhomocysteinemia."
PA449383,"Docetaxel's pharmacogenetics are shaped by variations in genes that affect its metabolism and efflux, notably through the enzymatic activity of CYP3A4 and CYP3A5, and transport via ABCB1, ABCC2, ABCC10, SLCO1B3, and SLCO1B1. Genetic polymorphisms in these enzymes and transporters can lead to differences in the drug's pharmacokinetics, efficacy, toxicity, and overall therapeutic outcomes, suggesting the possibility for personalized dosage adjustments in cancer treatment."
PA146096020,"Nitrendipine metabolism is significantly influenced by genetic variants in CYP3A4 and CYP3A5 enzymes, with variants like CYP3A5*3 leading to increased drug levels and potential side effects due to reduced enzyme activity. Additionally, variations in the ABCB1 gene affect nitrendipine's distribution and elimination by altering P-glycoprotein function, while interactions with CACNA1C affect its efficacy in modulating vascular tone and blood pressure by regulating calcium influx in vascular smooth muscle."
PA166186040,"Tianeptine's pharmacogenetics are shaped by CYP3A4, which handles its metabolic transformation in the liver, and OPRM1, the mu-opioid receptor responsible for its antidepressant action. Variations in CYP3A4 can alter tianeptine's metabolism and its pharmacokinetic profile, affecting drug effectiveness and tolerability, whereas genetic differences in OPRM1 can impact the drug's pharmacodynamics, explaining the variations in therapeutic responses and side effects among individuals."
PA164784025,"Entecavir, an antiviral medication for chronic hepatitis B, does not significantly interact with human liver enzymes such as those in the cytochrome P450 system, hence demonstrating minimal pharmacokinetic interactions. However, pharmacogenetic factors like variations in genes such as IFNL4 and IFNL3, which are related to interferon lambda and influence immune responses and viral clearance, could affect how the immune system reacts to treatment with entecavir, influencing its pharmacodynamics rather than its pharmacokinetics."
PA164754992,"Variations in the genes SLC22A1 and SLCO1A2, which code for the primary transporters of Rocuronium, can influence the drug's plasma concentration, affecting its effectiveness and the duration of muscle relaxation it provides. Additionally, mutations in receptor genes such as CHRNA2 and CHRM2, which govern its site of action, might modify Rocuronium's neuromuscular blocking effects, thereby affecting its efficacy or safety."
PA166210801,"The pharmacokinetics of ethylmorphine, a morphine derivative, are substantially affected by genetic variations in the CYP2D6 enzyme, responsible for its hepatic metabolism. Individuals with different CYP2D6 alleles demonstrate varied metabolization rates, ranging from poor to ultra-rapid, influencing the drug's effectiveness and safety by affecting its metabolism speed; thus, genetic testing may be necessary to tailor appropriate dosing strategies."
